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Background: Intimate partner violence (IPV) has the ability to negatively impact the 
lives of women living with HIV through decreased adherence, increased mental health 
symptoms and substance use and through physiologic responses to chronic stress.  
Objectives: This study addressed three specific aims: 1) To determine the prevalence of 
IPV in a sample of women attending an urban HIV clinic; 2) To examine the association 
between IPV and HIV treatment and adherence markers, including potential mediating 
effects of mental health symptoms; and 3) To explore participants’ perceptions of the 
impact of IPV on their HIV care. 
Design and Methods: This explanatory sequential mixed-methods study had two phases. 
Phase 1 included collecting survey data and medical records data from women receiving 
care at an urban HIV-specialty clinic. Phase 2 consisted of semi-structured in-depth 
interviews with a sub-set of women who reported IPV on survey measures.  
Sample: In total, 239 women completed IPV measures and had available medical records 
data. Nine of these women also participated in Phase 2 interviews.   
Results: Past year IPV was highly prevalent in the sample (51%; 95% CI: 45–58). In 
bivariate analysis IPV was independently associated having a CD4 count <200 (OR: 
3.284; 95% CI: 1.251-8.619; p=0.016) and a detectable viral load (OR: 1.842; 95% CI: 
1.006-3.371; p=0.048), but not with missing >25% of past year scheduled clinic visits. 
The association between CD4 count and IPV maintained its significance when 
controlling for demographic variables, substance abuse and symptoms of PTSD and 
depression (OR: 3.536; 95% CI: 1.114-11.224; p=0.032). Qualitatively, women’s focus 




managing labels and “I know what I’m suppose to do.”  Being a mother or caregiver was 
seen as an important role that women took on, and as such it often impacted their health 
care decisions.  Participants readily identified with this label and placed in as central to 
their identities and adherence. They were however resistant to accept the label of 
“victim/survivor” of IPV. They largely minimized the quantity and severity of violence 
when compared to what was reported on survey measures, and did not identify IPV as a 
primary barrier to HIV care.  
Conclusion: Our findings highlight two primary areas for future research. First, the 
association between IPV and a low CD4 count when controlling for demographic, 
behavioral and viral load measures indicates the potential for a physiologic pathway 
between trauma, including IPV and poorer immune functioning.  Further research to 
identify the specific mechanisms of this pathway is needed in order to establish 
appropriate biobehavioral interventions. Secondly, the discordance between reported IPV 
on survey measures and during qualitative interviews indicates that while the relationship 
between IPV and poorer HIV outcomes may exist quantitatively, women are not 
identifying IPV as a primary driver of their adherence or health care. Future research 
including should include qualitative components to understand women’s perceptions of 
IPV, how these perceptions change over time and how best to design interventions 
tailored to addressing the complex needs of this patient population.  In clinical practice, 
trauma-informed care models that focus on promoting safety and providing resources for 
all patients regardless of specific disclosures may begin to address the impact of IPV on 
HIV treatment outcomes.   







“Here’s to the crazy ones. The misfits. The rebels. The trouble-makers. The round 
pegs in the square holes. The ones who see things differently. They’re not fond of the 
rules, and they have no respect for the status-quo. You can quote them, disagree with 
them, glorify or vilify them. But the only thing you can’t do is ignore them. Because they 
change things. They push the human race forward. And while some may see them as the 
crazy ones, we see genius. Because the people who are crazy enough to think they can 
change the world, are the ones who do.” 
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CHAPTER ONE: INTRODUCTION 
Intimate partner violence (IPV) and its relationship to human immunodeficiency 
virus (HIV) has been the topic of a growing body of research over the past two decades. 
Worldwide, 33 million persons are infected with HIV, more than half of them being 
women and girls; while in the United States, 1.3 million people are infected with HIV 
(Joint United Nations Programme on HIV and AIDS, 2012 [UNAIDS]). Globally and in 
the United States, women are becoming infected with HIV at increasing rates when 
compared to men. In the United States, African-American women are facing a far greater 
disease burden than their Caucasian counterparts, with the rate of both new HIV 
infections and HIV-related deaths among black women being 17 times that of white 
women (Centers for Disease Control, 2012).  
The first review of the literature to discuss HIV and IPV was published in 2000. 
This review aimed to identify what was known regarding forced sex or IPV, risk of HIV 
acquisition, as well as risk of IPV among women living with HIV (Maman, Campbell, 
Sweat, & Gielen, 2000). The authors presented evidence that risk of HIV infection was 
higher in women with IPV histories and that IPV rates were higher in women who were 
HIV infected (Campbell et al., 2008; Maman, Campbell, Sweat, & Gielen, 2000). A 2008 
review added substantially to the understanding of the underlying complexities of the 
HIV and IPV epidemics. The authors reviewed a far wider range of studies that included 
assessing the role of forced sex, partner characteristics, and individual risk-taking 
behaviors. They also included a review and discussion of evidence related to biologic 
pathways impacting both the direct and indirect risk of HIV infection including biologic 




and inflammatory response. (Campbell et al., 2008). While this inclusion opened doors to 
a new line of research questions, the addition of biologic mediators in the relationship 
between IPV and HIV infection is still far less researched and understood than their 
behavior counterparts. The behavioral pathways of HIV acquisition in women with a 
history of IPV have been shown to include a variety of modalities including direct 
transmission through forced sexual contact, partners’ participation in more high-risk 
behaviors, and indirectly through increased sexual and drug use behaviors (Jewkes, 
Dunkle, Nduna, & Shai, 2010). The long-term consequences of stress including 
dysregulation of the immune and inflammatory responses of women who have 
experienced IPV has also been identified as a mechanism through which women are more 
susceptible to a number of negative health consequences including HIV infection 
(Campbell, Lucea, Stockman, & Draughon, 2013; Humphreys et al., 2012; A. B. Woods 
et al., 2005; S. J. Woods et al., 2005).   
More recently, greater attention is being paid to HIV and IPV as mutually 
occurring epidemics.  With the 2013 White House Report on the intersection of HIV and 
violence against women and girls, policy makers began to press upon the importance of 
addressing this disparity in the health of women (Interagency Federal Working Group, 
2013). Paralleling the release of this report, researchers began to examine the impact that 
trauma and violence, particularly IPV, has on HIV care. Multiple studies have shown IPV 
as not only a risk factor of HIV infection, but as a barrier to diagnosis, entry into care, 
antiretroviral use and viral suppression (Blackstock, Blank, Fletcher, Verdecias, & 
Cunningham, 2015; Blank et al., 2015; Espino et al., 2015; Hatcher, Smout, Turan, 




Jones, Villar-Loubet, Arheart, & Weiss, 2010; Malow et al., 2013; Ramachandran, 
Yonas, Silvestre, & Burke, 2010; Rose, House, & Stepleman, 2010; Schafer et al., 2012; 
Siemieniuk et al., 2013; Sullivan, Messer, & Quinlivan, 2015; Trimble, Nava, & 
McFarlane, 2013). The impact that IPV has on the care continuum makes it of utmost 
importance to gain a greater understanding of the specific mechanisms of action and 
identify areas for intervention.   
Purpose 
This study was designed to build on existing research regarding HIV care and 
treatment adherence among urban women living with HIV.  Using an explanatory 
sequential mixed-method approach, this study examined the relationship of past year IPV 
and mental health conditions on the ability of women living with HIV to engage in HIV 
care and treatment, as well as their disease progression.  
Conceptual Framework 
The conceptual framework used for the design of this study (Figure 1 below) is 
adapted from a framework used by Schafer and colleagues in one of the first published 
studies to examine biologic measures associated with HIV in relation to reported IPV 
(Schafer et al., 2012). The framework, while not adapted from a specific biobehavioral 
theory does includes aspects related to a broader biopsychosocial framework (Engel, 
1977), that acknowledges not only the biologic realities of HIV infection and its impact 
on an individual, but also the impact that social factors such as IPV, and psychological 
factors such as depression and PTSD have on the health or disease state of an individual. 
Subsequent to the study’s design and initiation, Campbell and colleagues published a 




progression (Campbell et al., 2013), which provides pathways (both observed in prior 
research and theoretical) to address a far wider range of trauma effects in the HIV disease 
process. One challenge with both frameworks is the number of bidirectional linear 
associations, limiting the ability to study these phenomena without large samples and 
extensive longitudinal follow up (Campbell et al., 2013; Schafer et al., 2012). 
In order to further address the real world complexities involved in the lives of 
urban women living with HIV, the study’s design and analysis were also informed and 
guided by syndemic theory. Syndemic theory, initially described in the medical 
anthropology literature by Singer in 1994 is defined as “a set of multiple intertwined 
health problems occurring in a population simultaneously experiencing poor physical and 
social conditions” (Singer, 1996, 2006).  
These multiple health and social problems, such as violence, HIV, and poverty act 
synergistically to create a greater negative impact on health than would otherwise be 
expected from the disease process alone. Singer first used the syndemic theory to 
describe the SAVA (Substance Abuse, Violence and AIDS) syndemic among urban 
residents of Hartford, Connecticut (Singer, 1994, 1996).  More recently, a nurse 
researcher, Gonzalez-Guarda and colleagues examined literature regarding Hispanic 
women and have included “mental health conditions” as a fourth interlinked piece of the 
SAVA syndemic (Gonzalez-Guarda, Florom-Smith, & Thomas, 2011; Gonzalez-Guarda, 
McCabe, Florom-Smith, Cianelli, & Peragallo, 2011). Gonzalez-Guarda further places 
the SAVA syndemic within a larger ecological framework highlighting the impact that 
individual, interpersonal, community, and society have on how the syndemic pieces 




types of gender-based violence have been examined within the framework including IPV 
and prostitution (Illangasekare, 2011; Romero-Daza, Weeks, & Singer, 2003) 
Syndemic frameworks emphasize that medical conditions such as HIV cannot be 
examined only as biologic and physiologic processes, but in the context of social and 
psychological factors that act as catalysts for each other and poorer health outcomes in 
general (Singer, 2009).  Syndemic models demand that in order to intervene or promote 
change in one area of the syndemic, full attention must be paid to the other aspects. 
Gonzalez-Guarda and colleagues note that the precise factors that impact individuals, 
their communities and their experience with the SAVA syndemic, particularly at the 
community and society levels, are culturally dependent and as such their model 
highlights the SAVA syndemic and associated factors in Hispanic women (Gonzalez-
Guarda, Florom-Smith, et al., 2011; Gonzalez-Guarda, McCabe, et al., 2011; Gonzalez-
Guarda, Peragallo, Urrutia, Vasquez, & Mitrani, 2008; Singer, 2009). 
Significance of the Study 
This study adds to the current body of literature regarding adherence to HIV care 
and progression of HIV disease in the context of IPV. Whereas the majority of research 
to date has focused on IPV as a risk factor for the acquisition of HIV (Campbell et al., 
2013; Draughon, 2012; Jewkes et al., 2010), or strictly issues related to women’s 
adherence to HIV care in the context of IPV (Blackstock et al., 2015; Blank et al., 2015; 
Espino et al., 2015; Hatcher et al., 2015; Kalokhe et al., 2012; Lopez et al., 2010; Malow 
et al., 2013; Ramachandran et al., 2010; Sullivan et al., 2015; Trimble et al., 2013), this 
current study includes CD4 count to measure overall disease state among women in the 




care particularly in urban, African-American women. The use of detailed and 
behaviorally specific IPV measures to identify women who report a broad range of IPV 
including physical, psychological and sexual violence also adds depth to the currently 
available research (Illangasekare et al., 2012; Schafer et al., 2012). The current study 
used multiple data sources to answer questions about the complex and multidirectional 
relationships between IPV, mental health disorders, substance abuse and HIV disease, 
which provides unique and critical knowledge of these syndemic factors to provide 
avenues for intervention and future research.   
Specific Aims 
This mixed-methods study had three specific aims. Aims 1 and 2 were addressed 
using quantitative methods while qualitative methods were used for Aim 3. 
Aim 1:  Determine the past year prevalence of IPV, reproductive coercion, and 
symptoms of depression and PTSD among adult HIV positive women attending an urban 
clinic.  
Aim 2:  Examine the relationship between IPV, depressive symptoms, and PTSD 
symptoms, with treatment adherence, CD4 count and viral load among adult HIV positive 
women attending an urban clinic. There were two proposed hypotheses for Aim 2:  
Hypothesis 1: HIV positive women who report past year IPV will have poorer 
clinic attendance, lower CD4 counts and viral loads that are more often detectable 
compared with HIV positive women who report no past year IPV or reproductive 
coercion.  
Hypothesis 2: The effect of past year IPV on HIV treatment outcomes will be 




Aim 3:  Explore HIV positive women’s perception of the role that IPV has on 
their mental health, treatment adherence, and disease progression 
Background 
In the past decades, increasing attention has been paid to the intersections of 
violence, particularly IPV, sexual violence, and HIV. Most of this work has discussed the 
IPV and HIV as commonly co-morbid conditions, each acting as a risk factor for the 
other and how, combined, they lead to increased morbidity and mortality for women 
(Campbell et al., 2008; Draughon, 2012; Dunkle et al., 2004; Gielen et al., 2007). The 
following review highlights key findings and concepts from a number of areas of HIV 
and IPV research in relation to the theory and framework presented above.  
HIV and Intimate Partner Violence 
Violence occurring in the setting of intimate relationships continues to be a highly 
prevalent issue in the United States and across the globe. The most recent Centers for 
Disease Control (CDC) population study estimates that one in three women in the United 
States will be a victim of intimate partner physical, sexual or stalking violence during 
their lifetime (Black et al., 2011). IPV is more than physical violence—it is a pattern of 
abuse and coercive behaviors including threat of physical or sexual violence, 
psychological abuse, or stalking (Saltzman et al., 2002). These patterns of abuse and 
coercion have been associated with a variety of negative physical and mental health 
outcomes, including sexual health consequences such as sexually transmitted infections, 
unintended pregnancy, chronic pelvis pain, and cervical cancer (Campbell et al., 2002; 
Campbell et al., 2000; Coker, 2007; Ellsberg et al., 2008).  




and psychological abuse have all been shown to increase a women’s risk for acquiring 
HIV infection (Draughon, 2012; Dunkle et al., 2004; El-Bassel et al., 1998; Ellsberg et 
al., 2008; Garcia-Moreno & Watts, 2000; Gielen et al., 2007; Krug et al., 2002; Miller, 
2006; Teitelman et al., 2008; Teitelman et al., 2009). The associations between the 
epidemics of violence against women and HIV have been widely explored. Several 
potential pathways of HIV acquisition among abused women have been postulated, such 
as increases in personal and abusive partner’s sexual risk behavior, increased drug and 
alcohol use, and increases in sexually transmitted infections, as well as acute and chronic 
stress responses leading to weakened immune response, greater HIV susceptibility and 
more rapid disease progression (Draughon, 2012; Dunkle et al., 2004; A. B. Woods et al., 
2005; S. J. Woods et al., 2005). Specifically, in the case of sexual assault, acute 
inflammatory reactions and injuries to the genitalia may increase the risk of HIV 
transmission above that of consensual intercourse, although this pathway has been 
minimally explored (Draughon, 2012; Ghosh, Rodriguez-Garcia, & Wira, 2013).   
Intimate Partner Violence and HIV Adherence and Outcomes 
While a 2015 meta-analysis reviewed 13 studies that reported on HIV treatment 
engagement or adherence (ART use/prescription, self-reported ART adherence and viral 
load measures) in the setting of women who had experienced IPV, only four studies were 
found that examined CD4 count as a specific biologic marker of HIV disease control and 
progression in relation to IPV (Hatcher et al., 2015; Illangasekare et al., 2012; Schafer et 
al., 2012). This is important as the focus on IPV as a barrier to adherence neglects the 
growing body of research linking IPV to chronic inflammatory responses and the 




experiencing both HIV and IPV.  
The data included in the 2015 meta-analysis specifically examined three 
engagement and adherence measures—current ART use, self-reported ART adherence, 
and viral suppression (Hatcher et al., 2015). Using meta-analytic techniques, each of 
these three outcomes was associated with IPV. Women who had experienced IPV were 
less likely to report current ART use and were more likely to report poor ART adherence. 
They were also more likely to have a detectable viral load, representing concurrency of 
self-reported and laboratory markers of adherence. The authors also compared the overall 
magnitude of this effect size to other variables such as substance abuse, depression, 
stigma and pill burden, and found IPV to have a greater impact than any other examined 
variable (Hatcher et al., 2015).   
Results related to CD4 count data have not been synthesized in meta-analysis, and 
individual study results have varied (Illangasekare et al., 2012; Schafer et al., 2012). Two 
of the four identified studies found significant relationships between IPV and CD4 count 
(Rose et al., 2010; Schafer et al., 2012). Both Schafer and colleagues and Rose and 
colleagues found associations between IPV and CD4 count less than 200 as well as 
detectable viral load. Notably, Rose also aimed to assess mediation effects of PTSD and 
medication adherence on these relationships (Rose et al., 2010).  The PTSD analysis was 
not conducted due to insignificant findings between PTSD and the outcome measures, 
while self-reported medication adherence did mediate the impact of IPV on both viral 
load and CD4 count. Their analysis was limited in several ways. First, their total sample 
size was 40 participants, limiting their statistical analysis. They also limited their 




testing mediation effect of PTSD because it was not significantly associated with the 
outcomes in their small sample. Lastly, the theoretical and clinical basis for medication 
adherence directly impacting CD4 count and viral load measures is well established 
(Chesney, 2006; Nieuwkerk & Oort, 2005).  It is not unexpected that this factor will 
directly impact these outcomes regardless of IPV status. Specifically with viral load, a 
commonly used proxy measure of ART adherence, including an additional adherence 
measure in statistical modeling would significantly impact the ability to identify other 
associations.  
Moreover, the clinical population examined in these two studies places limitations 
on generalizability. Both were in primarily rural settings and Schafer and colleagues 
included men and women in their sample and did not conduct gender-specific analysis, 
but instead controlled for gender in multivariate analyses (Rose et al., 2010; Schafer et 
al., 2012). The fact that the sample included more men (75%) than women (25%) and that 
the majority of their sample also identified as men who have sex with men may have 
impacted their results and should be further addressed in larger studies with the ability to 
complete gender-specific analyses (Schafer et al., 2012).  
Results published in 2012 and 2013 did not find statistically significant 
relationships between IPV and CD4 counts (Illangasekare et al., 2012; Siemieniuk et al., 
2013). Both studies were limited in their assessment of IPV, with one study using a three-
item screening tool—the Partner Violence Screen (Feldhaus et al., 1997; Illangasekare et 
al., 2012), and the second using a clinician-driven, one-item interview screening 
(Siemieniuk et al., 2013). Neither measure of IPV included behavior specific items, but 




looked quite different than the urban population in which the SAVA syndemic 
framework was developed (Siemieniuk et al., 2013). The sample was racially mixed 
between Caucasian and Black first-generation immigrants from Sub-Saharan Africa, and 
rates of lifetime drug (19%) and alcohol abuse (3%) were relatively low.  
It should also be noted that in addition to IPV, other violence and trauma 
exposures including childhood physical or sexual abuse and community violence, have 
been linked to poorer measures of HIV adherence and immunologic function (Kacanek et 
al., 2016; Machtinger et al., 2012; Mugavero et al., 2009). These studies provide 
additional theoretical support for examining the short and long-term biologic and 
behavioral consequences of trauma in the context of HIV.   
Biologic Impacts of IPV and Trauma 
Research has shown alterations in inflammatory and immune functioning in 
women with current or past IPV experiences, with some evidence of recovery of these 
functions with the cessation of violence (Garcia-Linares et al., 2004; Out et al., 2012; 
Sanchez-Lorente et al., 2010; Shafran et al., 1996). In 2012, the first study to examine 
telomere shortening in women who reported a history of abuse was published 
(Humphreys et al., 2012). The authors found that women who reported a history of abuse 
had statistically significantly shorter telomeres than non-abused controls. Telomeres are a 
potential marker of “biologic age” and may be useful in discussing early morbidity and 
mortality (Eisenberg, 2011). Similar work examining telomere length following 
childhood traumas including experiencing or witnessing violence has found similar 
patterns of telomere shortening (Asok, Bernard, Roth, Rosen, & Dozier, 2013; Drury et 




Shalev et al., 2013).  
In addition to telomere length, dysregulation of inflammatory markers has also 
been linked to experiences of trauma. Associations with levels of serum and salivary 
biomarkers including cortisol, interferon- γ (IFN- γ), interleuken-6 (IL-6), tumor necrosis 
factor- α  (TNF-α) and C-reactive protein (CRP) have all been noted in previous work, 
however much of this research has been in relatively small samples and included multiple 
types of lifetime trauma so specific time courses related to acute or chronic sources of 
trauma and stress are not readily known (Gill et al., 2008; Inslicht et al., 2006; Keeshin et 
al., 2012; Newton et al., 2011; Out et al., 2012; Pico-Alfonso, 2005; Pico-Alfonso et al., 
2004; Punyadeera, 2012; Woods et al., 2005).  In order to examine the impact of trauma 
symptoms as well as experiences, Woods and colleagues (2005) published results that 
examined a framework of inflammatory immune responses of abused and non-abused 
women in relationship to their reported depression and PTSD symptoms. They found that 
the relationship between IPV and inflammatory immune response (as measured by serum 
IFN-γ level) was mediated by PTSD symptoms. These results provide opportunities not 
only for additional research, but also avenues for clinical intervention through 
identification and treatment of PTSD. A 2012 review of biomarkers and associated 
disease states related to exposure to violence and abuse covered a wide range of topics 
including chronic pain, cardiovascular diseases, irritable bowel syndrome and cancer, and 
concluded that the accumulation of data are suggestive of physiologic causes; however, 
limitations in the study’s design warrant a great deal of further research (Keeshin, 
Cronholm, & Strawn, 2012).  




PTSD and depression have both been linked to poorer outcomes for women living 
with HIV such as poorer adherence, late entry into care, more rapid HIV disease 
progression, and early death (Cruess et al., 2003; Gielen et al., 2005; Ickovics et al., 
2001; Ickovics et al., 2006; Illangasekare, 2011; Leserman, 2000, 2003; Machtinger et 
al., 2012). As PTSD and depression are common in both abused women and women 
living with HIV, it is important to address the ways in which these mental health 
disorders affect women’s treatment and disease progression (Gerber et al., 2005; Larson 
et al., 2005; Laughon et al., 2007; Machtinger et al., 2012; Perez & Johnson, 2008; 
Woods, 2000).  
Pace and Heim (2011) published a review of the psychoneuroimmunology of 
PTSD. Their review found that PTSD has been linked to a number of inflammatory and 
immune related medical conditions including cardiovascular disease and diabetes. The 
biologic pathways that link PTSD, chronic stress, inflammation, and immune system 
dysregulation have been examined in the context of HIV and IPV separately, but not in a 
co-morbid sample. Among women who have experienced IPV, PTSD has been shown to 
predict and mediate inflammatory dysfunction and to be associated with higher levels of 
the inflammatory markers (C-reactive protein, IFN-γ) (A. B. Woods et al., 2005; S. J. 
Woods et al., 2005).   
In HIV settings, PTSD is associated with poorer disease control including lower 
CD4 counts and higher viral loads (Ickovics et al., 2006; Machtinger et al., 2012; M. 
Mugavero et al., 2006; Schafer et al., 2012). A 2012 meta-analysis examined prevalence 
of PTSD and traumatic events in HIV-positive women (Machtinger et al, 2012). The 




a 55% prevalence rate in a pooled sample of over 2,200 HIV positive women. In six 
studies reviewed that presented recent PTSD data, prevalence was estimated at 30%. No 
data were presented on HIV disease progression in their analysis, however the alarming 
rate of IPV and PTSD in these pooled samples of women living with HIV (more than 8 
times the estimated general population prevalence (Kessler, Chiu, Demler, Merikangas, 
& Walters, 2005) indicate a desperate need for interventions.   
Depression has been linked to poorer HIV treatment outcomes, including poorer 
adherence to clinic visits and higher rates of HIV-related mortality (Chander et al., 2006; 
Ickovics et al., 2001; Ickovics et al., 2006; Ironson et al., 2005; Leserman, 2000, 2003). 
Strength of much of this work is that it has been longitudinal in nature; however it has 
been primarily conducted in MSM populations, to the exclusion of women.  A review by 
Leserman (2003) presented a summary of longitudinal studies that examined HIV disease 
progress and stress or depression. Only two of the 24 articles included adult women in 
their samples, one included male and female children while the remainder included only 
male samples.  Measures of stress presented in this review may also overlap with PTSD 
findings in other studies, as some studies measured stress as “traumatic life events.” A 
more recent review of the impacts of substance abuse, depression, severe mental illness 
on risk for HIV, and treatment adherence and outcomes found mixed results regarding the 
impact of depression on HIV treatment adherence, viral suppression and mortality with 
possible mediation of mortality risk through adherence (Chander et al., 2006).  
HIV, IPV and Substance Abuse 
Substance abuse is widely identified as a risk factor for HIV acquisition via 




exchanging sex for drugs or money. With ten percent of worldwide HIV infections 
attributed to injection drug use and 40% of people living with HIV in the United States 
reporting a history of illegal drug use (Aceijas et al., 2004; Burnam et al., 2001). In 
addition to increased risk of acquisition, substance abuse has been associated with 
decreased antiretroviral prescription, medication adherence, and greater numbers of 
AIDS defining illnesses (Moore et al., 2004; Wood et al., 2003, 2004). In a nationally 
representative sample, one in eight persons living with HIV screened positive for 
substance use disorders, and nearly 40% reported any prior use of drug use (exclusive of 
marijuana) (Andersen et al., 2006). Research on the intersections of IPV and substance 
abuse have found bidirectional effects, in which substance abuse is both a risk factor for 
abuse, but is also used as a coping mechanism to deal with previous or ongoing abuse 
(Burke et al., 2005; El-Bassel et al., 1998). Interventions for addressing the co-occurrence 
of substance abuse and HIV exist, and both the SAVA syndemic framework and a 
trauma-informed care approach have been used to review these interventions (Auerbach 
& Smith, 2015; Blankenship, Reinhard, Sherman, & El-Bassel, 2015; Brezing, Ferrara, & 
Freudenreich, 2015; Gilbert et al., 2015). These reviews found interventions to have 
impacts on individual behaviors (condom use, needle sharing, HIV testing), but noted the 
methodological difficulty in addressing and measuring change across multiple constructs 
within the SAVA syndemic framework (Blankenship et al., 2015; Brezing et al., 2015; 
Gilbert et al., 2015).  
IPV and Reproductive Coercion 
Sexual health in violent intimate relationships has historically been measured 




prevalence of sexually transmitted infections including HIV in this vulnerable population 
(Jewkes et al., 2010; Reynolds et al., 2007). More recently, pregnancy and lack of 
reproductive control has also been addressed in the IPV literature. A 2005 systematic 
review found that women who experience IPV also experience more unintended 
pregnancies than non-abused women; they also identified a relationship between 
abortions and IPV (Pallitto et al., 2005); while poorer pregnancy outcomes such as low 
birth weight and premature deliveries have been linked to IPV during pregnancy in meta-
analysis (Shah & Shah, 2010).   
Research with female survivors of IPV has recently defined reproductive coercion 
as a component of the controlling abuse that many experience in their relationship. 
Specifically, reproductive coercion is defined as a male partner’s pregnancy-promoting 
behaviors including sabotage of birth control methods, and use of verbal pressure or 
physical force to influence pregnancy timing or outcome (Miller, Jordan, et al., 2010;  
Miller & Silverman, 2010). Reproductive coercion has been linked to unintended 
pregnancies, poorer pregnancy outcomes, and increased sexually transmitted infections 
(Miller, Decker, McCauley, et al., 2010; Miller et al., 2011; Miller, Decker, Raj, et al., 
2010; Miller et al., 2007; Miller, Jordan, et al., 2010; Miller & Silverman, 2010; Miller, 
2006; Silverman et al., 2010; Thiel de Bocanegra et al., 2010).   
Reproductive coercion has not previously been examined in an HIV positive 
population, although its relationship to high-risk sexual behaviors, such as lack of 
condom use, and forced sex has a strong theoretical relationship to HIV acquisition and 
subsequent treatment adherence and disease progression (Miller, Decker, McCauley, et 




al., 2010).   
Conclusions 
The presented literature provides substantial evidence that the overlapping 
epidemics of HIV, IPV, substance abuse, and mental health conditions need to be 
examined in the context of a complex syndemic approach, and that biologic and 
behavioral factors may be contributing to the relationship between IPV and HIV disease 
progression. This dissertation study aims to address some of the gaps in the literature 
identified herein.  
Using a mixed-methods approach, this research examined the prevalence of IPV 
among adult women participating in HIV care in an urban HIV clinic setting. 
Associations between IPV, mental health, substance abuse, and HIV-related treatment 
adherence and disease outcomes were assessed using survey and medical records data. 
Women’s perceptions of the relationships between these syndemic issues and their HIV 
care were examined using qualitative methods. This study provides a foundation for 
designing, tailoring, and testing interventions to address the complex and interconnected 
issues of IPV, substance abuse, and mental health co-morbidities among women living 
with HIV.   
As nurses provide both direct and indirect care to persons experiencing both IPV 
and HIV, the results of this study will provide additional knowledge of the impact of IPV 
on HIV treatment outcomes.  The focus on both biologic and behavioral pathways 
through which IPV may impact HIV treatment markers will add to the sparse literature on 
the topic.  It is additionally hoped that examining adherence measures (missed visits and 




opportunities for future research on biologic pathways through which IPV may impact 
CD4 count, irrespective of adherence.  
Dissertation Organization 
There are five chapters in this dissertation. Chapter One provides background 
information relative to the prior literature, conceptual framework, purpose and aims of 
the dissertation.  
Chapter Two (Manuscript One) consists of a presentation of study safety 
protocols, specifically those designed to address risk of suicide or intimate partner 
homicide identified during the course of the study.  Relevant results from the safety 
protocols are included and recommendations for future research are presented.   
Chapter Three (Manuscript Two) presents results from Aims 1 and 2, including 
the prevalence of IPV and its associations with three HIV treatment and adherence 
outcomes (CD4 count, viral load and missed clinic visits).  An addendum to Chapter 
Three presents prevalence data for reproductive coercion. 
Chapter Four (Manuscript Three) includes results related to Aim 3.  Qualitative 
data regarding women’s perceptions of IPV, substance abuse, and mental health in 
relation to their HIV care are presented in the context of quantitative data collected to 
address Aims 1 and 2.  
Chapter Five examines the results of the study as a whole, including a fuller 






Aceijas, C., Stimson, G. V., Hickman, M., Rhodes, T. (2004). United Nations Reference 
Group on HIV/AIDS Prevention and Care Among IDU in Developing and 
Transitional Countries. Global overview of injecting drug use and HIV infection 
among injecting drug users. AIDS, 18(17), 2295-2303.  
Andersen, R., Bozzette, S., Shapiro, M. F., St. Clair, P. A., Morton, S. C., Crystal, S….  
Athey, L. A. (2006). Disparities in Care for HIV Patients: Results of the HCSUS 
Study. Santa Monica, CA: RAND Corporation. Available from 
http://www.rand.org/pubs/research_briefs/RB9171.html. 
Asok, A., Bernard, K., Roth, T. L., Rosen, J. B., & Dozier, M. (2013). Parental 
responsiveness moderates the association between early-life stress and reduced 
telomere length. Developmental Psychopathology, 25(3), 577-585. 
doi:10.1017/s0954579413000011 
Auerbach, J. D., & Smith, L. R. (2015). Theoretical foundations of research focused on 
HIV prevention among substance-involved women: A review of observational 
and intervention studies. Journal of Acquired Immune Deficiency Syndrome, 69 
Suppl 2, S146-154. doi:10.1097/qai.0000000000000658 
Baron, R. M., & Kenny, D. A. (1986). The moderator-mediator variable distinction in 
social psychological research: Conceptual, strategic, and statistical considerations. 
Journal of Personality and Social Psychology, 51(6), 1173-1182.  
Black, M. C., Basile, K. C., Breiding, M. J., Smith, S. G., Walters, M. L., Merrick, M. T., 
. . . Stevens, M. R. (2011). The national intimate partner and sexual violence 




and Prevention.  
Blackstock, O. J., Blank, A. E., Fletcher, J. J., Verdecias, N., & Cunningham, C. O. 
(2015). Considering care-seeking behaviors reveals important differences among 
HIV-positive women not engaged in care: Implications for intervention. AIDS 
Patient Care and STDs, 29 Suppl 1, S20-26. doi:10.1089/apc.2014.0271 
Blank, A. E., Fletcher, J., Verdecias, N., Garcia, I., Blackstock, O., & Cunningham, C. 
(2015). Factors associated with retention and viral suppression among a cohort of 
HIV+ women of color. AIDS Patient Care and STDs, 29 Suppl 1, S27-35. 
doi:10.1089/apc.2014.0272 
Blankenship, K. M., Reinhard, E., Sherman, S. G., & El-Bassel, N. (2015). Structural 
interventions for HIV prevention among women who use drugs: A global 
perspective. Journal of Acquired Immune Deficiency Syndrome, 69 Suppl 2, 
S140-145. doi:10.1097/qai.0000000000000638 
Brezing, C., Ferrara, M., & Freudenreich, O. (2015). The syndemic illness of HIV and 
trauma: Implications for a trauma-informed model of care. Psychosomatics, 56(2), 
107-118. doi:10.1016/j.psym.2014.10.006 
Burke, J. G., Thieman, L. K., Gielen, A. C., O'Campo, P., & McDonnell, K. A. (2005). 
Intimate partner violence, substance use, and HIV among low-income women: 
Taking a closer look. Violence Against Women, 11(9), 1140-1161. doi:11/9/1140 
[pii]10.1177/1077801205276943 
Burnam, M. A., Bing, E. G., Morton, S. C., Sherbourne, C., Fleishman, J. A., London, A. 
S., . . . Shapiro, M. F. (2001). Use of mental health and substance abuse treatment 




Psychiatry, 58(8), 729-736.  
Campbell, J., Jones, A. S., Dienemann, J., Kub, J., Schollenberger, J., O'Campo, P., . . . 
Wynne, C. (2002). Intimate partner violence and physical health consequences. 
Archives of Internal Medicine, 162(10), 1157-1163.  
Campbell, J. C., Baty, M. L., Ghandour, R. M., Stockman, J. K., Francisco, L., & 
Wagman, J. (2008). The intersection of intimate partner violence against women 
and HIV/AIDS: A review. International Journal of Injury Control and Safety 
Promotion, 15(4), 221-231. doi:10.1080/17457300802423224 
Campbell, J. C., Lucea, M. B., Stockman, J. K., & Draughon, J. E. (2013). Forced sex 
and HIV risk in violent relationships. American Journal of Reproductive 
Immunology, 69 Suppl 1, 41-44. doi:10.1111/aji.12026 
Campbell, J. C., Woods, A. B., Chouaf, K. L., & Parker, B. (2000). Reproductive health 
consequences of intimate partner violence: A nursing research review. Clinical 
Nursing Research, 9(3), 217-237.  
Centers for Disease Control and Prevention. (2012). HIV Surveillance Report, 2010. 
Atlanta, GA: Author.   
Chander, G., Himelhoch, S., & Moore, R. D. (2006). Substance abuse and psychiatric 
disorders in HIV-positive patients: Epidemiology and impact on antiretroviral 
therapy. Drugs, 66(6), 769-789.  
Chesney, M. A. (2006). The elusive gold standard. Future perspectives for HIV 
adherence assessment and intervention. Journal of Acquired Immune Deficiency 
Syndrome, 43 Suppl 1, S149-155. doi:10.1097/01.qai.0000243112.91293.26 




systematic review. Trauma Violence Abuse, 8(2), 149-177. doi:8/2/149 [pii] 
10.1177/1524838007301162 
Cruess, D. G., Petitto, J. M., Leserman, J., Douglas, S. D., Gettes, D. R., Ten Have, T. R., 
& Evans, D. L. (2003). Depression and HIV infection: Impact on immune 
function and disease progression. CNS Spectrum, 8(1), 52-58.  
Draughon, J. E. (2012). Sexual assault injuries and increased risk of HIV transmission. 
Advanced Emergency Nursing Journal, 34(1), 82-87. 
doi:10.1097/TME.0b013e3182439e1a 
Drury, S. S., Mabile, E., Brett, Z. H., Esteves, K., Jones, E., Shirtcliff, E. A., & Theall, K. 
P. (2014). The association of telomere length with family violence and disruption. 
Pediatrics, 134(1), e128-137. doi:10.1542/peds.2013-3415 
Dunkle, K. L., Jewkes, R. K., Brown, H. C., Gray, G. E., McIntryre, J. A., & Harlow, S. 
D. (2004). Gender-based violence, relationship power, and risk of HIV infection 
in women attending antenatal clinics in South Africa. Lancet, 363(9419), 1415-
1421. doi:10.1016/S0140-6736(04)16098-4  
Eisenberg, D. T. (2011). An evolutionary review of human telomere biology: The thrifty 
telomere hypothesis and notes on potential adaptive paternal effects. American 
Journal of Human Biology, 23(2), 149-167. doi:10.1002/ajhb.21127 
El-Bassel, N., Gilbert, L., Krishnan, S., Schilling, R., Gaeta, T., Purpura, S., & Witte, S. 
S. (1998). Partner violence and sexual HIV-risk behaviors among women in an 
inner-city emergency department. Violence and Victims, 13(4), 377-393.  
Ellsberg, M., Jansen, H. A., Heise, L., Watts, C. H., & Garcia-Moreno, C. (2008). 




multi-country study on women's health and domestic violence: An observational 
study. Lancet, 371(9619), 1165-1172. doi:S0140-6736(08)60522-X [pii] 
10.1016/S0140-6736(08)60522-X 
Engel, G. (1977). The need for a new medical model: A challenge for biomedicine. 
Science, 196, 129-136. doi:doi:10.1126/science.847460 
Espino, S. R., Fletcher, J., Gonzalez, M., Precht, A., Xavier, J., & Matoff-Stepp, S. 
(2015). Violence screening and viral load suppression among HIV-positive 
women of color. AIDS Patient Care STDS, 29 Suppl 1, S36-41. 
doi:10.1089/apc.2014.0275 
Fagundes, C. P., Glaser, R., & Kiecolt-Glaser, J. K. (2013). Stressful early life 
experiences and immune dysregulation across the lifespan. Brain Behavior and 
Immunity, 27(1), 8-12. doi:10.1016/j.bbi.2012.06.014 
Feldhaus, K. M., Koziol-McLain, J., Amsbury, H. L., Norton, I. M., Lowenstein, S. R., & 
Abbott, J. T. (1997). Accuracy of 3 brief screening questions for detecting partner 
violence in the emergency department. Journal of American Medical Association, 
277(17), 1357-1361.  
Garcia-Linares, M. I., Sanchez-Lorente, S., Coe, C. L., & Martinez, M. (2004). Intimate 
male partner violence impairs immune control over herpes simplex virus type 1 in 
physically and psychologically abused women. Psychosomatic Medicine, 66(6), 
965-972. doi:10.1097/01.psy.0000145820.90041.c0 
Garcia-Moreno, C., & Watts, C. (2000). Violence against women: Its importance for 
HIV/AIDS. AIDS, 14 Suppl 3, S253-265.  




community hospital clinicians document a positive screen for intimate partner 
violence: A cross-sectional study. BMC Family Practice, 6, 48. doi:10.1186/1471-
2296-6-48 
Ghosh, M., Rodriguez-Garcia, M., & Wira, C. R. (2013). Immunobiology of genital tract 
trauma: Endocrine regulation of HIV acquisition in women following sexual 
assault or genital tract mutilation. American Journal of Reproductive 
Immunology, 69 Suppl 1, 51-60. doi:10.1111/aji.12027 
Gielen, A. C., Ghandour, R. M., Burke, J. G., Mahoney, P., McDonnell, K. A., & 
O'Campo, P. (2007). HIV/AIDS and intimate partner violence: Intersecting 
women's health issues in the United States. Trauma Violence Abuse, 8(2), 178-
198. doi:8/2/178 [pii] 10.1177/1524838007301476 
Gielen, A. C., McDonnell, K. A., O'Campo, P. J., & Burke, J. G. (2005). Suicide risk and 
mental health indicators: Do they differ by abuse and HIV status? Women's 
Health Issues, 15(2), 89-95. doi:S1049-3867(04)00135-5 
[pii]10.1016/j.whi.2004.12.004 
Gilbert, L., Raj, A., Hien, D., Stockman, J., Terlikbayeva, A., & Wyatt, G. (2015). 
Targeting the SAVA (substance abuse, violence, and aIDS) syndemic among 
women and girls: A global review of epidemiology and integrated interventions. 
Journal of Acquired Immune Deficiency Syndrome, 69 Suppl 2, S118-127. 
doi:10.1097/qai.0000000000000626 
Gill, J., Vythilingam, M., & Page, G. G. (2008). Low cortisol, high DHEA, and high 
levels of stimulated TNF-alpha, and IL-6 in women with PTSD. Journal of 




Gonzalez-Guarda, R. M., Florom-Smith, A. L., & Thomas, T. (2011). A syndemic model 
of substance abuse, intimate partner violence, HIV infection, and mental health 
among Hispanics. Public Health Nursing, 28(4), 366-378. doi:10.1111/j.1525-
1446.2010.00928.x 
Gonzalez-Guarda, R. M., McCabe, B. E., Florom-Smith, A., Cianelli, R., & Peragallo, N. 
(2011). Substance abuse, violence, HIV, and depression: An underlying syndemic 
factor among Latinas. Nursing Research, 60(3), 182-189. 
doi:10.1097/NNR.0b013e318216d5f4 
Gonzalez-Guarda, R. M., Peragallo, N., Urrutia, M. T., Vasquez, E. P., & Mitrani, V. B. 
(2008). HIV risks, substance abuse, and intimate partner violence among Hispanic 
women and their intimate partners. Journal of the Association of Nurses in AIDS 
Care, 19(4), 252-266. doi:10.1016/j.jana.2008.04.001 
Hatcher, A. M., Smout, E. M., Turan, J. M., Christofides, N., & Stockl, H. (2015). 
Intimate partner violence and engagement in HIV care and treatment among 
women: A systematic review and meta-analysis. AIDS, 29(16), 2183-2194. 
doi:10.1097/QAD.0000000000000842 
Humphreys, J., Epel, E. S., Cooper, B. A., Lin, J., Blackburn, E. H., & Lee, K. A. (2012). 
Telomere shortening in formerly abused and never abused women. Biology 
Research in Nursing, 14(2), 115-123. doi:10.1177/1099800411398479 
Ickovics, J. R., Hamburger, M. E., Vlahov, D., Schoenbaum, E. E., Schuman, P., Boland, 
R. J., . . . Group, H. I. V. E. R. S. (2001). Mortality, CD4 cell count decline, and 
depressive symptoms among HIV-seropositive women: Longitudinal analysis 




Association, 285(11), 1466-1474.  
Ickovics, J. R., Milan, S., Boland, R., Schoenbaum, E., Schuman, P., Vlahov, D., & the 
HIV Epidemiology Research Study Group (2006). Psychological resources 
protect health: 5-year survival and immune function among HIV-infected women 
from four US cities. AIDS (London, England), 20(14), 1851-1860. 
doi:10.1097/01.aids.0000244204.95758.15 
Illangasekare. (2011). The role of the intimate partner violence, HIV and substance abuse 
syndemic in women's mental health. (Doctor of Philosophy Dissertation), Johns 
Hopkins University, Baltimore, Maryland.    
Illangasekare, S., Tello, M., Hutton, H., Moore, R., Anderson, J., Baron, J., & Chander, 
G. (2012). Clinical and mental health correlates and risk factors for intimate 
partner violence among HIV-positive women in an inner-city HIV clinic. 
Women's Health Issues, 22(6), e563-569. doi:10.1016/j.whi.2012.07.007 
Inslicht, S. S., Marmar, C. R., Neylan, T. C., Metzler, T. J., Hart, S. L., Otte, C., . . . 
Baum, A. (2006). Increased cortisol in women with intimate partner violence-
related posttraumatic stress disorder. Psychoneuroendocrinology, 31(7), 825-838. 
doi:10.1016/j.psyneuen.2006.03.007 
Interagency Federal Working Group. (2013). Addressing the intersection of HIV/AIDS 
violence against women and girls and gender-related health disparities. 
Washington, DC: The White House. 
Ironson, G., Weiss, S., Lydston, D., Ishii, M., Jones, D., Asthana, D., . . . Antoni, M. 
(2005). The impact of improved self-efficacy on HIV viral load and distress in 




AIDS Care, 17(2), 222-236. doi:10.1080/09540120512331326365 
Jewkes, R. K., Dunkle, K., Nduna, M., & Shai, N. (2010). Intimate partner violence, 
relationship power inequity, and incidence of HIV infection in young women in 
South Africa: A cohort study. Lancet, 376(9734), 41-48. doi:S0140-
6736(10)60548-X [pii]10.1016/S0140-6736(10)60548-X 
Joint United Nations Programme on HIV and AIDS. (2012). Global Report: UNAIDS 
report on the global AIDS epidemic 2010. Geneva: Author.  
Kacanek, D., Malee, K., Mellins, C. A., Tassiopoulos, K., Smith, R., Grant, M., . . . Puga, 
A. (2016). Exposure to violence and virologic and immunological outcomes 
among youth with perinatal HIV in the pediatric HIV/AIDS cohort study. Journal 
of Adolescent Health. doi:10.1016/j.jadohealth.2016.03.004 
Kalokhe, A. S., Paranjape, A., Bell, C. E., Cardenas, G. A., Kuper, T., Metsch, L. R., & 
del Rio, C. (2012). Intimate partner violence among HIV-infected crack cocaine 
users. AIDS Patient Care and STDs, 26(4), 234-240. doi:10.1089/apc.2011.0275 
Kananen, L., Surakka, I., Pirkola, S., Suvisaari, J., Lonnqvist, J., Peltonen, L., . . . 
Hovatta, I. (2010). Childhood adversities are associated with shorter telomere 
length at adult age both in individuals with an anxiety disorder and controls. PLoS 
One, 5(5), e10826. doi:10.1371/journal.pone.0010826 
Keeshin, B. R., Cronholm, P. F., & Strawn, J. R. (2012). Physiologic changes associated 
with violence and abuse exposure: An examination of related medical conditions. 
Trauma Violence Abuse, 13(1), 41-56. doi:10.1177/1524838011426152 
Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). 




National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 
617-627. doi:10.1001/archpsyc.62.6.617 
Krug, E. G., Mercy, J. A., Dahlberg, L. L., & Zwi, A. B. (2002). World report on 
violence and health. Biomedica, 22 Suppl 2, 327-336.  
Larson, M. J., Miller, L., Becker, M., Richardson, E., Kammerer, N., Thom, J., . . . 
Savage, A. (2005). Physical health burdens of women with trauma histories and 
co-occurring substance abuse and mental disorders. The Journal of Behavioral 
Health Services & Research, 32(2), 128-140.  
Laughon, K., Gielen, A. C., Campbell, J. C., Burke, J., McDonnell, K., & O'Campo, P. 
(2007). The relationships among sexually transmitted infection, depression, and 
lifetime violence in a sample of predominantly African American women. 
Research in Nursing & Health, 30(4), 413-428.  
Leserman, J. (2000). The effects of depression, stressful life events, social support, and 
coping on the progression of HIV infection. Current Psychiatry Reports, 2(6), 
495-502.  
Leserman, J. (2003). HIV disease progression: Depression, stress, and possible 
mechanisms. Biologic Psychiatry, 54(3), 295-306. doi:S0006322303003238 [pii] 
Lopez, E. J., Jones, D. L., Villar-Loubet, O. M., Arheart, K. L., & Weiss, S. M. (2010). 
Violence, coping, and consistent medication adherence in HIV-positive couples. 
AIDS Education & Prevention, 22(1), 61-68. doi:10.1521/aeap.2010.22.1.61 
Machtinger, E. L., Wilson, T. C., Haberer, J. E., & Weiss, D. S. (2012). Psychological 





Malow, R., Devieux, J. G., Stein, J. A., Rosenberg, R., Jean-Gilles, M., Attonito, J., . . . 
Pape, J. W. (2013). Depression, substance abuse and other contextual predictors 
of adherence to antiretroviral therapy (ART) among Haitians. AIDS and Behavior, 
17(4), 1221-1230. doi:10.1007/s10461-012-0400-1 
Maman, S., Campbell, J., Sweat, M. D., & Gielen, A. C. (2000). The intersections of HIV 
and violence: Directions for future research and interventions. Social Science & 
Medicine (1982), 50(4), 459-478.  
Miller, E., Decker, M. R., McCauley, H. L., Tancredi, D. J., Levenson, R. R., Waldman, 
J., . . . Silverman, J. G. (2010). Pregnancy coercion, intimate partner violence and 
unintended pregnancy. Contraception, 81(4), 316-322. 
doi:10.1016/j.contraception.2009.12.004 
Miller, E., Decker, M. R., McCauley, H. L., Tancredi, D. J., Levenson, R. R., Waldman, 
J., . . . Silverman, J. G. (2011). A family planning clinic partner violence 
intervention to reduce risk associated with reproductive coercion. Contraception, 
83(3), 274-280.  
Miller, E., Decker, M. R., Raj, A., Reed, E., Marable, D., & Silverman, J. G. (2010). 
Intimate partner violence and health care-seeking patterns among female users of 
urban adolescent clinics. Maternal and Child Health Journal, 14(6), 910-917. 
doi:10.1007/s10995-009-0520-z 
Miller, E., Decker, M. R., Reed, E., Raj, A., Hathaway, J. E., & Silverman, J. G. (2007). 
Male partner pregnancy-promoting behaviors and adolescent partner violence: 
Findings from a qualitative study with adolescent females. Ambulatory Pediatrics, 




Miller, E., Jordan, B., Levenson, R., & Silverman, J. G. (2010). Reproductive coercion: 
Connecting the dots between partner violence and unintended pregnancy. 
Contraception, 81(6), 457-459.  
Miller, E., & Silverman, J. G. (2010). Reproductive coercion and partner violence: 
Implications for clinical assessment of unintended pregnancy. Expert Review of 
Obstetrics & Gynecology, 5(5), 511-515. doi:10.1586/eog.10.44 
Miller, J. (2006). A specification of the types of intimate partner violence experienced by 
women in the general population. Violence Against Women, 12(12), 1105-1131.    
Moffitt, T. E. (2013). Childhood exposure to violence and lifelong health: Clinical 
intervention science and stress-biology research join forces. Developmental 
Psychopathology, 25(4 Pt 2), 1619-1634. doi:10.1017/s0954579413000801 
Moore, R. D., Keruly, J. C., & Chaisson, R. E. (2004). Differences in HIV disease 
progression by injecting drug use in HIV-infected persons in care. Journal of 
Acquired Immune Deficiency Syndrome, 35(1), 46-51.  
Mugavero, M., Ostermann, J., Whetten, K., Leserman, J., Swartz, M., Stangl, D., & 
Thielman, N. (2006). Barriers to antiretroviral adherence: The importance of 
depression, abuse, and other traumatic events. AIDS Patient Care STDS, 20(6), 
418-428. doi:10.1089/apc.2006.20.418 
Mugavero, M. J., Lin, H. Y., Willig, J. H., Westfall, A. O., Ulett, K. B., Routman, J. S., . . 
. Allison, J. J. (2009). Missed visits and mortality among patients establishing 
initial outpatient HIV treatment. Clinical Infectious Disease, 48(2), 248-256. 
doi:10.1086/595705 




Fleming, K. N. (2011). Markers of inflammation in midlife women with intimate 
partner violence histories. Journal of Women's Health, 20(12), 1871-1880. 
doi:10.1089/jwh.2011.2788 
Nieuwkerk, P. T., & Oort, F. J. (2005). Self-reported adherence to antiretroviral therapy 
for HIV-1 infection and virologic treatment response: A meta-analysis. Journal of 
Acquired Immune Deficiency Syndrome, 38(4), 445-448.  
Out, D., Hall, R. J., Granger, D. A., Page, G. G., & Woods, S. J. (2012). Assessing 
salivary C-reactive protein: Longitudinal associations with systemic inflammation 
and cardiovascular disease risk in women exposed to intimate partner violence. 
Brain Behavior and Immunity, 26(4), 543-551. doi:10.1016/j.bbi.2012.01.019 
Pace, T. W., & Heim, C. M. (2011). A short review on the psychoneuroimmunology of 
posttraumatic stress disorder: From risk factors to medical comorbidities. Brain 
Behavior and Immunity, 25(1), 6-13. doi: 10.1016/j.bbi.2010.10.003 
Pallitto, C. C., Campbell, J. C., & O'Campo, P. (2005). Is intimate partner violence 
associated with unintended pregnancy? A review of the literature. Trauma, 
Violence & Abuse, 6(3), 217-235. doi:10.1177/1524838005277441 
Perez, S., & Johnson, D. M. (2008). PTSD compromises battered women's future safety. 
Journal of Interpersonal Violence, 23(5), 635-651. doi:0886260507313528 
[pii]10.1177/0886260507313528 
Pico-Alfonso, M. A. (2005). Psychological intimate partner violence: The major predictor 
of posttraumatic stress disorder in abused women. Neuroscience and Biobehavior 
Reviews, 29(1), 181-193. doi:10.1016/j.neubiorev.2004.08.010 




M. (2004). Changes in cortisol and dehydroepiandrosterone in women victims of 
physical and psychological intimate partner violence. Biologic Psychiatry, 56(4), 
233-240. doi:10.1016/j.biopsych.2004.06.001 
Punyadeera, C. (2012). Human saliva as a tool to investigate intimate partner violence. 
Brain Behavior and Immunity, 26(4), 541-542. doi:10.1016/j.bbi.2012.02.006 
Ramachandran, S., Yonas, M. A., Silvestre, A. J., & Burke, J. G. (2010). Intimate partner 
violence among HIV-positive persons in an urban clinic. AIDS Care, 22(12), 
1536-1543. doi:10.1080/09540121.2010.482199 
Reynolds, N. R., Sun, J., Nagaraja, H. N., Gifford, A. L., Wu, A. W., & Chesney, M. A. 
(2007). Optimizing measurement of self-reported adherence with the ACTG 
adherence questionnaire: A cross-protocol analysis. Journal of Acquired Immune 
Deficiency Syndrome, 46(4), 402-409.  
Romero-Daza, N., Weeks, M., & Singer, M. (2003). "Nobody gives a damn if I live or 
die": Violence, drugs, and street-level prostitution in inner-city Hartford, 
Connecticut. Medical Anthropology, 22(3), 233-259. 
doi:10.1080/01459740306770 
Rose, R. C., House, A. S., Stepleman, L.M. (2010). Intimate partner violence and its 
effects on the health of African American HIV-positive women. Psychological 
Trauma: Theory, Research, Practice and Policy, 2 311-317.. 
Saltzman, L. E., Fanslow, J. L., McMahon, P. M., & Shelley, G. A. (2002). Intimate 
partner violence surveillance: Uniform definitions and recommended data 
elements. Atlanta, GA: Centers for Disease Control and Prevention 




immune control over herpes simplex virus type 1 in female victims of intimate 
partner violence. Psychosomatic Medicine, 72(1), 97-106. 
doi:10.1097/PSY.0b013e3181c5080a 
Schafer, K. R., Brant, J., Gupta, S., Thorpe, J., Winstead-Derlega, C., Pinkerton, R., . . . 
Dillingham, R. (2012). Intimate partner violence: A predictor of worse HIV 
outcomes and engagement in care. AIDS Patient Care and STDs, 26(6), 356-365. 
doi:10.1089/apc.2011.0409 
Shafran, S. D., Singer, J., Zarowny, D. P., Phillips, P., Salit, I., Walmsley, S. L., . . . 
Tsoukas, C. M. (1996). A comparison of two regimens for the treatment of 
mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and 
clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. 
Canadian HIV Trials Network Protocol 010 Study Group. New England Journal 
of Medicine, 335(6), 377-383. doi:10.1056/NEJM199608083350602 
Shah, P. S., & Shah, J. (2010). Maternal exposure to domestic violence and pregnancy 
and birth outcomes: A systematic review and meta-analyses. Journal of Women's 
Health, 19(11), 2017-2031. doi:10.1089/jwh.2010.2051 
Shalev, I., Moffitt, T. E., Sugden, K., Williams, B., Houts, R. M., Danese, A., . . . Caspi, 
A. (2013). Exposure to violence during childhood is associated with telomere 
erosion from 5 to 10 years of age: A longitudinal study. Molecular Psychiatry, 
18(5), 576-581. doi:10.1038/mp.2012.32 
Siemieniuk, R. A., Krentz, H. B., Miller, P., Woodman, K., Ko, K., & Gill, M. J. (2013). 
The clinical implications of high rates of intimate partner violence against HIV-





Silverman, J. G., Decker, M. R., McCauley, H. L., Gupta, J., Miller, E., Raj, A., & 
Goldberg, A. B. (2010). Male perpetration of intimate partner violence and 
involvement in abortions and abortion-related conflict. American Journal of 
Public Health, 100(8), 1415-1417. doi:10.2105/ajph.2009.173393 
Silverman, J. G., McCauley, H. L., Decker, M. R., Miller, E., Reed, E., & Raj, A. (2011). 
Coercive forms of sexual risk and associated violence perpetrated by male 
partners of female adolescents. Perspectives on Sexual and Reproductive Health, 
43(1), 60-65. doi:10.1363/4306011; 10.1363/4306011 
Singer, M. (1994). AIDS and the health crisis of the U.S. urban poor: The perspective of 
critical medical anthropology. Social Science & Medicine, 39(7), 931-948.  
Singer, M. (1996). A dose of drugs, a touch of violence, a case of AIDS: Conceptualizing 
the SAVA syndemic. Free Inquiry in Creative Sociology, 24(2), 99-110.  
Singer, M. (2006). Syndemics (S. Boslaugh Ed.). Thousand Oaks, CA: Sage Publications, 
Inc. 
Singer, M. (2009). Introduction to syndemics: A systems approach to public and 
community health. San Francisco, CA: Jossey-Bass. 
Sullivan, K. A., Messer, L. C., & Quinlivan, E. B. (2015). Substance abuse, violence, and 
HIV/AIDS (SAVA) syndemic effects on viral suppression among HIV positive 
women of color. AIDS Patient Care STDS, 29 Suppl 1, S42-48. 
doi:10.1089/apc.2014.0278 
Teitelman, A. M., Ratcliffe, S. J., Dichter, M. E., & Sullivan, C. M. (2008). Recent and 




Obstetrics Gynecology Neonatal Nursing, 37(2), 219-227. doi:JOGN231 [pii] 
10.1111/j.1552-6909.2008.00231.x 
Teitelman, A. M., Seloilwe, E. S., & Campbell, J. C. (2009). Voices from the frontlines: 
The epidemics of HIV/AIDS and violence among women and girls. Health Care 
for Women International, 30(3), 184-194. doi:10.1080/07399330902739239 
Thiel de Bocanegra, H., Rostovtseva, D. P., Khera, S., & Godhwani, N. (2010). Birth 
control sabotage and forced sex: Experiences reported by women in domestic 
violence shelters. Violence Against Women, 16(5), 601-612. doi:16/5/601 [pii] 
10.1177/1077801210366965 
Trimble, D. D., Nava, A., & McFarlane, J. (2013). Intimate partner violence and 
antiretroviral adherence among women receiving care in an urban southeastern 
Texas HIV clinic. Journal of the Association of Nurses in AIDS Care, 24(4), 331-
340. doi:10.1016/j.jana.2013.02.006 
Wood, E., Montaner, J. S., Yip, B., Tyndall, M. W., Schechter, M. T., O'Shaughnessy, M. 
V., & Hogg, R. S. (2003). Adherence and plasma HIV RNA responses to highly 
active antiretroviral therapy among HIV-1 infected injection drug users. Canadian 
Medical Association Journal, 169(7), 656-661.  
Wood, E., Montaner, J. S., Yip, B., Tyndall, M. W., Schechter, M. T., O'Shaughnessy, M. 
V., & Hogg, R. S. (2004). Adherence to antiretroviral therapy and CD4 T-cell 
count responses among HIV-infected injection drug users. Antiviral Therapy, 
9(2), 229-235.  
Woods, A. B., Page, G. G., O'Campo, P., Pugh, L. C., Ford, D., & Campbell, J. C. 




relationship of intimate partner violence and IFN-gamma levels. American 
Journal of Community Psychology, 36(1-2), 159-175. doi:10.1007/s10464-005-
6240-7 
Woods, S. J. (2000). Prevalence and patterns of posttraumatic stress disorder in abused 
and postabused women. Issues in Mental Health Nursing, 21(3), 309-324.  
Woods, S. J., Wineman, N. M., Page, G. G., Hall, R. J., Alexander, T. S., & Campbell, J. 
C. (2005). Predicting immune status in women from PTSD and childhood and 


















Conducting Clinically-Based Research in Vulnerable Populations: Safety Protocols from 









Jocelyn C. Anderson, PhD (c), MSN, RN, FNE-A 
Nancy Glass, PhD, MPH, RN, FAAN 
Jacquelyn Campbell, PhD, RN, FAAN 
 






Background: Maintaining participant safety is of utmost importance during 
research involving participants who have experienced intimate partner violence. Limited 
specific guidance or results from safety protocols are available in the literature, 
particularly information related to use of technology-based approaches to informed 
consent, data collection, and contacting participants during the course of a study.   
Methods: We present details of a study safety protocol developed and utilized in a 
study of IPV in a sample of women receiving care at an urban HIV specialty clinic. The 
protocol includes information related to the use of various technological strategies to 
promote safety and allow autonomy in participant decision-making through the research 
process. These included voice-over-internet-protocol telephone numbers, iPad-based 
screening and data collection, computer administered risk messaging, and research team 
notifications. Specific protocols for management of participants at risk for suicide or 
intimate partner homicide are also discussed, and include results from participants’ risk-
sharing preferences in our sample.  
Discussion: Use of technology and partnership with clinic staff helped to provide 
an environment whereas research regarding IPV could be conducted without undue 
burden or risk to participants. Utilizing a computerized survey administration provided a 
variety of practical and safety benefits. The majority of participants who screened into 
high risk categories for suicide or intimate partner homicide did not choose to have their 
results shared with their health care providers, indicating the importance of allowing 





In 1990, Parker and Ulrich presented what was arguably the first published 
guidance on safety protocols for intimate partner violence (IPV) research. Since that time, 
additions to the literature have presented more challenges and strategies for the safe and 
ethical conduct of IPV research (Btoush & Campbell, 2009; Ellsberg & Heise, 2005; 
Sullivan & Cain, 2004). Most commonly these include recommendations around ensuring 
safely when contacting and interacting with participants, maintaining participant 
confidentiality, and issues related to disclosures of information such as mandatory 
reporting laws and Certificates of Confidentiality (Btoush & Campbell, 2009; Parker & 
Ulrich, 1990; Sullivan & Cain, 2004). These recommendations and other ethical 
discussions about IPV research revolves around participants’ autonomy in decision-
making regarding not only their participation in research, but also how research 
information will be shared as a result of voluntary or mandatory reporting policies that 
are part of research protocols (Btoush & Campbell, 2009; Fontes, 2004; Sullivan & Cain, 
2004). The more globally focused World Health Organization guidelines provide 
strategies to maintain safety during household level studies, including IPV-related 
questions for one respondent per household (Ellsberg & Heise, 2005). While the risks and 
benefits of IPV related research have been previously discussed in the literature, it is rare 
to see reporting of adverse events resulting from IPV research in the literature. The few 
studies that have presented data related to psychological harms from IPV and other 
trauma related research have not shown significant adverse effects (Fontes, 2004; Griffin, 
Resick, Waldrop, & Mechanic, 2003; Walker, Newman, Koss, & Bernstein, 1997). 
Relatively low rates of distress have been reported in these studies (Griffin et al., 2003; 
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Newman & Kaloupek, 2004; Walker et al., 1997; Yeater, Miller, Rinehart, & Nason, 
2012).  When asked, participants in IPV and other interpersonal trauma related research 
commonly report that they would be willing to participate again and have reported 
unintended benefits, such as being able to speak with someone about the violence or 
being referred to resources as part of a research study (Griffin et al., 2003; Walker et al., 
1997). A 2012 study found that when comparing experiences of college students who 
answered a series of trauma and sexual behavior questionnaires to a group that completed 
a series of cognitive tests, participants in both groups reported similarly low amounts of 
distress; thus, the authors concluded that trauma-related survey research meets the 
definition of minimal risk (Yeater et al., 2012).  One major gap in the published strategies 
is a lack of attention to use of technology throughout the research process.  Yet when 
Institutional Review Boards and scientific review committees consider research involving 
victims of abuse, the potential risks of increasing violence, homicide, and participants’ 
distress are all issues of vital concern. It is important to balance the sometimes 
unpredictable risks of participating in IPV related research and the agency and autonomy 
of women who are managing their risks daily and can often provide unique, creative, and 
individual strategies to minimize risks in the context of their life.    
Regarding technology use in IPV research, the publication by Btoush and 
Campbell (2009) begins to discuss password-protection and encryption of study data, 
which has since become standard data handling practice across clinical and research 
institutions (The Health Insurance Portability and Accountability Act of 1996 [HIPAA], 
1996; Department of Health and Human Services [DHHS], 1991).  In addition to 
standardization of digital data storage procedures, a number of internet, smartphone, and 
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computer-based strategies have been utilized in research and clinical care as well as in 
trauma and IPV-related research (Bloom et al., 2014; Garabedian, Ross-Degnan, & 
Wharam, 2015; Gilbert et al., 2016; Glass et al., 2015; Hegarty et al., 2015; Marcano 
Belisario et al., 2015). A second notable gap is the lack of specific guidance regarding 
determining and responding to individual participants’ risk levels and preferences for 
referrals or information. To begin to address these gaps, we present examples of 
strategies used to maintain research participants’ safety and autonomy from a study of 
IPV and health outcomes among women conducted in an urban HIV clinic. We will 
highlight steps taken to promote participants’ safety and autonomy throughout the study 
including the use of technology-based strategies for data collection and management.  
Study Overview 
The safety protocols and results presented herein are from a study designed to 
obtain information regarding the prevalence of IPV among women attending an urban 
HIV clinic. All participants were women living with HIV and obtaining HIV care 
services from the clinic where data were collected. In addition to IPV, this study collected 
self-report data regarding mental health and substance abuse topics. In total, 259 women 
consented to participation, two voluntarily withdrew from the study before completing 
survey measures, and 18 were removed from the dataset during medical records review 
because: 1) they were duplicate participants, or 2) they did not meet the study’s eligibility 
criteria (i.e., not HIV positive, not receiving HIV care at the study clinic). The study 
participants largely resembled the overall clinic population with a median age of 50 years 
(range 24–66).  They were primarily black (86.6%), not working outside the home 
(86.4%) and over half (57.3%) of the participants had completed high school or a GED. 
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Setting the Stage: Preparation and Training 
Clinic Partnership 
A key component of any study set in a clinical environment is establishing a 
relationship with the partner organization. This is particularly important to ensure safety 
and confidentiality for studies involving vulnerable persons, of which abused women are 
an example because of already existing power differentials from structures and systems 
and personal positions (e.g., health care provider, health care system, and patient power 
differentials) and for studies involving information about potentially stigmatizing 
information such as intimate partner violence, mental health problems, or substance 
abuse (DHHS, 1991)  For the purposes of this study, the relationship began during the 
early planning phases of the project and included members of the research team spending 
time in the partner clinic site, observing the clinic’s flow, and meeting members of the 
clinic staff to prioritize safety and confidentiality in recruitment, consent and data 
collection.  The partnership with the clinic was reflected in a number of protocol items 
that are discussed in subsequent sections.  
iPad-Based Data Collection 
The second choice made early in the study design process was the use of iPad-
based data collection.  This method held many benefits both practically and from a safety 
perspective.  In the busy clinic setting where there were no consistently available areas 
for private eligibility screening, the iPads provided an opportunity for women to 
complete all aspects of the screening, consent, survey measures, and risk follow up in a 
clinic waiting room setting without impacting privacy. The use of the tablet for screening 
purposes minimized duplicate participants by comparing the entered name and birth date 
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to those already in the dataset. It also allowed for risk messaging to be provided to the 
participant immediately following the survey measures and automated scoring, without 
having to wait for any scoring or review by the research team. We chose this not only for 
the ease of use by study team members, but importantly because computerized screening 
for IPV has shown higher rates of disclosures than face-to-face screenings (Hussain et al., 
2015; Trautman, McCarthy, Miller, Campbell, & Kelen, 2007). In addition, allowing the 
participant full autonomy in decision making regarding further discussions of risk at that 
visit as well as a greater amount of perceived privacy would encourage the participant to 
be fully candid in their responses.   
The computerized data collection process included benefits such as direct entry of 
data by the participant, the ability for the system to prompt participants regarding 
unanswered questions, and automatically capture length of time to complete the survey. 
Direct data entry by participants minimized risk of data entry errors while automatic 
prompts regarding incomplete fields helps to minimize missing data (Barentsz et al., 
2014; Weber, Yarandi, Rowe, & Weber, 2005). However, due to the sensitive nature of 
many of the questions, we did not use this technology to force responses to questions 
except those required for eligibility screening, participant identification and risk 
protocols. Participants received one missed item reminder per page of the survey and 
were given the option to return to the missed items or continue to the next screen without 
answering the skipped questions.  
Training  
Training for this study’s team members was conducted to ensure familiarity with 
general IPV knowledge and protocol details. This training included one-on-one or small 
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group didactic work as well as precepted time in the clinic setting.  Training included 
information on survey administration and safety measures for participants who had 
difficulty with reading or use of the tablet, assessing for and responding to participants 
who wished to speak about their IPV homicide or suicide risk, and an introduction to the 
clinic staff and workflow.  Training was conducted by Ms. Anderson, a nurse who has 
both a professional research and clinical background working with women who have 
experienced sexual and intimate partner violence.   
Protocols to Address Participant Safety Concerns  
Recruitment and Contact Information 
For communication with participants, this study used a generic university email 
address and a voice-over-internet-protocol (VOIP) phone number specific to the study. 
The same contact information was used for recruitment and follow-up. The VOIP 
allowed for maintaining privacy regarding the exact nature of the study in the event that 
persons other than the participant were making contact with the study. The technology 
allowed the investigators to call or text participants from a computer or cell phone that 
did not appear on caller ID as either a blocked or hospital phone number. This was 
important as phone numbers associated with the research team or the clinic may 
unintentionally disclose the nature of the study (as being related to HIV and/or IPV), 
while blocked numbers decrease the likelihood that participants will be able to identify or 
locate them for use in contacting the study team. Regardless of the physical telephone of 
the research team member, incoming calls to the study team appeared as coming from the 
study’s VOIP number and could be answered in a way to maintain participant safety (i.e., 
“women’s health study”) instead of including the name of the HIV clinic or the 
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investigator’s names which could be easily identified as being researchers who 
specialized in IPV from a simple internet search. The technology also allowed the 
number to be forwarded to any phone (cell or landline) in order to maintain timely 
answering and returning of calls. Outgoing contacts from the study team generically 
referred to a “women’s health study”; the university/hospital name was also included in 
outgoing messages if participants indicated that this was safe.  
Care was further taken to assure the safety of contact information for any 
participant follow-up communications.  Upon participants’ completion of study 
measures, a research team member was able to log into the data collection system and 
was notified if the participant had consented to being contacted for follow-up purposes.  
They were then able to fill in an electronic form with safe contact information provided 
by the participant.  Prompts for safety of phone calls, voicemails and text messages were 
built into the system for phone numbers. Free text boxes allowed notation of participants 
who preferred phone calls or message reference to the specific clinic or the 
hospital/university more generally.  The form provided options for participants to indicate 
whether utilizing information already on file in the electronic medical record could be 
used to contact them as well, so women did not need to re-provide information already on 
file, but could also indicate “no” if they chose to only be contacted through a specific 
phone number or email address.  
The electronic form was designed to be used in conjunction with a research 
assistant; it could not be accessed by the participant directly as a study team member 
login was required to access the contact information section.  This ensured that necessary 
safety information was obtained or if participants were unable or declined to provide 
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information that appropriate notations were made in the database; it also acted as a data 
safeguard to maintain contact information separate from participants’ survey data.  
Informed Consent 
Previous concerns have been raised about collecting written consent forms from 
participants when the risk of collecting, storing and providing participants with consents 
barring their names in association with the study details is substantial, such as in research 
related to sensitive topics—HIV, IPV, or sexual assault (DHHS, 1991; Pedroni & 
Kenneth, 2001). This is a particular concern in situations when other identifying 
information is not being collected, or can be removed from datasets after data collection 
is complete.  In accordance with the University’s IRB, verbal consent was obtained by 
trained research team members. The approved consent script was provided to participants 
on the iPads, and was reviewed by the participant and research team member together. 
Consent/declination was indicated by selecting the appropriate item on the iPad. This 
allowed for both written and verbal methods of communicating the consent information 
to potential participants.  
Mandatory reporting laws and policies vary greatly between institutions and 
jurisdictions. Despite variation in specifics, all locations have some requirement for 
reporting child abuse, elder/vulnerable adult abuse, and imminent risk of harm to self or 
others. It is important for research team members to be familiar with their reporting 
requirements and develop protocols for assuring that reporting is completed in a way that 
fulfills legal responsibilities.  It is also important for participants to be aware of what 
disclosures would trigger a mandatory report, and how such reporting would be handled 
by the research team (Btoush & Campbell, 2009; Sullivan & Cain, 2004).  For this study, 
48 
 
we included language in the consent documents detailing the items that would trigger 
mandatory reporting. We did not include any direct questions related to mandatory 
reporting topics in the survey items (i.e., there were no specific items in the survey about 
child abuse/neglect, but the consent process did include information about the limits to 
confidentiality, including mandatory reporting of child abuse and how such reporting 
requirements would be handled by the research team).  For those participants chosen for 
follow-up individual interviews as part of this study, the consent document was again 
verbally reviewed with participants who were then given another opportunity to ask 
questions or decline participation.  No mandatory reports were triggered during this 
study. 
Risk Screening  
A key safety priority was asking women about their interest in sharing issues of 
violence and mental health with their health care provider to receive additional support 
and referrals, or keeping all information shared with the research team confidential from 
health care providers in the partner clinic. We included two risk-screening protocols and 
responses in the study. These were related to risk of intimate partner homicide and risk of 
suicide, and were based on protocols utilized in a prior community-based IPV research 
study (Eden et al., 2015). Risk for intimate partner homicide was assessed with the 
Danger Assessment (Campbell, Webster, & Glass, 2009), which is a risk assessment tool 
designed and validated for clinical and research use to identify women at risk of being 
killed by their current or former intimate partners.  The tool is available freely for clinical 
and research use, with the scoring algorithm being available to those who complete an 
online or in-person training (Campbell, 2004).  Scoring ranges from -3 to 37 and there are 
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four danger risk categories—Variable, Increased, Severe, and Extreme.  We chose to 
include risk messaging for women scoring in the top two categories (Danger Assessment 
scores >13).   
Women who met the criteria for being at risk were shown an additional screen at 
the end of the tablet survey.  This screen included a list of local and national IPV related 
resources as well as two questions.  The first additional question asked if/how 
participants would like to receive a copy of the IPV resource lists.  Options included a 
paper copy provided in the clinic that day, a copy emailed to them, or that they did not 
want a copy of the resources. The second question asked if the participant wanted their 
Danger Assessment score and risk category shared with their healthcare team at the 
clinic.  If they indicated “yes”, they were asked to provide an updated safe contact 
method for the provider such as phone, email, or U.S. postal mail.  Women were also 
assured that answering yes to this question would indicate their consent to share only 
their risk information, not their answers to other survey questions.  This provided 
participants an opportunity to have this sensitive information shared with their health care 
provider through the research team instead of them having to bring it up during a direct 
patient-provider encounter. These communications took place within two business days 
of the patient’s participation in the study via the hospital/university email system. The 
previously established relationship with the clinic allowed for a research team member to 
access the electronic medical record to obtain the participant’s care provider information 
(i.e., nurse case manager, social worker, primary provider, psychiatrist, etcetera). 
Potential suicide risk was assessed using three questions in survey measures.  
High risk answers to any two of the three questions would trigger the participant to be 
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placed into the risk category. Two questions were given to all participants during the 
Center for Epidemiologic Studies Depression Scale (CES-D) (Radloff, 1977).  
Participants were asked how many days in the past two weeks that they endorsed the 
following statements “I wished I were dead” and “I wanted to hurt myself.”  Possible 
answers were a five-point Likert scale ranging from “Not at all or less than 1 day” to 
“Nearly every day for two weeks.”  Participants who answered “Nearly every day for two 
weeks” or “5 to 7 days” to either question were considered at risk for that question.  The 
third question we used to measure potential risk was an item on the Danger Assessment 
that asked participants if they had ever threatened or tried to kill themselves (Campbell, 
2004; Campbell et al., 2009). A “yes” was considered at risk for this question. The 
Danger Assessment was only given to participants who had indicated past year IPV on 
earlier screening tools. We considered at risk answers to any two of the three items to 
indicate potential suicide risk.  
 Participants who were in the at-risk group were shown an additional screen at the 
end of the survey (distinct from the IPV homicide risk screen) that included additional 
language regarding suicide risk.  This messaging included prompts for the participant to 
think about whether they had considered suicide, whether they had a plan, and whether 
they had a specific method or time to kill themselves.  The language for this messaging 
was adapted from previous internet-based work with women in abusive relationships and 
was originally developed in collaboration with an expert in trauma, IPV and mental 
health (Eden et al., 2015).  Women were then asked to indicate how they preferred to 
seek help if needed.  The four options provided to women for this item were: “I have my 
own healthcare provider, counselor, or other supportive person who I can call”; “I can 
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call the National Suicide Hotline at 1-800-273-TALK (1-800-273-8255) and talk to a 
confidential counselor over the phone”: “I want a research assistant from the study to talk 
with me today”: and “I’m OK right now, but if it becomes a problem for me, I’ll ask for 
help.”  Women were also asked if they wanted the research team to share their potential 
suicide risk and CES-D answers/score with their healthcare team.  As with the IPV 
homicide risk screen, women who answered “yes” were asked to provide safe and up-to-
date contact information for the provider to use. 
In addition to using survey items and including triggered risk messaging at the 
completion of the tablet-based survey, we also included information in the written 
protocol documents addressing participants who either indicated that they wanted to 
speak with a research team member about their IPV homicide or suicide risk factors and 
resources.  The protocol for suicide did include information for the research assistant to 
have in the clinic regarding assessing suicidality and use of community and hospital 
resources as immediate referrals for women who were at risk (i.e., the National Suicide 
Hotline, 911, or in-house emergency service activation). These documents were covered 
in research team member trainings and were available to study team members in hard 
copy and digital versions. This aspect of the protocol did not need to be utilized during 
the study. The clinic-based therapists and psychiatrist provided patients who had 
previously established mental health care at the clinic to schedule acute appointments 
within two business days for urgent but non-emergent issues per their standard policies. 
The research team did assist in obtaining such an appointment for one participant who 
consented to having her information shared with her health care provider.   
Of the 239 women included in the final dataset, 30 (13% of total sample, 25% of 
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those reporting past year violence) met this study’s criteria for being at high risk for 
intimate partner homicide.  One additional woman did not complete the Danger 
Assessment due to technical issues, but did receive resources and was offered referrals 
and provided answers to risk messaging questions.  Results from participants’ responses 
to the risk protocol question are presented in Table 2.1.  Of note, one of the primary study 
aims was to assess the prevalence of IPV in the clinic, so nearly half (n=117, 49%) of the 
sample did not report any type of past year IPV.  Seventeen women (7% of the total 
sample) met this study’s criteria for potential suicidality and completed this additional 
survey safety protocol. Of these 17 women, 10 (59%) had also screened as high risk for 
intimate partner homicide. Only one participant requested to speak with a research 
assistant about their suicidal thoughts and she did not endorse a current suicide plan, but 
indicated a need to talk with someone about her current life stressors and confirmed that 
she was at the clinic to see her psychiatrist that day. Nearly half (n=8, 47%) reported that 
they were comfortable speaking with their current healthcare providers about any suicidal 
thoughts they were having and seven women (41%) indicated that they did not currently 
feel at risk, but would ask for help if needed.  Additional results from the suicide safety 
protocol are shown in Table 2.1.  
For both the intimate partner homicide and suicide protocols, the majority (74% 
and 59%, respectively) of women declined to have their information shared with their 
clinic care team.  Anecdotal accounts from some participants included that their providers 
were already aware of the issues they screened as high risk for (sometimes prompting 
them to ask for the information not to be shared again, sometimes prompting them to 
consent to sharing), while others related that they did not currently consider themselves at 
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risk (i.e., not currently having suicidal thoughts, having recently left an abuser, or having 
an abuser who was in jail) and did not want to involve the healthcare team in non-acute 
issues.    
Discussion 
This study’s protocol adds to those previously published presenting strategies for 
the safe and ethical conduct of IPV research. Our experiences highlight the use of 
technology to implement rigorous safety protocols without creating undue burden to 
participants or research team members. The relatively low number of participants 
meeting our risk criteria can be used to help estimate resources needed when planning 
studies to examine IPV in clinical settings. Even with more liberal definitions of risk, 
especially for suicide in which risk determination was limited to two or three individual 
items that inquired about the broader topics of self-harm and suicidal thoughts, we did 
not find a volume of response that would overwhelm a clinic or community-based 
referral location. Our integration with clinic staff was hugely beneficial in navigating the 
clinical research process.  The partnership allowed for recruitment from a designated 
research area within the clinic as well as for direct provider referrals of participants when 
needed for mental health concerns.    
Importantly, it should be noted that the majority of our participants who triggered 
risk protocols did not ask to have their results shared with their providers, nor to speak 
with a research team member on-site following participation. While data regarding 
reasons for not sharing were not specifically collected, recorded research team notes 
indicated a wide spectrum of reasons including not wanting to share their experience of 
IPV or suicidality with their provider, or having already disclosed to their providers and 
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not feeling a need to tell them again.  Regardless of individual reasons, it is important to 
note that variation in participant requests regarding information-sharing need to be 
addressed in research protocols.  Creating methods for safely referring participants to 
community or clinic resources may be an important way of connecting research 
participants with services that can improve their health and well-being as long as these 
procedures are conducted in a manner that promotes autonomy in decision-making for the 
participants.   
Conclusions 
The underlying goal of all research involving human subjects is to gain 
knowledge in order to better understand and address conditions that impact their health 
and overall well-being. This type of clinical research can be completed utilizing methods 
that promote safe and ethical treatment of participants who may have a variety of social 
and health care factors making them vulnerable to risk of stigma or violence in the event 
of undesired disclosure. Responsible conduct of research requires that researchers 
conducting studies involving these potentially at-risk groups have an understanding of the 
complexity of the issues facing participants. As such, researchers must develop 
thoughtful plans for discussing mandatory disclosures, and providing opportunities 
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Participants’ Responses to Safety Protocol Questions 
 n (%) 
IPV Resources List Request (n=31)  
Email copy 2 (6.5) 
Paper copy 13 (41.9) 
No copy 16 (51.6) 
Share DA Risk with Provider (n=31)  
Yes 8 (25.8) 
No 23 (74.2) 
Suicide Risk Answer (n=17)  
I have my own healthcare provider, 
counselor, or other supportive person 
who I can call. 
8 (47.1) 
I can call the National Suicide 
Hotline at 1-800-273-TALK (1-800-
273-8255) and talk to a confidential 
counselor over the phone. 
1 (5.9) 
I want a research assistant from the 
study to talk with me today. 
1 (5.9) 
I’m OK right now, but if it becomes a 
problem for me, I’ll ask for help. 
7 (41.2) 
Share Suicide Risk with Provider (n=17)  
Yes 7 (41.2) 
No 10 (58.8) 















Impact of Intimate Partner Violence on Treatment Adherence and CD4 Cell Count of 






Jocelyn C. Anderson, PhD(c), MSN, RN, FNE-A 
Jacquelyn C. Campbell, PhD, RN, FAAN 
Nancy E. Glass, PhD, MPH, RN, FAAN 
Nancy Perrin, PhD 
Michele R. Decker, ScD 
Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN 
 






The substance abuse, violence and HIV/AIDS (SAVA) syndemic represents a 
complex set of social determinants of health that impacts the lives of urban women. 
Specifically, there is growing evidence that intimate partner violence (IPV) places 
women at risk for both HIV acquisition and poorer HIV-related outcomes. This study 
assessed prevalence of IPV in an urban HIV clinic setting, as well as the associations 
between IPV, symptoms of depression and PTSD on three HIV-related outcomes—CD4 
count, viral load, and missed clinic visits. In total, 239 adult women attending an HIV-
specialty clinic were included. Fifty-one percent (95% CI: 45–58%) of women in this 
sample reported past year psychological, physical, or sexual intimate partner abuse.  In 
unadjusted models, IPV was associated with having a CD4 count <200 (OR: 3.284, 95% 
CI: 1.251–8.619, p=0.016) and having a detectable viral load (OR: 1.842, 95% CI: 
1.006–3.371, p=0.048). IPV was not associated with missing >25% of past year clinic 
visits (OR: 1.571, 95% CI: 0.937–2.633, p=0.087). In multivariable regression, 
controlling for substance use, mental health symptoms and demographic covariates, IPV 
remained associated with CD4 count <200 (OR: 3.536 95% CI: 1.114–11.224, p=0.032). 
Substance use and depression were both associated with missing >25% of past year clinic 
visits. The association between IPV and lower CD4 counts, but not adherence markers 
such as viral suppression and missed visits, indicates a need to examine potential 
physiologic impacts of trauma that may alter the immune functioning of women living 
with HIV. Incorporating trauma-informed approaches into current HIV care settings in 





Despite improvements in the rates of testing and treatment for HIV, one in 10 
patients living with HIV and on ART still have a detectable viral load (Centers for 
Disease Control [CDC], 2015).  Women, and particularly urban racial and ethnic 
minority women, are increasingly affected by the HIV epidemic (CDC, 2015; UNAIDS, 
2012).  Various factors have been identified as being linked to increased risk of HIV 
acquisition among women who have experienced intimate partner violence (IPV) 
including, poorer mental health, substance abuse, ongoing sexual violence, increased 
frequency of sexually transmitted infections, and increased sexual risk behaviors 
(Campbell et al., 2008; Draughon, 2012; Jewkes, Dunkle, Nduna, & Shai, 2010). 
Relatively less has been examined regarding ways in which current or past IPV may 
impact long-term HIV treatment adherence or outcomes, although similar pathways have 
been proposed in the literature (Campbell, Lucea, Stockman, & Draughon, 2013; Schafer 
et al., 2012).   
 In 2013, the White House issued a report that acknowledged the importance of 
addressing the intersection of HIV and violence against women.  This report highlighted 
the importance of gaining a greater understanding of the impact of violence on the health 
of women and girls living with or at risk for HIV (Interagency Federal Working Group, 
2013).  Subsequently, a 2015 meta-analysis found that women who reported experiencing 
IPV were less likely to report current anti-retroviral therapy (ART) use, had poorer self-
reported ART adherence, and were less likely to report viral suppression (Hatcher, 
Smout, Turan, Christofides, & Stockl, 2015).  
Partner violence is not the only social determinants of health shown to impact 
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HIV treatment adherence and outcomes among urban women. Syndemic theory, first 
introduced in 1994, has been used to frame studies examining a wide range of social and 
health-related factors that act together to impact HIV risk and treatment (Singer, 2009). 
Specifically, the substance abuse, violence and HIV/AIDS (SAVA) syndemic highlights 
the interconnected risks of these distinct risk factors (Singer, 1994, 1996, 2009). While 
proposed pathways linking IPV and poorer HIV treatment outcomes have focused on 
behavioral pathways including poorer mental health, substance use and decreased 
adherence to ART, limited testing of these proposed mediating effects has been published 
in the literature to date (Hatcher et al., 2015; Rose et al., 2010). 
The purpose of this study was twofold: 1) to determine the prevalence of past year 
IPV among a sample of primarily African-American urban women attending an HIV 
specialty clinic, and 2) to examine the association between past year IPV and HIV 
treatment and adherence related outcomes including CD4 count, viral load, and missed 
clinic visits.  Our a priori hypothesis was that past year IPV would negatively impact 
each of the three treatment and adherence markers, and that this relationship would be 
mediated through reported past month mental health symptoms associated with PTSD 
and depression.    
Methods 
Study Design 
A cross-sectional, self-administered survey with associated medical record review 
was completed with consenting adult women who were patients at an urban HIV 
specialty clinic. Data were collected between March 2014 and November 2015. 
Recruitment and Data Collection 
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Women were eligible to participate if they were at least 18 years of age, spoke 
English, were living with HIV, had been a patient at an urban HIV specialty clinic for at 
least the past one year, and reported being in an intimate relationship at some point 
during the past year.  Participants could be referred to the study by a clinic provider, 
approach study staff directly at a designated research area in the clinic, or reach the 
research team through a phone number listed on flyers posted within the clinic.  
After establishing eligibility, an oral consent script was reviewed with potential 
participants.  Women had an opportunity to view the script and acknowledge consent via 
a secure study iPad.  A trained and skilled interviewer was available in the clinic to 
accommodate participants who reported vision or literacy concerns with completing the 
survey items. This study was approved by the Johns Hopkins Medical Institutions (JHMI) 
Institutional Review Board. Participants were compensated with a $10 gift card for their 
participation.  
A total of 485 women approached the research team during this study’s 
recruitment period (see Figure 3.1 for study flow diagram).  Of those, 53% (n=259) were 
both eligible and consented to study participation; however, two participants declined to 
complete any study measures after consent.  During review of medical records, 18 
participants were excluded for reasons listed in Figure 3.1; this resulted in 239 women 
included in the final sample.   
Measures 
Collected demographic information included age, race, ethnicity, education level 
completed, employment, insurance status, and characteristics regarding their relationship 
(partner’s gender, cohabitation). 
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Intimate partner violence. Standardized assessment of past year IPV included a 
four-question version of the Abuse Assessment Screen (AAS) which includes items for 
emotional, physical and sexual abuse as well as a fourth item about feeling unsafe in a 
relationship, and the 46-item Severity of Violence Against Women Scales (SVAWS) 
which includes items specific to abuse perpetrator behaviors across nine domains of 
violence including: symbolic violence; mild, moderate and serious threats of violence;  
mild, minor, moderate and serious physical violence; and sexual violence (Marshall, 
1992; McFarlane, Parker, Soeken, & Bullock, 1992).  All women were given the AAS 
and SVAWS.  Both the AAS and the SVAWS have been used in diverse samples of 
women in the United States and globally (Anderson, Stockman, Sabri, Campbell, & 
Campbell, 2015; Antoniou et al., 2010; Laughon, Renker, Glass, & Parker, 2008; 
Reichenheim & Moraes, 2004). These scales were used in combination to determine past 
year IPV.  Women who answered “yes” to any item on the AAS, or to having 
experienced any item in the moderate or severe violence categories on the SVAWS were 
classified as having experienced past year IPV. 
CD4 count, viral load and missed clinic visits. Three primary outcomes were 
obtained by reviewing participants’ medical records. Most recent CD4 count and viral 
load were obtained from recorded laboratory values taken on or before the day of survey 
completion.  These values were later dichotomized into clinically relevant groups (CD4 
count ≥200 cells/mm3 or <200 cells/mm3; viral load detectable [>20 copies/ml] or not 
detectable [≤20 copies/ml]). The third outcome was the proportion of missed clinic visits 
in the past one year.  This outcome was determined from the total number of scheduled 
visits to any outpatient clinic setting within the health system in the year prior to the 
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survey date and the corresponding number of missed visits.  For analysis, the proportion 
of missed visits was dichotomized into two groups—missed ≤25% of scheduled visits 
compared to missed >25% of scheduled visits.   
Mental health and substance use.  Mental health symptoms and substance abuse 
were assessed using previously validated measures.  The Center for Epidemiologic 
Studies Depression Scale (CES-D) and PTSD Checklist Civilian Version (PCL-C) were 
used to assess recent symptoms of depression during the past two weeks, and PTSD 
during the past one month (Blanchard, Jones-Alexander, Buckley, & Forneris, 1996; 
Radloff, 1977).  Both scales, while initially developed and tested in Caucasian samples, 
have been widely used in more ethnically diverse samples (Anderson et al., 2015; 
Canady, Stommel, & Holzman, 2009; Norris & Hamblen, 2004). The Drug Abuse 
Screening Tool (DAST-10) and Alcohol Use Disorder Identification Test  (AUDIT) were 
used to determine recent drug use within the past year, and alcohol use within the past six 
months (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001; Bohn, Babor, & Kranzler, 
1995; Skinner, 1982).  Standard cut-off scores were used for the CES-D (≥16), AUDIT 
(≥8) and PCL-C (≥45) (Babor et al., 2001; Radloff, 1977; Ruggiero, Del Ben, Scotti, & 
Rabalais, 2003).  One item from the DAST-10 (“In the past year, have you used drugs 
other than those required for medical reasons?”) was used in combination with data from 
medical records review to create a composite variable of participants’ reported or 
provider documented illicit drug use in the past one year. All instruments demonstrated 
good reliability in this analysis with Cronbach’s alphas greater than 0.85 (CES-D: 0.96; 
PCL-C: 0.95; AUDIT: 0.88).   
Data Analysis  
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Data were analyzed using SPSS Version 23 (IBM, 2014). Descriptive and 
exploratory data analysis was completed with all outcome variables, covariates and 
potential confounders (see Table 3.1). Bivariate analysis including chi-square and Mann 
Whitney U-tests were conducted to examine associations between demographic 
covariates, SAVA variables and potential confounders, and each of the three outcome 
variables. Multivariable logistic regression models that included demographic covariates 
associated with IPV or the selected outcome in bivariate analysis were then built. In all 
models, IPV, mental health, and substance use covariates were included. For the CD4 
count and viral load outcomes, analysis was limited to those participants who were 
prescribed ART within the one-year prior to the survey, while missed visits were 
calculated for all women for whom complete data was readily available.  To account for 
variation in the number of scheduled visits, a categorical variable for number of past year 
scheduled visits was included in the regression analysis for the missed visits outcome.   
Results 
The sample was primarily African-American (86.6%) and non-Hispanic (94.5%) 
women with a median age of 50 (IQR: 44–55).  Over half of the women (58%) had 
completed high school or obtained a GED. While we did not include direct income 
measures, insight regarding socioeconomic status can be gleaned from the overwhelming 
majority of participants that relied on public insurance including Medicare, Medicaid or 
Ryan White funding (96.7%) and the low rate of employment (12.6%).  Additional 
demographic data is presented in Table 3.1.  
IPV, Mental Health Symptoms, and Substance Abuse 
Over half of the sample participants (n=122, 51%, 95% CI: 45–58%) reported 
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past year physical, sexual or psychological IPV.  Nearly all women reporting IPV 
(n=119, 97.5%, 95% CI: 95–100%) reported psychological abuse, with a similar 
proportion reporting physical violence (n=110, 90.1%, 95% CI: 85–96%).  Fewer women 
(n=51, 41.8%, 95% CI: 33–51%) reported sexual violence (see Figure 3.2). 
Approximately one in four women reported depression symptoms meeting the CES-D cut 
off score for clinical significance (27%, 95% CI: 21–33%) and a similar proportion 
reported clinically significant PTSD symptoms (24%, 95% CI: 18–29%), while 16% of 
women reported symptoms of both PTSD and depression. In bivariate analysis, past year 
IPV was independently associated with past month PTSD symptoms and past two week 
depression symptoms, past year drug use and past year alcohol abuse (see Table 3.1).   
Associations with CD4 Count, Viral Suppression, and Missed Visits 
From medical record reviews, the majority of women had well-controlled HIV 
disease with 10% (n=25) having a most recent CD4 count <200 (95% CI: 4–14%). 
Almost one-third of women (n=71) had detectable viral loads (30%, 95% CI: 24–36%).  
Only fifteen women (6%) had both a detectable viral load and CD4 count less than 200.  
Over half (57%) of women missed 25% or more of their scheduled visits in the year prior 
to their survey date (95% CI: 51–64%). The number of scheduled clinic visits in one year 
had a wide range (1–358 scheduled visits) related to the health system’s inclusion of 
programs for clinic patients such as daily methadone maintenance treatment, which 
substantially increased the number of scheduled visits for some participants.  The median 
number of annual scheduled visits was 26 (IQR: 16–41), and the median number of 
missed visits in the past year was 7 (IQR: 3–13). Proportion of missed visits for 
participants ranged from zero to 84% with a median of 29.6% missed scheduled visits 
69 
 
(IQR: 16.67–43.33%).  
When examining associations between IPV and each of the outcome variables, 
CD4 count <200 (OR: 3.284, 95% CI: 1.251–8.619, p=0.016) and detectable viral load 
(OR: 1.842, 95% CI: 1.006–3.371, p=0.048) were both associated with past year IPV 
(See Tables 3.2 and 3.3), indicating that women who had experienced past year IPV were 
approximately three times more likely to have a low CD4 count and nearly two times 
more likely to have a detectable viral load.  The missed clinic visit outcome was not 
associated with past year IPV (Table 3.4). PTSD symptoms were not associated with any 
of the three outcome variables in bivariate analysis, and depression was associated only 
with missing >25% of clinic visits (OR: 2.357, 95% CI: 1.266–4.386, p=0.007) not CD4 
count or viral load measures (Tables 3.2–3.4). When demographic, mental health and 
substance abuse covariates were added to the regression models (Tables 3.2–3.4), past 
year IPV maintained significant association to CD4 count outcome (OR: 3.536, 95% CI: 
1.114–11.224, p=0.032), but not the detectable viral load outcome (OR: 1.699, 95% CI: 
0.859–3.363, p=0.128). In addition to past year IPV, having a detectable viral load was 
associated with having a CD4 count less than 200. Age and education were both 
associated with improved outcomes in the final viral load model. Having graduated from 
high school decreased the odds of having a detectable viral load by 63% (OR: 0.367, 95% 
CI: 0.185–0.728, p=0.004) and women in the 45–55 and 56 and older age groups having 
progressively lower odds of having a detectable viral load.  Both past year drug use (OR: 
2.826, 95% CI: 1.525–5.236, p=0.001) and depressive symptoms (OR: 2.330, 95% CI: 
1.012–5.362, p=0.047) showed a significant association with missing more than one-




Intimate partner violence is associated with a myriad of poorer health issues 
among women living with HIV.  The finding that past year IPV was an independent 
predictor of CD4 count when adjusting for mental health and substance abuse covariates 
adds to the current body of knowledge regarding both the impact of IPV on HIV 
adherence and care. Previous studies have demonstrated the relationship between IPV 
and lower rates of ART use and viral suppression; however, the relationship between past 
year IPV and lower CD4 count was not replicated with the adherence measures viral load 
or missed scheduled visit outcomes (Machtinger, Haberer, Wilson, & Weiss, 2012; 
Schafer et al., 2012; Siemieniuk et al., 2013).  While much of the published literature 
focuses on the behavioral impact of IPV on adherence to care—through mental health 
symptoms, perpetrator interference, and increased risk-taking behaviors, our results seem 
to indicate that additional physiologic mechanisms, such as immune and inflammatory 
processes related to stress, should be considered (Campbell et al., 2013; Siyahhan Julnes 
et al., 2016). Prior researchers examining biologic stress in women who have experienced 
IPV have shown alterations in the inflammatory and immune system markers (Garcia-
Linares, Sanchez-Lorente, Coe, & Martinez, 2004; Out, Hall, Granger, Page, & Woods, 
2012; Sanchez-Lorente, Blasco-Ros, Coe, & Martinez, 2010; Shafran et al., 1996). Even 
more recently, IPV has been linked to changes in telomere length—showing the potential 
impact of IPV at the level of an individual’s DNA (Humphreys et al., 2012). This finding 
supports placing HIV disease progression to the list of chronic health conditions impacted 
by trauma exposure, and raises additional questions about the effects of IPV on 
inflammatory and immune responses.  
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Our results also highlighted the impact of IPV on both physical and mental health 
outcomes on women living with HIV.  Higher rates of reported depressive and PTSD 
symptoms were reported by women who reported recent IPV; however, contrary to 
previous work in which depression and PTSD have been associated with altered immune 
function and increased morbidity and mortality among patients living with HIV, in our 
sample these mental health symptoms were not associated with measured laboratory 
outcomes (viral load and CD4 count) (Chander, Himelhoch, & Moore, 2006; Cruess et 
al., 2003; Leserman, 2003; Machtinger et al., 2012; Siyahhan Julnes et al., 2016). 
Multiple factors may have contributed to the lack of significance of this relationship in 
our results, primarily sample size and the use of CD4 count as the only measure of 
immune function. Assessment of additional biomarkers and a more diverse sample in 
terms of past trauma experiences and rate of PTSD may provide more insight into that 
relationship. The missed visit outcome did show a stronger tendency to be impacted by 
traditional behavioral covariates, with depression and past year drug use being associated 
with missing more than 25% of clinic visits. Improved treatment for substance abuse and 
depression may result in improved HIV care adherence and downstream outcomes. While 
these findings may appear disparate, they highlight the challenges of statistically 
assessing the myriad of bidirectional associations between trauma, mental health, 
substance abuse, medication adherence, and immune system functioning.   
This study also found that past year IPV rates were higher in this sample than 
previously reported in the same urban clinic setting—51% versus 26.5% (Illangasekare et 
al., 2012).  This is likely related to differences in the chosen definition and measurement 
of IPV used in this study compared to the prior estimate. Women were allowed to self-
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identify their partner status and were not required to report being married or co-habitating 
in this study, but rather in a relationship (i.e., married, dating, living together, hooking 
up). This definition likely increased the number of women who reported being partnered 
in the past year.  Similarly, we included measures of psychological abuse and physical 
and sexual violence in order to holistically capture the spectrum of women’s experiences. 
This is in contrast to a previously reported study conducted in the clinic that included 
only one tool consisting of three items, the Partner Violence Screen (Feldhaus et al., 
1997; Illangasekare et al., 2012). Women were also informed of this study’s focus on 
relationships and violence during the consent process, possibly raising their sensitivity to 
the issue. This may suggest that the standard clinical screening methods for assessing IPV 
exposure may be less sensitive in this setting, and that modifications of these instruments 
to include specific behavioral cues may be needed to assess for IPV in the urban clinic 
environment. 
Limitations 
Cross-sectional, self-reported data limits any inferences regarding causation.  
Particularly with regards to measuring both CD4 count and viral load at only one time 
point, it is not possible to determine whether the overall trajectory of a participants’’ HIV 
disease was improving or deteriorating, and whether the rate of improvement or 
deterioration was consistent with what would be expected based on their time since 
diagnosis, length of time on ART and length of time since achieving virologic 
suppression. Women who entered care at a late stage in their disease process may have a 
stable CD4 count <200 despite being adherent to ART and virally suppressed.  In order to 
further assess these relationships, multiple data points are necessary. 
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Additionally, the time frame of instruments varied from past two weeks (CES-D) 
to the past year (IPV measures, DAST-10). Use of the same one-year time frame for both 
IPV and drug use limited the ability to assess substance use as a potential mediator 
between IPV and the HIV treatment outcomes.  However, the syndemic framework 
would suggest that these relationships are more complex and cyclical than they are 
unidirectional and linear. Reliance on these survey measures also introduces 
opportunities for recall and social desirability bias. Participant-entered electronic data 
collection and clear discussion of the separation of the research data from clinical data 
during the consent process were utilized to minimize social desirability bias.   
While all three outcomes examined in this analysis were collected from medical 
records, the possibility of measurement issues still exists.  Abstracted CD4 count and 
viral load measurements were obtained from the day of the survey or the closest 
measurement recorded prior to the survey date. In most cases these values were from 
within the one-year timeframe of the IPV survey variable (94% of CD4 count measures 
and 96% of viral load measures), however a small number of participants laboratory 
measures were from outside this timeframe. Additionally, while we were able to include 
a large number of scheduled clinic visits, we were limited to having access to only one 
health system’s records and it is entirely conceivable that participants sought care at other 
medical facilities that we were not able to capture. The decision to include all clinic visits 
types also introduces potential bias as attendance at HIV clinic visits is likely to impact 
HIV care differently than intermittent specialty visits (such as neurology or gynecology) 
or long-term substance abuse treatment or mental health visits.  
A variety of other life stressors and traumas were outside the scope of this study, 
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but have similar theoretical links to negative biologic outcomes related to chronic stress 
response.  It is likely that with our urban sample, there is a great deal of trauma history 
among this study’s participants that we were not able to measure, including childhood 
trauma, community violence and incarceration.  Given the likelihood of repeated or 
ongoing violence in the lives of the study participants, it is important to note that while 
51% reported an experience that was classified as past year IPV, they may not recognize 
or identify these behaviors as problematic or of importance to their health. A trauma-
informed approach to identification, treatment, care, and referral for current and lifetime 
IPV should include specific behavioral questions, not simply a general question about 
having experienced IPV (Substance Abuse and Mental Health Service Administration 
[SAMHSA], 2015; Machtinger, Cuca, Khanna, Rose, & Kimberg, 2015). Similarly, the 
complexity of issues faced by many of the participants related to substance use, mental 
health, violence and poverty presents challenges to those designing interventions. This 
study’s results suggest that addressing substance use and mental health symptoms may 
improve adherence to scheduled visits, but not necessarily influence laboratory treatment 
markers. The relationships of younger age, less education, and a detectable viral load 
indicate that there may be a gap in knowledge or “learning curve” involved in 
establishing adherence as a priority (Blank et al., 2015). Interventions with an emphasis 
on education and the importance of medication adherence and attending scheduled visits 
for long-term health, especially with younger women with limited education, may 
provide benefits to reduced viral load levels and overall adherence to care. 
Research Implications  
This is one of the first studies to find a relationship between IPV and CD4 counts; 
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additional research is needed to further examine this relationship (Rose et al., 2010; 
Schafer et al., 2012).  Future studies should include longitudinal assessment of both IPV 
and biologic measures—both clinical markers and inflammatory stress markers.  
Particular attention to identifying specific biologic mechanisms such as chronic stress and 
alterations in the hypothalamus-pituitary-adrenal axis or epigenetic changes as a result of 
violence which may have downstream effects on immune functioning in HIV patients 
(Keeshin, Cronholm, & Strawn, 2012; Siyahhan Julnes et al., 2016).   
Assessment of interventions to address adherence to HIV treatment among urban 
women should include attention to multiple factors from a trauma-informed perspective 
(SAMHSA, 2015; Machtinger, Cuca, et al., 2015). Behavioral interventions such as 
Dating Matters® and Sister to Sister have been used to address concurrent risk HIV and 
IPV risk in young women, and may be useful as a model to address healthy relationships 
and relationship violence in an HIV context (Jemmott, Jemmott & O’Leary, 2007; Tharp 
et al., 2011).   
Clinical Implications  
This study’s results add to the growing literature regarding HIV care outcomes for 
women experiencing violence. Previous work has shown IPV to be associated with a 
lower likelihood of being prescribed and adhering to ART, while our findings suggest 
that additional biologic mechanisms may also be contributing to poor HIV outcomes 
among women.  Despite widespread support and recommendations from professional and 
regulatory organizations, universal screening for IPV is not consistently implemented in 
HIV care settings.  Trauma-informed programs, which include raising awareness of the 
relationship between IPV and health, confidential and non-judgmental questions about 
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experiences of psychological abuse, physical and sexual violence, harm reduction, safety 
planning and referrals to community partners and advocates integrated in all levels of 
clinical services, is essential in the urban clinic environment in which multiple medical 
and social factors are impacting patients health and well-being (Machtinger, Cuca, et al., 
2015; Machtinger, Lavin, et al., 2015). This becomes particularly important given our 
results and those of similar work examining the impact of broader trauma experiences 
and PTSD on immune and inflammatory markers on patients living with HIV, as patients 
may be virally suppressed and still experiencing immune dysfunction as a result of 
trauma-related factors (Siyahhan Julnes et al., 2016).   
Syndemic models demand that in order to intervene or promote change in one 
area of the syndemic, full attention must be paid to the other aspects. While this study 
found a relationship between IPV and the CD4 count outcome, it is important to note how 
the findings from the viral load and missed visit outcomes can be viewed through a 
syndemic lens and in conjunction with previous work conducted regarding IPV, entry to 
care, and medication adherence.  The missed visit outcome showed significant 
relationships between both symptoms of depression and past year drug use, and recent 
work examining PTSD found links to immune and inflammatory biomarkers in a sample 
of virally suppressed patients living with HIV (Siyahhan Julnes et al., 2016).  These 
multiple health and social problems, such as violence, HIV, and poverty act 
synergistically to create a greater negative impact on health than would otherwise be 
expected from the disease process alone.  Thus, each of these factors in turn will have a 
negative downstream impact on women’s health. The study clinic has already integrated 
mental health and substance abuse treatment programs into its medical home model, 
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however, violence screening and intervention are not as readily available. In addition to 
implementing universal education with a focus on the impact of violence and trauma on 
health in HIV care settings, addressing IPV and trauma history through community 
referrals to appropriate advocates and programs is one area in which attention may be 
useful.  Developing or strengthening partnerships with community resources and 
incorporating trauma-informed mental health, substance abuse and violence services into 
standard HIV care presents an opportunity to address these issues of utmost importance 
to patients’ health and well-being.  
Conclusions 
This study’s findings support both biologic and behavioral pathways through 
which IPV can impact women’s HIV care and outcomes. While the cumulative impact of 
IPV and other lifetime experiences of trauma on the immune system are not yet fully 
known, additional research is needed to further examine the multiple physiologic 
pathways that may contribute to increased risk of low CD4 count in these women. With a 
better understanding of the specific biologic changes and timelines in which their impacts 
are realized, we may begin to examine methods and opportunities for interrupting these 
changes and developing biobehavioral interventions to address IPV in the context of HIV 
and other SAVA syndemic factors such as substance use and mental health. The high 
prevalence of IPV and its impact on CD4 counts also demands close attention to 
identifying and addressing ongoing sources of violence in patients’ lives in order to fully 
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Table 3.1  
 
Participant Demographics by Past Year IPV Status 
 
 Overall c 
(n=239) 
IPV + c 
 (n=122) 




Age d (range 24-66) 50 (44-55) 50 (43-55) 52 (44-56) 0.175 
Race     0.623 
Native American 2 (0.8) 2 (1.6) 0 (0)  
Black/African American 207 (86.6) 106 (86.9) 101 (86.3)  
White/Caucasian 9 (3.8) 5 (4.1) 4 (3.4)  
Multiple races/mixed/other 10 (4.2) 4 (3.3) 6 (5.1)  
Did not respond 11 (4.6) 5 (4.1) 6 (5.1)  
Hispanic (n=229) 3 (1.3) 2 (1.7) 1 (0.9) 0.587 
Education (n=236)    0.050 
8th grade or less 22 (9.2) 18 (14.8) 4 (3.4)  
Some high school 77 (32.2) 42 (34.4) 35 (29.9)  
High school diploma/GED 81 (33.9) 35 (28.7) 46 (39.3)  
Some college 40 (16.7) 21 (17.2) 19 (16.2)  
Associate’s/vocational 
degree 
9 (3.8) 3 (2.5) 6 (5.1)  
Bachelor’s/4 year degree 6 (2.5) 2 (1.6) 4 (3.4)  





231 (96.7)  












49 (20.5)  








Employed 30 (12.6) 9 (7.4) 21 (17.9) 0.014 
CES-D ≥16 (n=237) 64 (27.0) 48 (39.3) 16 (13.9) <0.001 
PCL ≥45 (n=237) 56 (23.6) 41 (33.6) 15 (13.0) <0.001 
Past Year Drug Useb 120 (50.2) 69 (56.6) 51 (43.6) 0.045 
AUDIT ≥8 (n=237) 45 (19.0) 32 (26.2) 13 (11.3) 0.003 
Notes: Items in bold were statistically significant. IPV: intimate partner violence; CES-D: 
Center for Epidemiologic Centers Scales – Depression; PCL: post-traumatic checklist; 
AUDIT: Alcohol Use Disorders Identification Test. 
a p-values are for chi-square analysis examining differences between women reporting 
past year IPV and those not reporting past year IPV, except Age in which differences 
were assessed and reported using Mann Whitney U-tests.  
b Reported on survey or documented in medical records. 
c n (%)  

































































































Level of Education [n=221] 
< HS graduation 































































































































Notes: Items in bold were statistically significant. IPV: intimate partner violence; CES-D: Center for Epidemiologic Centers Scales – 
Depression; PCL: post-traumatic checklist; AUDIT: Alcohol Use Disorders Identification Test; Ref=reference category; n=219 
women prescribed anti-retroviral therapy and with complete survey data for all included covariates. 
a column % 
b bivariate associations 
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aORc 
(95% CI) 
n=219 p value 













































































Level of Education [n=221] 
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Notes: Items in bold were statistically significant. IPV: intimate partner violence; CES-D: Center for Epidemiologic Centers Scales – 
Depression; PCL: post-traumatic checklist; AUDIT: Alcohol Use Disorders Identification Test; Ref=reference category; n=219 
women prescribed antiretroviral therapy and with complete survey data for all included covariates 
a column % 
b bivariate associations 
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aORc 
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n=234 p value 













































































Level of Education [n=236] 
< HS graduation 


































































































































































Notes: Items in bold were statistically significant. IPV: intimate partner violence; CES-D: Center for Epidemiologic Centers Scales – 
Depression; PCL: post-traumatic checklist; AUDIT: Alcohol Use Disorders Identification Test; Ref=reference category; n=234 
women with complete survey data for all included covariates. 
a column % 
b bivariate associations 
c adjusted for displayed covariates
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Note: MRA: medical records abstraction 
 
Approached for Participation 
(n=485) 
Excluded  (n=226) 
• Not meeting inclusion criteria 
(n=147) 
• Declined to participate (n= 79) 
 
Participants excluded from data during MRA  
(n=18) 
• Duplicate participant (n=11) 
• Unable to locate records for patient 
(n=4) 
• Patient did not meet eligibility criteria 
(not HIV+, not receiving HIV care at 




Competed Screening and Consent 
(n=259) 
Included in Analysis 
(n=239) 
Withdrew from participation prior to 
completing survey measures (n=2) 
 
Competed Survey Measures 
(n=257) 
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Notes: Zero participants reported only sexual violence. Diagram created using eulerAPE 
(Micallef & Rodgers, 2014). Diagram proportions are approximate. 
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ADDENDUM TO CHAPTER THREE: MEDIATION ANALYSIS  
One component of Aim 2 was to examine mediation effects of mental health 
symptoms on the HIV adherence and treatment markers in the sample.  In addition to our 
hypothesis that women reporting past year IPV would have poorer HIV adherence and 
treatment outcomes, we also hypothesized that these effects would be mediated by 
symptoms consistent with depression and PTSD. This analysis and results were outside 
the scope of manuscript two and are included in this addendum.  
Methods 
Testing of mediation or indirect effects using Sobel’s method was conducted to 
examine for potential impact of mental health variables (symptoms of depression or 
PTSD) had on the relationship between IPV and each HIV related outcome. Parameter 
coefficients from a series of models were used with Sobel’s method to estimate the 
indirect effect (Hayes, 2009; MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002). 
This method allowed for testing of indirect effects in the absence of statistically 
significant direct effects (Hayes, 2009; Hayes 2013). While mediation analysis has 
historically relied on a series of steps initially described by Baron & Kenny (1986), 
which required a statistically significant direct effect between the independent variable 
and the outcome, more recently this restriction has been criticized as overly limiting 
(Hayes, 2009; Hayes, 2013). In complex social and biologic processes, the questions of 
who, how, when or to what degree a variable effects an outcome may be important to 
answer even if the direct pathway is not statistically significant because of competing 
mediators which impact the outcome differently or limitations in sample size (Hayes, 
2009; Hayes 2013).   
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Results  
Separate regression models were used to assess for potential mediation effects of 
symptoms of depression and PTSD on the relationship between past year IPV and each of 
the three outcome variables (CD4 count <200, detectable viral load, proportion of missed 
visits >25%), for a total of six sets of regression models. In all but one model, these 
results were not statistically significant (Table 3a.1).  As stated in Chapter 3, in bivariate 
testing, IPV was associated with CD4 count, viral load, PTSD and depression, but not 
missed visits (See Tables 3.2-3.4; 3a.1). For the missed schedule visit outcome, 
depression was found to significantly decrease the association between past year IPV and 
having missed >25% of scheduled clinic visits in the prior year (OR: 1.571, 95% CI: 
0.937–2.633 versus OR: 1.359 95% CI: 0.790–2.339, Sobel: 2.04, p=0.041).  
Discussion 
In five of the six tested models, we did not find evidence of mental health 
symptoms impacting the relationship between past year IPV and HIV treatment 
adherence or outcomes.  The significant indirect effect of  symptoms of depression on the 
relationship between IPV and the missed clinic visit outcome in the absence of a direct 
relationship between IPV and missing >25% of clinic visits is consistent with depression 
having a significant direct impact on clinic attendance in a multiple variable model (See 
Table 3.4) and with having limited power to examine this outcome due to the its limited 
variation. While we found inconsistency in the impact of mental health symptoms on the 
examined HIV treatment and adherence outcomes, our finding that symptoms of 
depression were responsible for a portion of the impact between IPV and missed visits 
does still provide support for the SAVA framework and direction for future clinical and 
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Table 3a.1  
 
Logistic Regression Model and Sobel Test Results from Mediation Analysis of PTSD and Depression on the Association between IPV 




OR (95%CI) a 
IPV-Outcome 
OR (95%CI) a 
IPV-Mediator 
OR (95%CI) b 
IPV+Mediator- 












(1.157-8.266) 0.438 0.661 























(0.887-2.579) 1.055 0.291 
Note: Items in bold were statistically significant. IPV: intimate partner violence; CD4: CD4 count <200; VL: viral load detectable; 
MV: missed visits proportion >25% 
a bivariate associations 
b adjusted for IPV and tested mediator only 
c p-value for Sobel test
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ADDENDUM TO CHAPTER THREE: REPRODUCTIVE COERCION 
In addition to the primary aim of determining prevalence of intimate partner 
violence (IPV), a secondary aim of this study was to investigate the prevalence of 
reproductive coercion within the HIV clinic setting.  Reproductive coercion in the context 
of an intimate partner relationship is commonly defined as a male partner’s behaviors 
which interfere with autonomous reproductive decision-making of a female partner. This 
can include restriction of access to or use of birth control methods or the use of coercion, 
threat or force in order to influence the timing or outcome of a pregnancy (Miller, 
Decker, McCauley, et al., 2010; Miller et al., 2007; Miller, Jordan, Levenson, & 
Silverman, 2010). In the United States, prevalence of reproductive coercion has been 
explored in samples from family planning clinics, obstetrics/gynecology clinics, IPV 
service provider settings (i.e., shelters, hospital-based IPV programs) and college 
campuses (Clark, Allen, Goyal, Raker, & Gottlieb, 2014; Kazmerski et al., 2015; 
McCauley et al., 2015; Miller et al., 2014; Sutherland, Fantasia, & Fontenot, 2015). 
Prevalence of reproductive coercion had not previously been reported in a sample of 
women living with HIV.  This addendum to Chapter Three provides information on this 
study’s findings related to reproductive coercion among a sample of urban women living 
with HIV.   
Methods 
Reproductive coercion was measured with a 9-item tool developed for use in 
family planning clinics, and has been utilized by researchers in both observational and 
intervention research (Miller et al., 2011; Miller, Decker, Raj, et al., 2010).  No formal 
validation of the tool could be found in the existing literature. The tool includes a series 
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of nine yes or no questions used to assess for reproductive coercion. The tool includes 
two sub-domains of reproductive coercion. The first, birth control sabotage, includes 
direct efforts by the male partner to interfere with a woman’s birth control method and 
the second, pregnancy coercion, includes coercive or violent behaviors intended to 
pressure a woman into becoming pregnant when she does not wish to be.  A ‘yes’ answer 
to any of the nine questions was considered a positive screen for reproductive coercion; 
five of the nine items were specific to the birth control sabotage sub-domain and four 
were related to the pregnancy coercion sub-domain.  
 Women who reported being in a same sex relationship (n=13) were not asked 
about their reproductive coercion measures and two additional women did not complete 
the measure, leaving 224 women in this analysis. Notably, the median age of women in 
this study was 50 (range 24–66).  Since we did not limit reproductive coercion questions 
to women of traditional childbearing age or include an item regarding current physiologic 
ability/inability to become pregnant (i.e., there were no items about being post-
menopausal, or having had a hysterectomy or tubal ligation), we used age as a proxy 
measure and grouped women into two age categories for reproductive coercion analysis 
(age groups 18–44; 45 and older).  
Results 
Overall, prevalence of reproductive coercion was 15% (95% CI: 10–20%) with 
each of the sub-domains having a prevalence of approximately 10% (birth control 
sabotage, 10.2%, 95% CI: 6–14%; pregnancy coercion, 10.6%, 95% CI: 7–15%) (See 
Table 3a.1). There were no statistical differences noted in the prevalence estimates 
between women aged 18–44 and those aged 45 and older.   
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 We also examined individual item responses for the nine items (See Table 3a.2); 
past year prevalence of individual items ranged from 2.2% (n=5) for having a partner 
who took away or interfered with access to birth control to 7.6% (n=17) for the item 
regarding removing a condom during sex in order to promote pregnancy. Differences 
between age groups were again non-significant; however, the small number of 
individuals reporting each behavior limits the interpretation of this insignificant finding.   
An association was noted between reproductive coercion and IPV.  Of the 34 
women in the sample who reported past year reproductive coercion, 24 (71%) also 
reported past year IPV while only 10 women (29%) reported reproductive coercion 
without other past year abuse or violence (Χ2=6.36, p=0.012).  No associations were 
found between reproductive coercion and the HIV adherence and treatment outcomes 
(CD4 count, viral load, missed visits) on bivariate analysis in the entire sample or a 
subsample of women age 18–44 (See Table 3a.3), and reproductive coercion was not 
included in additional model testing for the primary study Aim 2.  
Qualitative Findings Related to Reproductive Coercion 
Two of the nine women who participated in the qualitative interviews indicated 
reproductive coercion on survey measures. However, neither identified reproductive 
coercion as being of concern to them during their qualitative interviews.  One woman 
who reported experiencing multiple pregnancy coercion and birth control sabotage 
behaviors by her partner during the survey stated when asked about decisions regarding 
children,  
“I was told that he didn’t want any more kids and I told him that I did, I only had 
one.  He said he had, what twelve [children]?  Maybe more?  He was unsure.  He 
 102 
had a little wild spree for like 10 years and we eventually planned on it and she 
came.  We had a baby.” (Participant 823)   
Her daughter was nearly one at the time of the interview, and during the four months 
between her survey and interview she had ended her relationship with the child’s father. 
Concern regarding the power dynamic in this relationship was also noted by her 
providers in medical records, citing concerns regarding the 20-year age difference 
between the participant and her child’s father. Additional information regarding this 
participant’s affirmative answers to reproductive coercion or IPV survey measures was 
not easily elicited during the interview. Whether the participant’s feelings about the 
desire for this pregnancy had changed during the interim or whether she was reluctant to 
describe her experiences with reproductive coercion with the research team are unclear.    
The second woman indicated that she had had a hysterectomy and was therefore 
not able to become pregnant at the time of the survey or interview. When reviewing her 
answers to individual reproductive coercion measure items, the only question she 
answered ‘yes’ to was the item “made you have sex without a condom so you would get 
pregnant.” In her broader discussion of her relationship with her partner, she did indicate 
that frequency of intercourse was at times an item of contention and that she would 
usually agree to have sex with her partner even if she was not interested in sex at a 
particular time because of her love for her partner. She also discussed the importance of 
using condoms because her partner was not HIV-infected. This raised concern regarding 
differences in perception of the reproductive coercion items. Whether this woman was 
reporting the partner’s behavior (sex without a condom), without including the requisite 
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underlying intent of the behavior (to get her pregnant) that the question sought is 
unknown, but appears possible.   
Discussion 
The reproductive coercion prevalence rate that we found is consistent with the 
higher end of prior estimates from urban family planning and obstetrics/gynecology 
settings (13-16%) (Clark, Allen, Goyal, Raker, & Gottlieb, 2014; Kazmerski et al., 2015), 
but higher than recent studies conducted in samples of mixed urban/rural family planning 
clinics and female college students (5–8%) (Miller et al., 2014; Sutherland et al., 2015). 
When considering that reproductive coercion is one type of coercive controlling behavior 
found in the context of relationship abuse, this is consistent with the overall high 
prevalence of IPV noted in our sample. The similarity in reported rates of past year 
reproductive coercion between women aged 18–44 and those age 45 and older does raise 
questions; particularly when taken in the context of the limited qualitative data in which a 
woman who reported only condomless sex as a specific reproductive coercion behavior 
on survey measures but denied any ability to become pregnant during the interview. The 
nature of having women report their partners’ behavioral intentions does become 
difficult. Forcing or coercing sex without the use of a condom may be related to 
pregnancy intention, but may also be related to a number of other factors including 
partner preference, embarrassment regarding condom use, or establishing feelings of trust 
or control in a relationship (Browne & Minichiello, 1994). The intention may or may not 
be directly known by the woman reporting the behaviors, and similarly a woman’s ability 
to become pregnant may or may not be known by her partner.  
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The use of a measure of reproductive coercion in a sample of women who are 
likely past reproductive age without assessing their ability to become pregnant poses 
significant limitations.  Whether women in the sample were reporting based on behaviors 
irrespective of intent or were reporting intent irrespective of pregnancy potential is 
unknown.  When examining the subsample of women of reproductive age, the prevalence 
of reproductive coercion was similar to that of the women over the age of 45—indicating 
perhaps that the partners’ behavior patterns were not drastically different between these 
age groups in our sample, even if a pregnancy outcome was not possible. Additional 
research regarding the phenomena of reproductive coercion and its overlap with condom 
refusal behaviors is needed to assess both perceptions of reproductive coercion intent as 
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Prevalence of Reproductive Coercion, Birth Control Sabotage and Pregnancy Coercion 









45 and older 
(n=158) Χ2 p 
Reproductive Coercion 34 (15.0) 11 (16.4) 23 (14.6) 0.13 0.722 
Birth Control Sabotage  23 (10.2) 7 (10.4) 16 (10.1) 0.01 0.942 
Pregnancy Coercion  24 (10.6) 8 (11.9) 16 (10.1) 0.16 0.687 





















In the past year, has someone you were dating or 
going out with:     
Pregnancy Coercion Told you not to use any birth control (such as pills, 
shot, ring, etc.)? 12 (5.4) 3 (4.5) 9 (5.7) 1.000 
Said he would leave you if you did not get pregnant? 9 (4.0) 3 (4.5) 6 (3.8) 0.728 
Told you he would have a baby with someone else if 
you did not get pregnant? 14 (6.3) 6 (9.1) 8 (5.1) 0.362 
Hurt you physically because you did not agree to get 
pregnant? 8 (3.6) 2 (3.0) 6 (3.8) 1.000 
Birth Control Sabotage Taken off the condom while you were having sex so 
that you would get pregnant? 17 (7.6) 6 (9.0) 11 (7.0) 0.590 
Put holes in the condom so you would get pregnant? 7 (3.1) 4 (6.1) 3 (1.9) 0.199 
Broken a condom on purpose while you were having 
sex so you would get pregnant? 10 (4.4) 3 (4.5) 7 (4.4) 1.000 
Taken your birth control (such as pills) away from 
you or kept you from going to the clinic to get birth 
control so that you would get pregnant? 
5 (2.2) 2 (3.0) 3 (1.9) 0.636 
Made you have sex without a condom so you would 
get pregnant? 14 (6.2) 5 (7.5) 9 (5.7) 0.763 





Proportion of Participants Reporting Reproductive Coercion by HIV Adherence and 
Treatment Outcomes 
 
 CD4 Count <200 CD4 count ≥200 p 
Reproductive coercion 










159 (86) 0.213a 
Reproductive coercion 










44 (86) 0.580 a 















134 (87) 0.060 b 
Reproductive coercion 










32 (87) 0.697 a 















78 (83) 0.498 b  
Reproductive coercion 










18 (75) 0.182 a 
    
aFisher’s Exact test 
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The impact of intimate partner violence (IPV) on women’s ability to navigate and adhere 
to HIV care has become a prominent focus of national health care policy. In order to 
more wholly understand how women view this impact in their lives, we conducted a 
qualitative follow up to a larger study examining relationships between the SAVA 
(substance abuse, violence, and HIV/AIDS) syndemic factors of IPV and mental health 
on urban women’s HIV care adherence and treatment outcomes. Utilizing syndemic 
theory as a framework for data collection and analysis, nine women who reported partner 
violence on survey measures participated in semi-structured, in-depth interviews 
regarding their experiences with IPV, substance use, and mental health. Particular 
attention was paid to gleaning information about the way in which women described 
these syndemic factors as impacting or not impacting their HIV care. Women’s 
descriptions of managing their HIV care focused heavily on the roles and labels they 
chose to identify with in their lives.  Women reported being mothers or caregivers as an 
import role in their lives, which often acted to facilitate or motivate them to engage in 
HIV care. Participants identified the SAVA syndemic factors of substance abuse and 
mental health issues as barriers to seeking or adhering to care.  Participants did not 
however focus on the label of “victim/survivor” of IPV.  They minimized the amount and 
severity of violence in general when compared to what they reported on quantitative 
survey measures, and did not identify IPV as a factor that limited their ability to adhere to 
HIV care. Our findings highlight the importance of establishing not only theoretical 
understanding and statistical significance of syndemic factors’ impact on HIV care and 
treatment among urban women, but in understanding how women’s perceptions of these 
factors might impact their help-seeking behaviors or utilization of services.   
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Background 
Urban women face a myriad of interconnected health and social inequities 
including poverty, violence, discrimination, high rates of incarceration, mental health 
disorders and substance abuse (Galea & Vlahov, 2002; Williams, 2008). These co-
occurring social determinants of health are often referred to as a syndemic, “a set of 
enmeshed and mutually enhancing health problems that, working together in a context of 
noxious social and physical conditions, that can significantly affect the overall disease 
burden and health status of a population” (Singer, 2009). Syndemic theory moves beyond 
traditional biomedical descriptions of disease or co-morbidity to explore the possibility 
that certain social and medical conditions act synergistically to produce outcomes in 
excess of the cumulative impact of any one condition. Syndemic theory has been used to 
examine treatment adherence, behavioral risk factors, and mental health outcomes in 
patients living with HIV (Biello et al., 2016; Friedman et al., 2015; Gonzalez-Guarda, 
McCabe, Leblanc, De Santis, & Provencio-Vasquez, 2016; Herrick et al., 2013; 
Illangasekare, 2011; Kuhns et al., 2016). 
The SAVA syndemic specifically highlights the interplay between substance 
abuse, violence and HIV/AIDS (Singer, 1994, 1996, 2009). SAVA syndemic framework 
has been used in both nursing and public health research to examine the theoretically 
bidirectional and even cyclical risks of HIV and intimate partner violence (IPV) 
(Gonzalez-Guarda, Peragallo, Urrutia, Vasquez, & Mitrani, 2008; Illangasekare, Burke, 
Chander, & Gielen, 2013). Despite growing evidence that concepts noted in the syndemic 
framework including IPV, substance abuse, and mental health symptoms contribute to 
poorer health care outcomes for persons living with HIV, limited research has been 
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conducted to translate this framework into specific intervention practices (Gilbert et al., 
2015; Tsai & Venkataramani, 2016).  
Specifically, IPV and HIV have been noted as co-occurring phenomena in the 
literature for nearly two decades (Campbell et al., 2008; Maman, Campbell, Sweat, & 
Gielen, 2000). More recently, a small number of studies began to present data on the 
impact of IPV on antiretroviral therapy (ART) initiation and adherence (Blackstock, 
Blank, Fletcher, Verdecias, & Cunningham, 2015; Blank et al., 2015; Hatcher et al., 
2015; Schafer et al., 2012; Siemieniuk et al., 2013). This intersection has also achieved 
recognition among multiple key leaders and stakeholders including the White House, 
whose 2013 report, “Addressing the Intersection of HIV/AIDS, Violence Against Women 
and Girls and Gender-Related Health Disparities”, highlighted the disparities found in 
HIV risk behaviors and treatment among women. These disparities include higher rates 
of IPV, which are often directly linked to an HIV diagnosis, increased HIV risk behaviors 
(substance use, unprotected sex), and decreased use of ART among women who had 
previously experienced violence (Interagency Federal Working Group, 2013).  This 
interagency report suggested addressing violence and trauma with women in HIV care 
settings as a method of improving outcomes; noting however that there have been very 
few evidence-based trauma-informed interventions targeting this particular population.  
A syndemic framework suggests that full attention must be paid to each aspect of 
the syndemic in order to understand and intervene. However, the perspectives of patients 
regarding the relationships presented in the SAVA syndemic are largely overlooked in 
the current literature (Illangasekare, 2011; Illangasekare et al., 2013). In order to 
successfully design, implement, and test interventions stemming from a SAVA 
framework, additional information about patient preferences and priorities is necessary. 
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Specifically, given the multitude of potential barriers to adherence and programs already 
in place to address individual aspects such as IPV, substance abuse and mental health, a 
more complete understanding of how these factors act in tandem or isolation to effect 
adherence and health care outcomes is required. Thus, this study aims to better 
understand women’s perceptions of the impact that SAVA syndemic factors (IPV, mental 
health and substance use) have on their HIV care. Situated within a larger study of the 
association between SAVA syndemic factors (IPV, mental health symptoms and 
substance abuse) on HIV treatment and adherence markers in an urban clinic sample of 
primarily low income, African-American women living in Baltimore, Maryland, we 
aimed to explore the perceptions of women living with HIV regarding the role of IPV, 
mental health symptoms, and substance abuse in their treatment adherence and HIV care.  
Methods 
Study Design 
This explanatory sequential mixed methods study consisted of two phases.   
Phase 1 included collection of survey data and review of medical records from eligible 
and consenting women (n=239) attending an urban HIV specialty clinic and took place 
between March 2014 and November 2015. Phase 2 consisted of individual, in-depth, 
semi-structured interviews with purposively selected participants based on preliminary 
analysis of Phase 1 data and was conducted between June 2015 and February 2016 (n=9). 
The presented findings are from the analysis of Phase 2 qualitative data, with individual 
participant responses to Phase 1 survey items used to provide context to women’s 
interpretation of the impact of SAVA factors on their health.  
Recruitment, Eligibility, Consent and Data Collection 
Recruitment and data collection was conducted in an urban HIV specialty clinic. 
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In addition to HIV care services, on-site specialty care at the clinic include among others, 
psychiatry and substance abuse treatment services. Participants self-referred or were 
recruited to the study via clinic provider referral.  Participants were eligible if they were 
women, 18 years or older, English speaking, patients in the study clinic for at least one 
year, and reported being in a relationship within the past year. Eligibility screening, 
consent, and survey data were collected via tablet computer with the assistance of trained 
research staff. Participants had an opportunity to indicate interest and provide contact 
information to participate in Phase 2 at the completion of Phase 1 interviews. Purposive 
sampling among participants who indicated interest in Phase 2 was used to achieve 
maximum variation among the sample regarding syndemic variables including substance 
abuse, mental health symptoms, and HIV disease status (Patton, 2002; Sandelowski, 
1995). These were determined by reviewing Phase 1 survey instrument scores related to 
key syndemic concepts. This included review of measures of IPV (the Abuse Assessment 
Screen and the Severity of Violence Against Women Scale, Danger Assessment), mental 
health symptoms (Center for Epidemiologic Studies—Depression, Post-traumatic 
Checklist—Civilian) and substance use (Drug Abuse Screening Test, Alcohol Use 
Disorders Identification Tool) (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001; 
Blanchard, Jones-Alexander, Buckley, & Forneris, 1996; Bohn, Babor, & Kranzler, 1995; 
Campbell, Webster, & Glass, 2009; Canady, Stommel, & Holzman, 2009; Marshall, 
1992; McFarlane, Parker, Soeken, & Bullock, 1992; Radloff, 1977; Ruggiero, Del Ben, 
Scotti, & Rabalais, 2003; Skinner, 1982).  Medical records were reviewed including 
laboratory data to obtain the most recent CD4 count and viral load on or before the date 
of the survey. By design, only women reporting past year IPV were included in Phase 2, 
while variation in reported mental health symptoms and substance use behaviors was 
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sought. Variation in HIV disease control—women who had achieved viral suppression 
and had CD4 counts >200 (GC: good control) versus women with detectable viral loads 
and CD4 counts <200 (PC: poor control)—was also used as a sampling criteria. Eleven 
women who agreed to be contacted and fulfilled the sampling frame criteria were 
contacted for Phase 2 interviews; nine women responded and consented to participate, 
and two did not respond to the interview request.  Because of the ongoing nature of the 
study’s recruitment effort and in order to minimize the burden of having to come to the 
clinic for an additional visit, efforts were made to schedule interviews around 
participants’ scheduled clinic visits. Interviews were scheduled at a time and location 
convenient for the participant with the opportunity for participants who did not have a 
scheduled clinic visit in the near future to request that the interview be completed by 
telephone. After reviewing informed consent forms, interviews were conducted by the 
lead author (JCA) and were digitally recorded. Participants received a $10 gift card for 
completing Phase 1, and an additional $25 gift card for completion of the Phase 2 in-
depth interview. The Johns Hopkins Medical Institutions’ (JHMI) Institutional Review 
Board approved this study. 
The authors who have extensive clinical and research experience in IPV, mental 
health, HIV/AIDS, and substance abuse developed the semi-structured interview guide. 
The guide acted as the basis for interviews and included questions regarding each of the 
syndemic concepts being investigated—IPV, mental health, and substance use; however, 
the interviews were reflexive in nature which allowed the interviewer flexibility during 
exchanges with the participant in exploring the topics of interest (Banner, 2010; Patton, 
2002; Sandelowski, 1993). Revisions to the interview guide were made after the initial 




The digital recordings were professionally transcribed. The SAVA syndemic 
framework described above acted as an initial theoretical guide for the qualitative 
descriptive analysis methods (Thorne, Kirkham, & MacDonald-Emes, 1997). Analysis 
was ongoing during the data collection process, and consisted of a series of steps as 
follows:  1) reading each transcript to verify accuracy of the transcripts to recorded audio; 
2) continued review of each transcript and associated field notes were completed to gain 
an understanding of the overall responses to the interview (Corbin & Strauss, 2008; 
Sandelowski, 2000); 3) detailed reading of each transcript and eclectic combination using 
attribute, in vivo and  open coding methods (Onwuegbuzie & Teddlie, 2003); 4) second 
level coding involved pattern and structural methods; 5) grouping of codes into categories 
and themes (Saldana, 2013). Analytic memos were used throughout the analysis process 
regarding new codes, categories and themes to track researcher’s decision-making 
process (Corbin & Strauss, 2008). Completed interviews with participants were 
transcribed and analyzed throughout the data collection process. Coding using the 
qualitative analysis software HyperResearch (ResearchWare, 2013) and primary analysis 
of themes and categories was completed by the lead author (JCA), with ongoing 
discussion and review of codes, categories, and themes with co-authors occurring 
throughout the analysis process.  
Data Integration  
Quantitative and qualitative data were initially analyzed separately. Data were 
integrated during later phases of analysis using matrices and tables to assist in comparing 
quantitative findings to qualitative themes. During the data integration process, 
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participants were grouped according to reported SAVA factors to examine similarities 
and differences between groups. Additionally, case summaries assisted in comparisons 
between women’s reported experience based on categories identified in quantitative 
responses such as HIV treatment markers, mental health symptoms, and substance abuse. 
In order to highlight the quantitative context of participant quotes, each quotation is 
followed by a parenthetical which includes key SAVA syndemic findings from the 
participant’s self reported survey data. This data includes: participant ID; participant age; 
past year report on AAS or report of moderate, severe or sexual violence on the SVAWS 
(as IPV+/-) (Marshall, 1992; McFarlane, Parker, Soeken, & Bullock, 1992); past year 
illicit substance use or past six-month AUDIT score >7 (as substance use, SU+/-) (Babor, 
Higgins-Biddle, Saunders, & Monteiro, 2001); past month PCL-C score >44 and/or past 
two week CES-D score >15 (as mental health, MH+/-) (Canady, Stommel, & Holzman, 
2009; Ruggiero, Del Ben, Scotti, & Rabalais, 2003); and HIV disease control group (as 
GC: good control, PC: poor control).  
Results 
Interview participants ranged in age from 25 to 51, were primarily African-
American (n=7, 78%), had completed high school (n=6, 67%), and were unemployed 
(n=6, 67%). See Table 4.1 for demographic data on interview participants.  In our 
thematic analysis of the nine interviews, two main themes emerged related to women’s 
HIV diagnosis and care. The first theme was “(Re)establishing identity and managing 
labels”.  This theme contained three subthemes: 1) normalizing versus stigma, 2) 
minimizing violence, and 3) the importance of being a mom or caregiver. This theme was 
characterized by how women viewed themselves and portrayed themselves to the world 
as living with HIV. The second theme, “I know what I need to do”, had two supporting 
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subthemes: 1) accepting responsibility, and 2) barriers to overcome. The second theme 
related to women’s understanding of the imperative of treatment to manage their HIV 
disease, and personally overcoming challenges to achieve adherence.  
(Re)establishing Identity and Managing Labels 
Women in this study shared how they established (or re-established) their identity 
following their HIV diagnosis. This was an ongoing process for women who reported 
continuing struggles with disclosure of their HIV status among their social and family 
networks. Most commonly, this identity establishment occurred through self-selection of 
what roles or labels the patient identified with during the interview. As participants were 
chosen for the qualitative interviews after both survey and medical records data had been 
collected, the research team and interviewer had a great deal of information about the 
women’s SAVA defined risk factors prior to the interviews (i.e., HIV diagnosis, 
adherence and treatment markers, substance abuse behaviors, survey reports of IPV, 
depression, PTSD). It became evident from the data that there were certain roles or labels 
that patients were more likely to accept or reject. Participants’ survey responses, medical 
records, and interview described SAVA factors (see Table 4.2). The importance of which 
labels a participant chose to accept personally or publically became evident in their 
narratives and did appear to link to their adherence to treatment. Women who indicated 
less acceptance of their HIV diagnosis reported a more difficult time adhering to their 
HIV care regimen.  One woman who had been diagnosed 15 years earlier and was not 
adherent to antiretroviral therapy (ART) summed up her overall HIV care experience 
with the following statement,  
“I’m just dealing with it…because I don’t have a choice.  I have to.  I have to deal 
with it.  I think it gets better, in time.  Maybe it does, maybe it don’t, but it’s there.  
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It’s there.  That’s the way I look at it.” (596, 57y/o, IPV+, SU-, MH-, PC) 
Normalizing versus stigma. Participants chose to accept or avoid certain labels 
due to the perceived stigma or perceived support associated with each label. The HIV 
diagnosis itself was a challenging label for most participants to deal with.  One 
participant noted the challenges in the process of establishing an identity separate from 
her diagnosis.  She repeatedly referred to herself, as “I’m HIV”, and discussed her fears 
of disclosing her diagnosis with others. As a result, she disclosed her HIV diagnosis first 
to her (then) teenaged sons. Her fear of disclosure and lack of social support are likely 
linked to her providers’ documentation of difficulties with consistent ART adherence and 
resistance to engage in mental health care services.  
Participants who had a history of substance abuse (n=7 lifetime, n=4 past year) 
readily acknowledged their status as “in recovery” and connected their HIV diagnosis to 
their drug use. Participants “in recovery” were also able to identify how their substance 
use, mental health issues, and HIV treatment adherence were linked—in effect, 
normalizing this factor as important to their health. One participant described her 
concurrent recovery efforts as follows.  
“I'm currently on my fourth step, which has been a little bit rough because it 
brings up a lot of past issues. Like I said, I jumped head into Narcotics 
Anonymous completely. To the literature, to doing step work. At times, that was a 
little bit stressful for me too, because there was some things I just didn't wanna 
face [related to prior abuse history]….I did start [psychiatric] medication, so it 
made me a lot more stable. I was able to think straight.” (676, 35y/o, IPV+, SU+, 
MH+, PC) 
Another participant discussed the challenges in getting into drug treatment programs and 
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how her HIV diagnosis allowed her to seek the substance abuse treatment she needed,  
“Well, I’m in the program because I got sick. Other than that, I wouldn’t even be 
gettin’ the assistance that I’m get gettin’” (653, 46y/o, IPV+, SU-, MH+, GC) 
Participants with no substance abuse history were quick to clarify that they did not 
become infected with HIV through “the life”, referring to drug use or prostitution, but 
from a trusted relationship partner or in the case of one participant, vertical transmission 
from her mother. Regardless of their substance abuse history, participants appeared aware 
that an HIV diagnosis is commonly associated with substance abuse and the 
accompanying social stigma. All participants talked about limiting the disclosure of their 
HIV status to some degree. Even women who were very active in substance abuse 
programs, actively sharing their recovery journeys via social media audiences placed 
limits on the sharing of their HIV status. One participant who discussed her regular use of 
social media within the context of Narcotic Anonymous said about disclosing her HIV 
status,  
“For the most part, my status is need-to-know basis only. It's kind of hard for me 
to tell people…I try to keep it a little bit more quiet.” (676, 35y/o, IPV+, SU+, 
MH+, PC) 
The importance of being a mother or caregiver. Overall, women with children 
strongly identified with their role as a caregiver. Being a good mother was a priority, as 
six participants identified children as a factor that positively impacted their HIV care. 
During the interview, participants shared how they chose to enter care, stay in care, or get 
clean from drugs in order to be a better mother. One participant discussed her relationship 
and love for her son in the following statement. 
“Especially for like me and my son…we’re like one because I know him so well.  
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He knows me.  People envy that. There’s women that envy that. They envy that. 
They see me giving my child love.” 
She continued by discussing her risk behaviors, and shared how she was able to protect 
her son from these behaviors and how that was different from other mothers “in the life.” 
.  “I done did everything there is out there to do.  My son ain’t never seen me in the 
bed with no man, sucking no man’s dick or none of that, never. You know what I 
mean?  I’m not going to disclose names but a girlfriend of mine, her son is the 
same age as mine. He walked in and he saw that.”  (536, 43y/o, IPV+, SU+, MH-
, PC) 
Children and/or pregnancy were identified as both motivation for and a means to gain 
access to care, or to help women prioritize remaining in HIV care and adherence to 
treatment to achieve viral control. However, they also noted the challenges with 
continued sobriety and treatment adherence following pregnancy.  One participant 
shared,  
“I didn't find out I was positive until I was seven months pregnant with 
[participant’s oldest son]. Thank God he came out negative. All my kids came out 
negative. I took my medication with them, and they, they're healthy.  After that, I 
continued with my drug use. I got on the program. I was on the methadone 
program. I would stay clean on them, and then I'd have my relapse. Every couple 
of years, I had a little relapse here and there, but I still wasn't compliant with my 
medicine, with my HIV meds.”   (475, 28y/o, IPV+, SU+, MH+, PC) 
The focus on children as a facilitator of care engagement did align with whether women 
had an active relationship with their children.  In contrast, one woman who had achieved 
a long period of sobriety and adherence to her HIV care, but had minimal contact with 
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her adult children described the relationship very differently. She did not seem to focus 
on her role as a mother as one that was important to her identity. Her more tenuous 
relationship with her children also highlights the importance of support from the health 
care system, especially when other sources of social support and identity are limited.  
“Well, my son is more to loving me, and talking to me, and being a part of my life 
than my daughter. My daughter refuses to talk to me. She's bitter because I went 
to jail. She says I was a total embarrassment. I should've never gotten on drugs. 
Well, oh well. I don't know what to tell you. The shit happened and I had to live 
on.…Many families mended back together. Some don't. I'm in that category. I 
don't have my blood natural family. I don't have support from them. I have 
support from my network is the best friend I told you about and this clinic.” (745, 
50y/o, IPV+, SU+, MH+, GC) 
Similarly, a participant who did not have children voiced a desire for additional support 
dealing with the stresses of everyday life, 
“They need to have more support for the doctors need to get a little bit more 
involved in the every day-to-day life with their patients.  I would like for my 
doctor to ask me questions about what’s going on, I mean, at my home front, give 
me suggestions and ideas that I can take home and use for, you know, if it’s a 
hard day, stuff like that.” (743, 25y/o, IPV+, SU-, MH+, GC) 
Minimizing violence. While participants tended to highlight their maternal and 
caregiving roles, there were other labels they were more hesitant to accept.  All nine 
women interviewed were selected for participation because they had reported past year 
IPV on survey measures. However, the majority of women did not define themselves as a 
survivor or victim of IPV, and did not connect partner violence with their HIV care or 
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adherence (see Table 4.2). For example, one participant who scored 25 (Extreme Danger 
category) on the Danger Assessment scale—a measure of risk for repeat severe or lethal 
violence by a partner during the survey—stated in the interview:  
“No, he never hit me. He never hit me. He was verbally abusive. I didn't know at 
the time he was high. He was on drugs. Drinking. I just can't tolerate any of that 
anymore. I used to when I participated. Because I live such a different life now, I 
just have no patience for any of it.”  (745, 50y/o, IPV+, SU+, MH+, GC) 
Another participant who also reported high levels of physical and sexual violence on 
survey measures, including a Danger Assessment score of 35, stated,  
“It would be shoving, throwing the water on each other…It was just different 
stuff.  It was definitely physical.  It wasn’t actual marks being left, but it wasn’t 
those… [participant stopped talking].”  (823, 25y/o, IPV+, SU-, MH+, GC) 
This participant reported that her health care provider had asked her about IPV in her 
relationship but she noted that she did not disclose IPV to the provider despite the 
physical and sexual violence she reported on the survey measures. 
Participants denied having partners who directly interfered with their ability to 
adhere to their current HIV care. Participants focused discussions primarily on their 
control over their health and their situations, minimizing the impact that their partners 
were able to have on adherence.  However, participants did note that partners could be an 
influencing factor on their ability to remain abstinent from drugs or alcohol. 
“Had I not been in therapy with [psychiatrist], I would have probably more or 
less relapsed with this guy. I would've probably got back on drugs, because I 
loved him and liked him.” (745, 50y/o, IPV+, SU+, MH+, GC) 
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“My husband would always give me alcohol. My husband never don't use, and he 
only drinks when I drink, right, because he's got nothing. He works all the time. I 
would always ask him for alcohol. He was a very big enabler for me. He really 
thought he was helping me, but he really wasn't.” (475, 28y/o, IPV+, SU+, MH+, 
PC) 
Participants also described strategies they used to minimize partners’ interference 
in their lives and health care including separate living arrangements, limiting a partner’s 
access to health care information, and use of the justice system to promote safety and 
behavior changes for themselves and their partner.   
“I know his probation officer. A lot of women, oh, I caught hell from my 
girlfriends. ‘You shouldn't. You shouldn't.’ Love is a strange emotion. I don't think 
there are any rules….I don't throw it up in his face, but he always knows there's 
room for me. I doubt everything that he says and everything that he does. Not 
doubt. Maybe I'm saying the wrong word. I watch him very carefully, because the 
moment a flag goes up, he will go permanently. I chose to give him another 
chance, because I loved him.” (745, 50y/o, IPV+, SU+, MH+, GC) 
 
“He said if I wanted him to leave, then I needed to get the police involved. That’s 
exactly what I did. Went and changed all the locks on my house. Went downtown, 
got a restraining order.” (676, 35y/o, IPV+, SU+, MH+, PC) 
“I know what I’m supposed to do” 
The second main theme identified during analysis was elicited frequently when 
participants were asked specifically about the things that made it easier or more difficult 
to adhere to prescribed HIV care, participants often echoed statements about the necessity 
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of coming to the clinic or taking medications such as “I know what I’m suppose to do,” “I 
just made up my mind,” “I don’t have a choice,” and “I decided to listen [to her provider 
regarding ART].” This sense of asserting control over the decision to adhere to care 
complimented the control that women wanted over their identity and the labels ascribed 
to them. The potential negative outcomes that participants associated with being non-
adherent included death, hospitalization, disability, and loss of child custody were all 
mentioned by individual participants.   
Accepting responsibility for care. The participants were knowledgeable about 
the risks of not adhering to prescribed HIV medications and clinic appointments and its 
impact on the disease process. The understanding that adherence to medications was life-
saving and within each individual’s control was clearly articulated throughout the 
majority of interviews. The notable exception was one participant who reported being 
actively engaged in drug use behaviors both during this study’s survey and interview.  
Despite reporting ongoing substance use, she did not associate her drug use with a lack of 
adherence to treatment and care. She stated multiple times throughout the interview that 
things were “good” or “fine”, and that there were “no problems” when asked to discuss 
how she thought her drug use impacted her health care. This was in direct contrast to her 
medical records, which indicated substantial challenges to adherence, which her health 
care providers attributed to drug and alcohol use as well as a detectable viral load and low 
CD4 count.  
Barriers to overcome.  Despite having an understanding of the medical necessity of 
HIV treatment and care, participants did report a variety of barriers to adherence. 
Participants identified commonly noted barriers such as lack of insurance and pharmacy 
access, limited transportation options to attend clinic appointments, and side effects of the 
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medication. In contrast to participant’s limiting the role of the abusive partner on 
adherence, they identified other aspects of the SAVA syndemic framework as having a 
direct impact on their ability to adhere to treatment and care (see Table 4.2). Participants 
described how both substance use and symptoms associated with depression and post-
traumatic stress altered their behaviors and thus limited attention to their health. The 
following two quotes provide examples of SAVA concepts as barriers to HIV care.   
“Nine months after being off of street drugs, I decided that I wanted to get high for 
five days, which violated me for probation. I had a nervous breakdown. Went to the 
psych ward. I'm not medicated at this point. I'm not really seeing doctors. I'm not 
doing nothing I'm really supposed to be doing. I'm barely scraping by.” (676, 35y/o, 
IPV+, SU+, MH+, PC)  
 
 “Well, I’m a type of person when I get…because I have bipolar and schizophrenia 
the littlest things can set me off, the littlest thing.  Like this month, it’s my rent…I 
mean it’s my bills.  I have more bills than I have money.  It gets me to a, it gets me to 
a depression state where I just be like, ‘You know, I’m not doing nothing, I don’t even 
care, forget this, I’m not taking no more of this medicine, I’m not doing this, I’m not 
paying nothing.’  I just go into this real depressed state and I just I shut down.  Just 
like when my father died, I shut down.  Everything just was on hold. Like, I didn’t 
take my medicine or nothing.” (743, 25y/o, IPV+, SU-, MH+, GC) 
Substance use in particular was noted as something that would interfere with care even 
for women who had extended periods of sobriety. Of note, while several women reported 
past year drug use on Phase 1 survey measures, all but one reported a period of at least 30 
days of sobriety at the Phase 2 interview. When examining substance abuse reporting in 
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the context of quantitative data regarding HIV disease control, we noted that participants 
who reported past year drug use on survey measures, tended to also fall into the group of 
participants with poorer HIV adherence and treatment markers (See Table 4.2).  
Discussion 
While this study’s purpose and design were based on the SAVA syndemic 
framework and included specific items related to the impact of IPV, depression, PTSD 
and substance abuse on women’s HIV care, we did not find that women acknowledged or 
reported each of the SAVA syndemic factors as equally important to their lives or their 
health care regimen. Women in this study were more likely to accept the label of “addict” 
or “in recovery” than they were the labels of “HIV-positive” or “victim/survivor of IPV 
or domestic violence”.  They were also far more willing to discuss the even more positive 
label of mother or caregiver, and how fulfilling this role was important. Control over 
disclosures and these labels appeared important to all women, despite varying levels of 
comfort with different labels.     
Importantly, despite the severity of the IPV women reported in the survey 
component of this study, women seemed to minimize these experiences of violence and 
the relevance of IPV to adherence to treatment and care during their interviews. This 
findings is not unique to our study, women in prior studies have presented various 
reasons for choosing not to identify as “abused”.  Prior work has highlighted the belief of 
some women that survivors of violence are strong and independent, and therefore feeling 
it was not necessary to disclose IPV or seek support or services, particularly after 
violence has ended (Amar, Bess, & Stockbridge, 2010; Campbell, Rose, Kub, & Nedd, 
1998; Gillum, 2009; Postmus, 2015; Tillman, Bryant-Davis, Smith, & Marks, 2010). 
Participants’ underlying beliefs about violence are particularly relevant given the setting 
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in which the current study was conducted. The clinic serves a primarily low income, 
African-American community in which social factors such as unemployment, low 
education levels and high rates of incarceration also impact patient’s lives and how they 
interpret violence. These intersecting sources of discrimination and stigma may serve to 
provide differential interpretation of the violent partner behaviors measured in this 
study’s survey. Prior research has explored cultural interpretations of IPV and found that 
not all women define specific acts of physical violence as IPV (Sokoloff & Dupont, 
2005). This dissonance between identified risk factors for poorer HIV care outcomes and 
women’s stated experienced and priorities presents a challenge to clinicians and 
researchers hoping to develop intervention programs, particularly for addressing the 
intersection of IPV and HIV.  
While sharing substance abuse-related concerns with health care providers was a 
relatively well accepted practice, sharing violence-related issues or concerns even with 
health providers was not a priority. They largely did not describe violence as a problem in 
their lives for which they required outside support or attention. The lack of disclosure to 
health care providers reflects ongoing safety and health challenges that may limit 
participant’s ability to utilize professional. Women’s relative ease of identifying and 
accepting the label of “in recovery” may be due to their reported participation in 
substance abuse treatment programs that place emphasis on acknowledging their 
addiction as part of the recovery process. This acknowledgement is seen as literally the 
first step in the recovery process and is accompanied by social support systems (DeLucia, 
Bergman, Formoso & Weinberg, 2015). However, there is no such model for IPV 
survivors. In fact, women in abusive relationships may have previously seen negative 
consequences from disclosure to family, friends or health care providers whose focus 
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often fixates on getting a woman to leave an abusive relationship (Illangasekare, 2011; 
Postmus, 2015; Sylaska & Edwards, 2014). A previous qualitative study conducted in 
Baltimore to examine social support with women who reported multiple SAVA syndemic 
factors noted that help-seeking and social support for IPV were more limited than mental 
health or substance abuse issues (Illangasekare, 2011). That study’s results also stated 
that fear of judgment about being in or staying in an abusive relationship was cited by 
women as a reason for not utilizing their usual sources of social support, such as friends 
and family members.  
Women in this sample also presented strategies for asserting control through 
sharing their diagnosis with their family and beyond.  They shared that particular care 
and attention was needed in maintaining limits regarding who was aware of their HIV 
diagnosis and the label of being “HIV-positive”. This finding is consistent with prior 
research in both the intersection of IPV and HIV, which has shown that women who have 
experienced partner violence are less likely to disclose their HIV status to a current 
partner (Tam, Amzel, & Phelps, 2015), and a broader disclosure framework that has 
presented individual, dyadic and social consequences of disclosing concealable identities 
(Chaudoir & Fisher, 2010). Women in the current study often held a number of socially 
stigmatized identities related to their experiences with violence, HIV, mental health and 
substance use. They have a great deal of experience in managing disclosures and as such 
have identified aspects of their identities in which the anticipated outcomes of disclosure 
are not consistent with their goals.    
Limitations 
The small sample size limits the generalizability of this study’s findings.  
Additionally, most study participants were contacted for and/or participated in the 
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interviews in conjunction with a scheduled clinic visit. This limited engagement of some 
women (particularly those who were identified with poor adherence) as they did not 
consistently attend their scheduled clinic appointment. The experiences of those women 
who were not engaging with the clinic on any type of regular basis may differ from those 
who were active in attending the clinic appointments and adhering to treatment protocols. 
Data collection for the two phases of this study took place over a two-year period 
between March 2014 and February 2016, therefore there was up to a year between the 
self-reported survey in Phase 1 and the invitation to complete the in-depth interview in 
Phase 2.  Given the time span between phases, participants experienced a variety of life 
events during the time between phases. Participants reported ending abusive 
relationships, starting new relationships that were healthy or abusive, relapsing into drug 
use, and entering substance abuse treatment programs. All of these historical changes 
may have impacted the ability to integrate findings from the two data collection phases. 
Chronologic distance from the immediacy of an abusive relationship may have 
contributed to some participants’ minimization of the impact of IPV on their daily 
activities.  
While the researchers had a great deal of survey and medical record information 
about the participants, we were challenged when identifying women for interviews who 
did not report any mental health symptoms or previous diagnosis.  While not all women 
reported active symptomology on the survey, all nine participants had a documented 
mental health diagnosis and/or were involved in psychiatric follow-up sessions through 
the clinic (See Table 4.2).  While this sample characteristic limits the generalizability of 
findings, it does demonstrate the importance of the factors identified on the SAVA 
syndemic framework for interventions with women who have an HIV diagnosis.   
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Implication for Practice 
Our study’s findings hold important clinical significance. Women’s continued 
reluctance to discuss or identify as having experienced IPV despite having reported 
partner behaviors that fit the definitions of IPV indicates a need to further understand 
how framing of IPV during screening and referral may impact patients’ disclosure and 
acceptance of referrals or other interventions.  Trauma-informed care models that include 
universal education about the impact of violence and trauma on health is one strategy to 
advance women’s comfort level with discussing these personal issues and with accepting 
referrals for follow-up care and community programs (SAMHSA, 2015; Machtinger, 
Cuca, Khanna, Rose, & Kimberg, 2015). The majority of participants in this analysis did 
not associate their experience with IPV with their health. Trauma-informed practices such 
as including universal education and standardized language related to the impact of 
violence and trauma on health, identification of traumatic events and its effects (i.e., 
PTSD, substance abuse), harm reduction and warm referrals (i.e., clinic providers 
contacting appropriate services with the woman such as domestic violence hotline and 
shelter information, legal services, sexual assault forensic services) can be used to help 
change the focus from disclosure to providing information, safety strategies and links to 
resources for safety planning, improved health and well-being (Bair-Merritt et al., 2014; 
Machtinger, Cuca, Khanna, Rose, & Kimberg, 2015; Miller et al., 2011; Nelson, 
Bougatsos, & Blazina, 2012; SAMHSA, 2015). 
Participants in this study presented safety behaviors, adherence strategies, and the 
positive maternal and caregiving roles as important to them. These are relevant 
components to consider when designing both clinic and community-based interventions. 
The importance of understanding patient priorities and including them in care planning 
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has shown promise in primary and acute care settings to improve outcomes including 
patient satisfaction, decreased health care utilizations, and improved medication 
adherence (Canadian Agency for Drugs and Technologies in Health [CADTH], 2015). 
Women’s reluctance to accept the role or label of victim or survivor of IPV may indicate 
that addressing adherence through patient identified barriers in addition to provider-
identified barriers and priorities may be beneficial. In this study’s sample, many women 
identified strongly with their roles as parents or caregivers.  Similarly, other research has 
shown that women are often willing to disclose IPV in order to provide safety for a child 
or to protect their safety and their child’s safety when pregnant (Rasool, 2016; Spangaro 
et al., 2016). Leveraging women’s desires to be a good mother may be another way in 
which to introduce the idea of violence as an issue of concern.  Framing messages related 
to IPV as related not only to women’s health, but also to their ability to fulfill the roles 
important to them may be useful. 
Lastly, women did highlight the importance of multiple SAVA syndemic factors 
in their treatment and care. Substance abuse and mental health symptoms were viewed 
individually and in combination to affect women’s ability to adhere to their HIV care. 
This finding supports the need to holistically address multiple contextual factors in 
addressing the HIV epidemic (Singer, 1996, 2009). Women in this study did not identify 
IPV as a factor impacting their own health, and they identified the criminal justice system 
as a primary source of support for issues related to IPV.  This was in contrast to issues of 
substance abuse that even women who had not used illicit drugs, or had several years of 
sobriety were clearly able to link adherence to treatment and care. Similarly, women were 
able to list multiple sources of support and interventions to address issues of substance 
abuse such as recovery groups, individual therapy, social support persons (both formal 
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such as a Narcotic Anonymous sponsor and informal such as close friends of family) and 
medication programs. Tapping into already established structures such as support groups 
and individual therapy sessions to incorporate information-sharing and creating safe 
places to discuss safety and healthy relationships and provide resources might be useful 
in improving adherence for IPV survivors.  
Implications for Research 
While the SAVA syndemic framework provides a lens through which to examine 
the multiple issues facing urban women living with HIV/AIDS, our results do present 
challenges with translating these research questions and findings into practice.  While 
other research has highlighted the associations between substance use, mental health, IPV 
and HIV care, not a great deal of attention has been paid to how women experience and 
prioritize these factors in their lives. Women’s choices regarding what labels and roles 
they identified with varied, and was not universally inclusive of the SAVA concepts they 
reported in survey measures. As such, identifying individual and cumulative effects of 
these factors becomes difficult if research measures of socially stigmatized identities are 
not consistent with what women identify with in practice. Syndemic theory provides an 
excellent framework for assuring that care is taken to address the multiple intertwined 
issues facing urban women, but translating these issues into realistic practices may 
require attention to individual perspectives and goals, not simply including a policy or 
intervention for each factor.  Additional research to examine whether both quantitative 
and qualitative reporting of labels and identities is similar or dissimilar over time would 
help to address the timing issues raised in this sample. Understanding how the roles and 
identities that women associate with change over time and whether these roles directly or 
indirectly impact their adherence to HIV care and subsequent treatment outcomes would 
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provide insight to tailoring interventions to appropriate clinical populations.   
Conclusions 
The women who participated in this study faced a wide range of competing issues 
that impact their health. They managed these priorities by asserting control over the 
factors that they could, which included close control over aspects of their identity—
aspects that they acknowledged during the study and those that they shared more widely. 
Women were much more willing to accept and share some roles (caregiver, “in 
recovery”) than they were others (“victim/survivor” of IPV, “HIV-positive”). This 
disconnect suggests that traditional one-time IPV screening at patient intake may not be 
sufficient to address the underlying pervasive issue of IPV, particularly in an urban 
environment in which patients face the impact of multiple social determinants of health 
regularly. In order to wholly address the disparities in HIV risk and outcomes noted by 
The White House in their 2013 interagency report and the 2015 National HIV/AIDS 
Strategy, additional methods to address trauma in the context of health are required 
(Interagency Federal Working Group, 2013; White House Office of National AIDS 
Policy, 2015). Our results suggest that simply including traditional IPV screening 
components in HIV care settings may not address the underlying violence issues if 
women are not identifying or recognizing IPV as a primary concern for themselves and 
their health. Trauma-informed care approaches that focus on promoting safe 
environments, liberally sharing safety planning and support resources with all patients, 
and repeated routine discussions of trauma and violence as health care concerns may be 
helpful in addressing the negative clinical impacts of IPV in HIV clinical settings. The 
syndemic framework guided this study and was useful in identifying social factors 
impacting care, but does have limitations in direct interaction with patients who may not 
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Demographic Characteristics of Interview Participants 
 
Agea  43 (25-57) 
Raceb  
Black 7 (78) 
White 1 (11) 
Mixed/other 1 (11) 
Education levelb  
8th grade or less 1 (11) 
Some high school 2 (22) 
High school diploma/GED 2 (22) 
Some college 3 (33) 
Associate’s/vocational degree 1 (11) 
Bachelor’s/4 year degree 0 (0) 
Graduate Work/Degree 0 (0) 
Insurance typeb 
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SAVA Factors Endorsed by Participants on Survey Measures (Survey), Documented by a Health Care Provider in Medical Records 
(MRA) or Noted by Participants to be Associated with HIV Care During Interviews (Interview) 
   SAVA Factors 
  
 






























































Poor HIV control 
group 
475 28/M             
536 43/B             
596 57/B             
676 35/W             
Good HIV control 
group 
653 46/B             
743 25/B             
745* 50/B             
746 51/B             
823 25/B             
Notes: W: white; B: black; M: multiple; MRA: medical records abstraction 
All participants were asked in survey and interview about each SAVA factor; positive survey results indicated above were quantified as 
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follows: 
IPV: past year, any positive response to an item on the Abuse Assessment Screen or any positive response to a moderate 
physical, severe physical or sexual violence item on the Severity of Violence Against Women Scale 
Mental health: Score of >44 on the Posttraumatic Checklist- Civilian (past month), Score >15 on the Center for Epidemiologic 
Studies-Depression (past two weeks) 
Substance abuse: past year, Positive response to item 1 on the Drug Abuse Screening Test (“Have you used drugs other than 
those required for medical reasons?”) 
Alcohol abuse: past six months, Score of >7 on the Alcohol Use Disorders Identification Tool 
*Participant not prescribed antiretroviral therapy has a detectable viral load and CD4 count >200 classified as “good control” based on 
adherence to current treatment plan. 
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CHAPTER FIVE: DISCUSSION 
Intimate partner violence (IPV) has been identified as an important risk factor for 
HIV acquisition among women. More recently, a small but growing body of literature has 
presented IPV as a risk factor for later entry to HIV care, decreased rates of ART use, and 
poorer ART adherence. The overall purpose of this dissertation was to examine the 
impact of IPV on HIV care adherence, and subsequent treatment outcomes among a 
sample of urban women attending an HIV-specialty clinic in Baltimore, Maryland. The 
SAVA syndemic framework was used to approach three specific aims, including 
determining the prevalence of IPV and other syndemic factors—mental health symptoms, 
substance use—in a sample of urban women living with HIV (Aim 1); identifying 
associations between IPV, mental health, substance use and HIV treatment adherence, 
and disease progression (Aim 2); and exploring women’s own perceptions of the impact 
of SAVA syndemic factors on their health (Aim 3).  For this purpose, 239 women were 
recruited from an urban HIV clinic, consented to complete a self-administered survey, 
and medical records review to address Aims 1 and 2. Nine of these women who reported 
past year IPV on survey measures subsequently participated in individual in-depth 
interviews in order to address Aim 3.  A brief summary of key findings and detailed 
discussions of their individual and combined contribution to the literature are presented in 
this chapter.  This is followed by study limitations and strengths as well as implications 
for practice, policy, theory and research.   
Past Year Report of IPV 
We found a significantly higher past-year prevalence (51% versus 27%) of IPV 
when compared to the previous estimate from the study clinic (Illangasekare et al., 2012). 
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This is likely a manifestation of difference in measurement. The prior study used the 
Partner Violence Screen (PVS), a three-item measure of IPV with one item for physical 
abuse, one item on feeling safe in a current relationship, and one item about ongoing 
violence from a previous partner (Feldhaus et al., 1997). For this current study, we used 
multiple measures of IPV to estimate past year prevalence. This decision was made in 
order to examine the underlying hypothesis that diverse forms of violence independently 
affect immune functioning and subsequent HIV disease progression. Participants first 
completed the Abuse Assessment Screen (a four-item screening tool that includes one 
item each for psychological, physical and sexual abuse, and one general relationship 
safety item) as an initial part of this study’s eligibility criteria. Survey participants also 
completed the Severity of Violence Against Women Scale (SVAWS). The SVAWS is a 
46-item tool measuring nine domains—symbolic violence, threats of mild violence, 
threats of moderate violence, threats of serious violence, mild violence, minor violence, 
moderate violence, serious violence, and sexual violence (Marshall, 1992). Each SVAWS 
item measures a specific violent behavior such as hitting, kicking, name calling, or forced 
sex (see Appendix C) as compared to more general clinical screening tools such as the 
AAS and the PVS.     
The 51% IPV prevalence among women in this study was comparable to the 2012 
meta-analysis estimate of 55% among women living with HIV (Machtinger, Wilson, 
Haberer, & Weiss, 2012). The same meta-analysis found the IPV prevalence higher 
among women living with HIV when compared to overall IPV prevalence among women 
in the U.S. (55% versus 36%). In addition to the 2012 meta-analysis, multiple literature 
reviews have commented on the challenges in comparing prevalence estimates given the 
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variations in measurement and sampling techniques (Campbell et al., 2008; Machtinger et 
al., 2012; Maman, Campbell, Sweat, & Gielen, 2000). While comparing screening 
methods was not an aim of this study, it should be noted that inclusion of items from the 
moderate violence, serious violence, and sexual violence categories from the SVAWS did 
contribute to our prevalence estimate.  Ninety-two women (38%) screened as positive for 
past year IPV on the AAS, and an additional 30 women (13%) were as having 
experienced past year IPV based on answers provided to perpetrator specific behaviors on 
the SVAWS. The reporting across diverse measures demonstrates that not all women 
having experienced past year IPV self-identify as a victim/survivor on screening items 
such as those on the AAS, but with by asking items on validated measures that described 
threats, physical and sexually abusive behaviors by partners, women reported IPV within 
the past year.   
Impact of IPV on HIV Treatment Outcomes 
The key finding from this study is the relationship between IPV and CD4 count; 
women reporting past year IPV were 3.5 times more likely to have a CD4 count >200 
compared to women not reporting past year IPV when controlling for demographics, viral 
suppression, mental health and substance abuse. This finding adds to the small body of 
literature on the impact of IPV on the overall health status of women living with HIV 
(Illangasekare et al., 2012; Rose, House, & Stepleman, 2010; Schafer et al., 2012; 
Siemieniuk et al., 2013). The importance of understanding the potential physiologic 
pathways such as chronic inflammation and immune dysregulation through which trauma 
such as IPV may affect CD4 count presents an immediate need for additional research to 
improve women’s health. Only through having a greater understanding of these 
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mechanisms can we identify opportunities to intervene in the biologic pathways in 
addition to the behavioral pathways such as adherence, substance use, and sexual risk 
behaviors. These biologic pathways currently present an untapped potential source of 
improving outcomes for patients living with HIV.   
Despite a significant independent relationship between IPV and low CD4 counts, 
the impact of IPV on having a detectable viral load was less clear. The literature 
describing the impact of IPV on viral suppression is still quite sparse. A 2015 meta-
analysis included seven studies that reported on a laboratory-based viral load 
measurement, and definitions of viral suppression varied across these studies from levels 
of <500 copies/ml to <200 copies/ml based on the laboratory testing and clinically used 
definitions in use at the time of data collection (Blank et al., 2015; Espino et al., 2015; 
Hatcher, Smout, Turan, Christofides, & Stockl, 2015; Illangasekare et al., 2012; Rose et 
al., 2010; Schafer et al., 2012; Siemieniuk et al., 2013; Sullivan, Messer, & Quinlivan, 
2015). Individually, three of these studies found significantly lower rates of viral 
suppression among women reporting IPV (Espino et al., 2015; Rose et al., 2010; 
Siemieniuk et al., 2013), while the remaining studies had non-significant findings. When 
combined in meta-analysis, the data from these seven studies showed that women 
reporting IPV had a 36% decreased odds of viral suppression when compared to women 
who did not report IPV (OR: 0.64, 95% CI: 0.46–0.90) (Hatcher et al., 2015). While our 
multivariable results for the viral suppression outcome did not maintain statistical 
significance when controlling for demographic and SAVA syndemic factors, the bivariate 
relationship between IPV and viral suppression was not dissimilar (OR: 0.54, 95% CI: 
0.30–0.99, p=0.05) to those reported by Hatcher and colleagues (2015) and Schafer and 
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colleagues (2012), however less precise. The loss of significance when other factors were 
added to the model may be a factor of sample size.  
In contrast to the CD4 count and viral load outcomes, we did not find any 
associations between IPV and missed clinic visits. Two prior studies also failed to find a 
relationship between IPV and missed HIV specialty care clinic visits (Illangasekare et al., 
2012; Schafer et al., 2012). However, Illangasekare and colleagues (2012) did note that 
women who had experienced IPV were twice as likely to have missed gynecology 
appointments, indicating that perhaps not all clinic visit types are equally attended or 
missed.  While missed gynecology visits may not contribute largely to variation in viral 
suppression, it does present opportunities for clinician and researchers to better 
understand what makes HIV care similar or different from other types of care and 
establish improved practice models that minimize re-traumatization in order to improve 
overall patient adherence and outcomes.   
Impact of Multiple Syndemic Factors on HIV Treatment Adherence: Substance 
Abuse and Mental Health  
Using a syndemic theory, we also examined other key factors associated with the 
SAVA syndemic in this study’s sample. Consistent with prior research, we found high 
rates of drug and alcohol use as well as reported symptoms associated with mental health 
conditions. All of these factors were individually associated with IPV. We did not find 
consistency in these factors being related to the three HIV adherence and treatment 
outcomes examined (CD4 count <200, detectable viral load, missing >25% of past year 
scheduled clinic visits). 
 A similar study examined and presented findings in regards to the impact of 
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PTSD on immune and inflammatory markers in a mixed gender clinical sample of 
patients living with HIV, and found a relationship between patient’s reporting symptoms 
of PTSD and a series of immune markers including CD8+ T cells, CD8 naïve cells, and 
CD8 memory cells (Siyahhan Julnes et al., 2016). They did not find a difference in mean 
CD4 count between those who met criteria for PTSD and those who did not using a 
guided interview screening tool administered by a board-certified psychiatrist, but their 
results present a potential pathway through which immune function may be affected by 
trauma (specifically PTSD). In this current study, we also did not find PTSD to be 
directly associated to CD4 counts, and were unable to measure additional biomarkers that 
may mediate this relationship. These differences may have been difficult to detect in our 
sample in part because of the high correlation between IPV and PTSD.  Women in our 
sample were 3.37 (95% CI: 1.74–6.53; p<0.001) times more likely to report past month 
PTSD symptoms if they also reported past year IPV and similarly, 4.01 (95% CI: 2.11–
7.62; p<0.001) times more likely to report past two week symptoms of depression.  
Reporting past two week symptoms of depression was associated with having 
missed >25% of scheduled clinic visits within the past year (aOR: 2.330, 95% CI: 1.012-
5.362, p=0.047).  In order to further examine pathways through which IPV may impact 
HIV treatment adherence and outcomes, we assessed mediation effects of symptoms of 
depression and PTSD on the relationship between IPV and each primary outcome. Only 
one of these pathways showed a significant mediation effect. Symptoms of depression 
significantly decreased the relationship between IPV and missing >25% of past year 
clinic visits (OR: 1.571, 95% CI: 0.937–2.633 versus OR: 1.359 95% CI: 0.790–2.339, 
Sobel: 2.04, p=0.041).  As the association of IPV with missed clinic visits was not 
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initially significant, interpreting the impact of depression on the association is limited. 
However, the consist relationship between depression and missed clinic visits highlights 
the importance of multiple interconnected factors affecting adherence and health 
outcomes among women living with HIV.  
While our findings differ from prior results which have shown that symptoms of 
both depression and PTSD have been directly associated with poorer HIV treatment 
outcomes including premature death and more rapid CD4 count decline (Cruess et al., 
2003; Ickovics et al., 2001; Ickovics et al., 2006, Leserman, 2000, 2003) both PTSD and 
depression are also notably more prevalent in samples reporting IPV than those that do 
not (Bonomi & Glass, 2008; Bonomi et al., 2009; Campbell, 2002; Gielen et al., 2005; 
Illangasekare, 2011; Illangasekare et al., 2013; Machtinger et al., 2012). The high rates of 
mental health symptoms and IPV in this sample may limit the ability to parse out the 
differential effects of each aspect. An overall limitation of the available literature on HIV, 
PTSD, depression and IPV is that studies examining one phenomenon often do not 
measure each of the others. As such, while overall conclusions can be inferred regarding 
the existence of a relationship between traumatic experiences such as IPV and poorer 
HIV treatment outcomes, the differential effects of individual trauma or the biologic and 
behavioral responses to trauma are difficult to discern from existing research including 
this study.   
Substance use was prevalent in our sample, with 50% of participants having either 
self-reported or provider-documented illicit drug use in the past year (compared to 10% 
of the U.S. general population), and had a direct impact on the missed clinic visit 
outcome (aOR: 2.826, 95% CI: 1.525–5.236, p=0.001) (National Councel for Health 
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Statistics, 2016).  Alcohol use was also far more prevalent in this our sample than in the 
general population (19% versus 6% of the U.S. general population) (National Councel for 
Health Statistics, 2016). The relationship between drug and alcohol use and the HIV care 
has been previously documented, with substance use impacting entry into care, adherence 
to care and morbidity (Dale et al., 2016; Gwadz et al., 2016; Kuchinad et al., 2016; 
Nicholas et al., 2014; Vagenas et al., 2015).  While alcohol abuse was not associated with 
negative HIV adherence and care outcomes in our sample, this current study’s finding 
related to the impact of drug use on clinic visit attendance is congruent with prior 
research highlighting the challenges of engaging in care during periods of active 
substance use (Gwadz et al., 2016; Kuchinad et al., 2016; Nicholas et al., 2014). As with 
PTSD and depression, both drug and alcohol use were more commonly reported by 
participants who also reported past year IPV. These associations, while not novel to the 
literature, support the need for a multifactorial approach when designing interventions to 
improve HIV adherence and treatment outcome among SAVA syndemic affected 
women.  
Women’s Experiences: Minimizing IPV and Managing Labels 
While a key finding from this study was the quantitative relationship between IPV 
and lower CD4 counts among urban women living with HIV, the women who 
participated in Phase 2 interviews (n=9) described their experiences differently.  While 
some participants did share current or past IPV, they did not report that abusive partners 
interfered with attending clinic visits or taking medications. While participants selected 
for interviews were by design selected to cover the range of outcomes (CD4 count 
>/<200, viral load detectable/undetectable and missed visits >/<25%), their reports that 
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IPV was not a driving factor in adherence was consistent with quantitative results, which 
did not link past year IPV with missing >25% of past year scheduled clinic visits, nor 
viral suppression in multivariable analysis.  
Not only did women interviewed not associate IPV with their current HIV care, 
but they often minimized the violence in general during qualitative interviews when 
compared to their responses to quantitative survey measures. This discordance in 
reporting is consistent with a disclosure model proposed by Chaudoir and Fisher (2010). 
Women may have previously experienced negative outcomes such as victim-blaming 
from disclosure of IPV (Amar, Sutherland, Laughon, Bess, & Stockbridge, 2012; Rose et 
al., 2011; Sutherland, Fontenot, & Fantasia, 2014; Sylaska & Edwards, 2014). Further, 
disclosure of IPV is often met with questions about why a woman stays in an abusive 
relationship or assumes that leaving the relationship is the only safe option. These 
responses from formal and informal support systems to disclosures can perpetuate 
avoidance of further disclosure and contribute to a “downward spiral of concealment” 
(Chaudoir & Fisher, 2010). This disclosure process model also importantly includes 
cultural and social norms regarding what is disclosed, to whom and at what times as an 
outcome factor that will further factor into decisions regarding disclosure or concealment.  
Women in our sample may have had a variety of reasons for not identifying with or 
disclosing IPV during interviews that remain unknown to the research team, but prior 
research may provide some guidance in interpreting this discordance. 
Our sample consisted primarily of urban African-American, low income women. 
This sample, while consistent with the clinic demographic may have contributed to their 
historical background, including prior experiences of discrimination and racisms in ways 
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that further impacted their perceptions of violence and willingness to disclose to either 
formal or informal support systems (Flicker et al., 2011; Gillum, 2009; Paranjape, 
Tucker, McKenzie-Mack, Sokoloff & Dupont, 2005; Thompson, & Kaslow, 2007; 
Tillman, Bryant-Davis, Smith, & Marks, 2010). While we did not systematically capture 
previous experiences of historical abuse or neglect across the lifespan during quantitative 
survey measure or qualitative interviews, six of the nine woman interviewed did disclose 
childhood abuse and/or a past lifetime experiences of IPV—indicating that they may be 
accustomed to a level of violence in their lives, have accepted it as being “normal”, and 
help-seeking behaviors may be viewed as signs of weakness (Amar et al., 2012; 
Campbell, Rose, Kub & Nedd, 1998; Gillum, 2009; Postmus, 2015; Sokoloff & Dupont, 
2005; Tillman et al., 2010). In addition to the SAVA syndemic factors directly inquired 
about, transactional sex and homelessness were also reported by more than one woman 
during qualitative interviews. These topics were not the primary focus on the analysis or 
results, however, it does suggest a high level of cumulative trauma experienced by 
participants as would be consistent with prior samples of women living with HIV 
(Brezing, Ferrara, & Freudenreich, 2015; LeGrand et al., 2015; Machtinger, Wilson, 
Haberer, & Weiss, 2012).  
Time between participation in survey measures and in-depth interviews may also 
have contributed to the discrepancies in reporting of IPV. There was over a year between 
Phase 1 and Phase 2 data collection for some participants. During this time period, 
women reported ending abusive relationships, starting new relationships, entering 
substance abuse treatment programs, relapsing into active drug use, or being hospitalized 
for opportunistic infections. Particularly, the changes in relationship status may have led 
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to the limited discussion of IPV and the association with adherence and health during the 
in-depth interviews as it was seen as a past issue and not a current one. However, prior 
work has shown the effects of IPV on health and PTSD resulting from IPV and other 
trauma lasts long after the abuser is gone (Ford-Gilboe et al., 2015; Wuest et al., 2009; 
Wuest et al., 2010). The difference in data collection method may also have played a role. 
Prior research conducted in clinical settings found that screening using paper-and-pencil 
or computer-based methods resulted in higher rates of IPV and substance abuse 
disclosure than in-person screenings (Delker, Aharonovich, & Hasin, 2016; Rhodes et al., 
2006; Trautman, McCarthy, Miller, Campbell, & Kelen, 2007).  
While temporal distance from IPV may have played a role in women minimizing 
its impact on their lives and health, for both substance use or mental health issues, 
distance from an acute situation appeared to provide women a safe way to discuss these 
barriers to care. Women who had a history of substance abuse (some despite over a 
decade of abstinence) readily identified as “in recovery”, and were active in programs to 
maintain sobriety including Narcotics Anonymous, methadone or buprenorphine 
programs, and individual therapy. In contrast, there is not the ongoing easily accessible 
support for survivors of partner violence, nor a general community recognized and 
honored designation of “survivor” of except within small circles of IPV service 
providers. Again, lack of support systems and prior negative experiences with disclosures 
may have influenced women’s decisions to discuss these issues of IPV during the 
interviews (Flicker et al., 2011; Gillum, 2009; Illangasekare, 2011; Paranjape, Tucker, 
McKenzie-Mack, Sokoloff & Dupont, 2005; Thompson, & Kaslow, 2007; Tillman, 
Bryant-Davis, Smith, & Marks, 2010. Further, the study clinic has clear procedures in 
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place for addressing mental health and substance abuse, which are not standard for 
addressing issues of violence.  This differential awareness and sensitivity regarding the 
issues may color what participants chose to discuss with the research team.  
Despite being resistant to accept the label of victim/survivor of IPV during 
interviews, the participants readily identified with their roles as mothers or caregivers. 
Participants discussed taking steps to enter into treatment or adhere to HIV regimens in 
order to care for or be there for their children. The importance of the role of mother as a 
stressor and source of strength and pride for women experiencing violence has been 
previously noted in the literature (Jones & Vetere, 2016). Prior research has also shown a 
similar phenomenon in which women are willing to take actions such as involving the 
criminal justice system or leaving an abuser in order to protect their children (Jones & 
Vetere, 2016; Rasool, 2016; Zink, Elder, & Jacobson, 2003). The relationship between 
children and care seeking is not limited to the IPV literature. However, in the HIV 
literature, children have been found to be associated with decreased engagement in care 
(Blank et al., 2015; Mellins, Kang, Leu, Havens, & Chesney, 2003). Further work to 
examine if the relationship between children and HIV care engagement and adhernece 
varies based on expereiences of violence is needed.  
Limitations and Strengths 
 The findings of this study must be interpreted within the context of its limitations.  
The cross-sectional nature of this study limits the ability to draw inferences regarding 
causality. The use of time limited self-reported variables within predefined windows (i.e., 
past year IPV, past year drug use, past month symptoms of PTSD, past two week 
symptoms of depression) helped to increase our ability to place variables within a 
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timeline, including our decision to test the mediation effects of symptoms of PTSD and 
depression on the relationship between IPV and CD4 count, viral load and missed clinic 
visits. A longitudinal design would have allowed a greater ability to assess potential 
causal relationships.  However, the SAVA syndemic framework indicates that the 
relationships in question between substance abuse, intimate partner violence, HIV 
diagnosis and care are not simply a direct linear pathway. Figure 5.1 shows a depiction of 
the key domains of the SAVA syndemic (mental health, violence, substance use, and 
sexual risk taking behaviors) overlying the background of HIV (Draughon, 2015). In this 
model, each concept is shown with a direct relationship to each of the other concepts in 
the framework. While each individual SAVA construct has been previously linked to risk 
of HIV acquisition and/or challenges in entering or adhering to care more complex 
statistical methods such as structural equation modeling as utilized in a growing number 
of studies may provide future opportunities to examine these complex relationships 
(Coulter, Kinsky, Herrick, Stall, & Bauermeister, 2015; Halkitis et al., 2013; Mustanski, 
Andrews, Herrick, Stall, & Schnarrs, 2014; Wilson & Widom, 2011). Clarity in statistical 
modeling of syndemics has also recently been called for by Tsai & Venkataramani who 
argue that statistical models of syndemic that fail to include the interaction effects of each 
set of variables are not truly testing for the synergistic effects, but simply additive effects 
or in the case of summary scores, a “cumulative impact of adversity” that is even more 
challenging to interpret (2016). Examining the compounding effects of type and severity 
of IPV and other traumas on mental health symptoms and behavioral factors and the 
synergistic effects of these on physiologic processes such as inflammation and immune 
response with longitudinal studies is also imperative to a better understanding of 
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chronology. Mixed method studies that include opportunities to examine participant 
perceptions in addition to these statistical methods might provide the most 
comprehensive picture in understanding the SAVA syndemic and designing interventions 
to address its impact.  
The use of self-reported measures may have introduced bias in the form of both 
issues with recall or social desirability. For instance, we noted that there was a proportion 
of participants who we identified on past year medical records review as having used 
illicit drugs (n=28, 12%) who did not answer ‘yes’ to having used illicit drugs on the 
survey measures. The use of computer-based, participant-enter data collection methods 
and confirmation of substance abuse reporting with medical records were steps taken to 
minimize these reporting biases (Delker, Aharonovich, & Hasin, 2016; Rhodes et al., 
2006; Trautman, McCarthy, Miller, Campbell, & Kelen, 2007). Our choice to combine 
both self-report and medical records data into one “past year drug use” dichotomous 
variable may have over estimated the prevalence of past year substance abuse in the 
sample and decreased our ability to discern differences in outcomes between those who 
were truly engaging in continued substance use. 
The use of survey measures as opposed to clinical diagnoses for mental health 
variables may have contributed to our findings by under or over-identifying participants 
with the underlying diagnosis. We chose measures for PTSD and depression that are both 
widely available and have been utilized in a variety of settings including other samples of 
abused women and/or African American women (Anderson, Stockman, Sabri, Campbell, 
& Campbell, 2015; Blanchard, Jones-Alexander, Buckley, & Forneris, 1996; Canady, 
Stommel, & Holzman, 2009; Radloff, 1977; Ruggiero, Del Ben, Scotti, & Rabalais, 
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2003; Searle et al., 2015). Of particular importance was the selection of a PTSD measure 
that did not require identification of one primary trauma for which responses must be 
keyed to. This decision allowed participants who had experienced multiple traumatic 
events or ongoing traumas such as IPV to complete survey measures without having to 
identify one specific instance or event in order to answer questions.  While these survey 
methods may have increased sensitivity and decreased specificity compared to a 
diagnostic interview or documented diagnosis by a health care provider, they allowed us 
the ability to identify those participants currently experiencing symptoms (within the past 
month). This served to both minimize recall bias, and provide an opportunity to assess for 
mediation effects of mental health symptoms on the relationship between IPV and each 
of the three HIV adherence and treatment outcomes.  
Use of medical records to measure in place of self-reported adherence or 
outcomes measures for each of our three outcomes provided additional validity to our 
results. The cross-sectional design and reliance on medical records data do present a 
challenge to establishing any temporality to the data. There was a small proportion of 
laboratory values (n=16, 6.3% for CD4 count; n=9, 3.8% for viral load) outside the one-
year period in which other study variables (including IPV) were measured. The 
proportion of laboratory measures from more than one year prior to the survey was 
statistically similar across outcome measures (CD4 count </>200; viral load 
detectable/undetectable; missed visit proportion </>25%) and SAVA variables (IPV, 
PTSD, depression and substance use) so while this impedes generalizations regarding 
timing and causality, there is not reason to believe that it would otherwise systematically 
bias our results. Independent collection of blood samples during data collection to assure 
 164 
consistency in timing of laboratory specimens in relations to survey measures could have 
strengthened the design and interpretation of findings. Inclusion of additional markers of 
inflammation or immune function could also be used to address the biologic versus 
behavioral impacts of IPV on HIV outcomes (see Figure 5.2).   
 While the missed clinic visit outcome was time bounded to be consistent with the 
survey measures of IPV and substance abuse, we were limited to access to one health 
system’s records. Since receiving HIV care at the study clinic was part of the eligibility 
criteria for participation in this study, all participants had at least one scheduled visit in 
the past year. There was a group of women who were high utilizers of the health care 
system (n=40, 16.7% with more than one scheduled visit per week on average; n= 7, 
2.5% with more than two scheduled visits per week on average). This included women 
who received intensive substance abuse treatment programs (i.e., daily methadone or 
buprenorphine programs) through the Johns Hopkins Medical Institution (JHMI) system.  
As women may have received health care services outside the JHMI system, we might 
not have captured their “regular” clinic attendance patterns.  We chose to include all 
scheduled visits (not just HIV care related visits), to obtain a more holistic picture of 
women’s care attendance. As one previous study did find IPV to be associated with a 
greater likelihood of missed gynecologic visits, future work to examine the relationship 
between IPV and adherence to various types of clinic visits is warranted (Illangasekare et 
al., 2012). 
 The use of a primarily self-referred convenience samples for the study also limits 
our ability to generalize outside of the sample. Women who chose to approach the 
research team and participate in the study may have differed from those women who did 
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not. Human subjects’ protection concerns limit the ability to utilize probability sampling 
methods given the small size of the overall clinic population. Larger multisite studies 
may be better able to achieve a representative sample. Similarly, for Phase 2, participants 
were selected for interviews using the quantitative data and a theoretical sampling frame 
based on key SAVA syndemic concepts. The nature of this small, explanatory phase of 
the study limits our ability to generalize regarding the perceptions even of the entire 
sample, much less all women living with HIV.     
  While power calculations based on results of relevant recent studies indicated 
that sample size was adequate to examine the primary aims of this study (See Appendix 
A), including determining the prevalence of IPV and assessing for relationships between 
IPV and the CD4 count/viral load, it likely limited the ability to explore additional 
aspects of the complex and often bidirectional or cyclic relationships between the SAVA 
syndemic factors including IPV, mental health symptoms, substance abuse, and HIV 
treatment outcomes.   
Implications for Practice 
The relationship between IPV and CD4 count presents an immediate clinical need 
to be investigated. Our results suggest that IPV impacts HIV disease progression.  The 
case studies presented by Machtinger and colleagues (2015) in their publication “From 
Treatment to Healing: The Promise of Trauma-Informed Primary Care” highlighted the 
devastating impact that both past and current trauma can have on patients living with 
HIV. Alongside both our results and others that demonstrate differences in immune 
markers between patients who report violence or trauma and those that do not, these 
anecdotes become even more compelling (Hatcher et al., 2015; Siyahhan Julnes et al., 
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2016).  
While the SAVA framework and quantitative results from Phase 1 of this study 
identified multiple SAVA aspects impacting HIV adherence and treatment outcomes, the 
participants did not as readily identify these complex connections during Phase 2 
interviews. The reluctance of Phase 2 interview participants to identify as having 
experienced partner violence during qualitative interviews and their consequent difficulty 
making direct connections between their IPV experiences and HIV treatment, presents 
challenges for clinician attempts at identifying women who may benefit from IPV 
specific service referrals, and ultimately thwarts efforts to address the impact that 
violence is having on women’s HIV disease process. Consistent with prior research, our 
results suggest that computer-based screening for IPV may produce higher disclosure 
rates (Hussain et al., 2015; Klevens, Sadowski, Kee, Trick, & Garcia, 2012; Rhodes et 
al., 2006; Trautman et al., 2007). Use of computer-based screening methods may be one 
tool that can be added to clinical services to provide a holistic assessment of patient 
experiences. Computer-based screening methods utilized in conjunction with trauma-
informed care approaches may also be particularly useful in the clinical context. Trauma-
informed care approaches highlight that while screening is important, disclosures are not 
the ultimate goal of these programs and stress the importance of creating health care 
settings as safe spaces to discuss and obtain help for issues if needed (SAMHSA, 2015; 
Brezing, Ferrara, & Freudenreich, 2015; Machtinger, Cuca, Khanna, Rose, & Kimberg, 
2015; Reeves, 2015). Providing routine opportunities for disclosure and normalizing 
discussions of the impact of trauma and violence on health and decreasing stigma within 
the context of health care issues might help women be more willing or able to identify 
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IPV as a factor in their own lives. Routine discussions of how violence affects health also 
provides opportunities for providers to share community and clinic IPV and trauma-
related resources universally with all patients, and not just limited to those who disclose 
current or acute concerns with IPV.   
 Such trauma-informed programs move beyond traditional IPV screening efforts 
that focus on asking patients about current safety concerns and providing a one-time 
referral or phone number for IPV-related services. Machtinger and colleagues (2015) 
presented four main components to creating a trauma-informed HIV practice—
foundation, environment, screen, and response. Foundation involves the need for the 
clinic leadership to support and build the necessary tools for systematically implementing 
trauma-informed practices. This includes building partnerships with community 
organizations (i.e., domestic violence shelters, hotlines, forensic nurse examiner 
programs), developing tools for use in medical records systems, and providing ongoing 
support and evaluation of clinic efforts.  Environment builds from this foundation to 
develop a clinic space that is calm and supportive of patients and providers. This can 
include minimizing noise in waiting areas, providing privacy for patient check in/out, and 
keeping patients informed regarding wait times. Screening may include screening not 
only for current individual traumas (such as IPV), but also historical traumatic 
experiences and the sequella of trauma (such as substance use, suicidality, PTSD and 
depression).  Response involves both on-site and off-site referrals for mental health 
services, use of the medical records system to track and repeat screenings, providing 
follow-up options, and utilizing warm referrals (where a clinician provides direct 
assistance in contacting other providers with the patient) to community partners for 
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additional services. Trauma-informed care models are increasingly being implemented in 
practice particularly in behavioral health and substance abuse treatment settings 
(SAMHSA, 2015; Morrison et al., 2015). The focus of trauma-informed programs on 
providing routine education to all providers and patients regarding the impact of trauma 
on health regardless of reported trauma disclosures may be particularly helpful in 
instances such as those we uncovered in qualitative data whereas women minimized their 
experiences with violence and its impact on their health. Our findings that the individual 
SAVA syndemic aspects of IPV, substance use, and mental health all impact some aspect 
of HIV care adherence or outcomes support the use of a multifaceted, systematic and 
interdisciplinary approach to addressing the complex outcomes of trauma. As nurses are a 
critical element of the health care system in providing care to patients living with HIV, 
and the importance of individual context in trauma-informed care models is fully 
congruent with nursing’s holistic perspective of health, nurses are poised to become 
leaders in implementing compassionate trauma-informed practices in HIV care settings.  
Implications for Policy 
 At the national policy level, there has been much recent attention given to 
disparities in HIV risk and care.  The vision statement noted in the National HIV/AIDS 
Strategy clearly states: 
“The United States will become a place where new HIV infections are rare, and 
when they do occur, every person, regardless of age, gender, race/ethnicity, 
sexual orientation, gender identity, or socio-economic circumstance, will have 
unfettered access to high quality, life-extending care, free from stigma and 
discrimination.” (The White House Office on National AIDS Policy, 2015). 
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In order to achieve this vision, an important action item is to address violence against 
women and girls, which contributes to poorer HIV adherence and treatment outcomes. 
Our findings adds important knowledge related to women’s experiences and perceptions 
of the relationship between IPV and HIV care. While we found an association between 
IPV and having a CD4 count <200, we did not find the same relationship between IPV 
and viral load or missed clinic visits. There is potential for a physiologic pathway through 
which trauma directly relates to how future policy can begin to address trauma-induced 
disparities in care. Attention must be paid not only to adherence intervention and linkage 
to care, but also to a more comprehensive understanding of the physiology behind these 
processes.  
Our finding regarding the discordance in women’s reporting of IPV on survey 
measures and during follow-up interviews also has relevance to policy makers in 
determining what types and methods of IPV screening may be best suited for widespread 
clinical practice. Screening for IPV has been widely promoted by the American Nurses’ 
Association for over a decade and additional nursing and medical specialty organizations 
have followed their lead in the interim years (American Medical Association, 2007; 
American Nurses Association, 2000; Emergency Nurses Association & International 
Association of Forensic Nurses, 2013), yet universal screening has not been consistently 
implemented (Ghandour, Campbell, & Lloyd, 2015; Paterno & Draughon, 2016). Two 
area in which barriers to screening has arisen as an issue in the literature are: 1) health 
care providers’ lack of time or reimbursement for screening and 2) lack of knowledge, 
skills or resources by the provider in order to respond to positive screens (Ghandour, 
Campbell, & Lloyd, 2015; Jaffee, Epling, Grant, Ghandour, & Callendar, 2005; Paterno 
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& Draughon, 2016). Prior research has shown that screening without acknowledging 
positive screening results has limited ability to produce changes in outcomes (Gielen, 
Burke, McDonnell, Illangasekare, & Mahoney, 2010; Moyer & Force, 2013). Policy 
makers have begun to address the issue of time and payment in the Affordable Care Act 
provisions which call for “screening and brief counseling” for IPV to be a universally 
covered prevention intervention (Ghandour, Campbell, & Lloyd, 2015; Institute of 
Medicine, 2011; Patient Protection and Affordable Care Act, 2010). Computerized 
screenings have the potential to further address both concerns. Computerized screenings 
are of low resource intensity, and can be used to implement a variety of protocols 
including patient and provider initiated referral to services, lethality assessment and 
tailored risk messaging (Eden et al., 2015; Glass, Eden, Bloom, & Perrin, 2010). We 
found that less than half of the participants in our sample who triggered our safety risk 
protocols for suicide and intimate partner homicide consented to sharing of this 
information with their health care team. While we did not systematically collect data 
regarding reasons for declining this referral, our use of computer-based data collection 
allowed us to capture this data and provide resources based on a participant’s noted 
preference. With the goal of a comprehensive trauma-informed response being not simply 
to promote disclosures, but to increase awareness and provide resources to all patients, 
validated screening tools implemented via computer or online methods as part of the 
trauma informed care protocol may be one way to engage patients in this process. 
Computer-based screening and referrals via internet-based resources provides one option 
for patients and can be integrated into trauma-informed health care system responses to 
alert providers regarding responses, trigger referrals ot appropriate on-site services, and 
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allow patients additional privacy and autonomy during the screening, disclosure and 
referral process (Eden et al., 2015; Glass, Eden, Bloom, & Perrin, 2010).   
As trauma-informed care approaches are further developed and tested in clinical 
settings, their importance in HIV care settings should also be realized. In order to address 
the high prevalence of violence and trauma experienced by patients living with HIV, 
funding programs such as The Ryan White HIV/AIDS Program should consider 
incorporating trauma-informed care models in their service delivery. Such models 
directly speak to providing culturally sensitive, high quality care to all patients living 
with HIV and further the mission of the Ryan White Program of providing 
comprehensive HIV care to those who in greatest financial need.  
Implications for Theory and Research 
 The SAVA syndemic theory guided the conduct of this study. We found the 
theory to be helpful in providing a broad overview of the factors that are important to 
consider when addressing HIV adherence and treatment outcomes among urban women. 
Syndemic theory highlights the importance of addressing multiple factors simultaneously 
as the combined effects of individual factors have a greater impact than their respective 
parts. The SAVA theoretical framework aligns closely with the holistic view of health 
and individualized responses to health from which nursing draws its underlying 
philosophies and is therefore apropos for use in nursing research. The often cyclic and 
symbiotic nature of the relationships presented by the theory, however, does become 
challenging to statistically test and interpret mathematically, and our initial conceptual 
framework presented in Chapter One (see Figure 1.1) fails to capture much of this 
nuance. In order to better understand the effects of these relationships in the lives of our 
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study participants, we employed multiple methods of data collection and analysis which 
allowed us to examine individual factors using statistical methods, but also to explore 
women’s stories and perceptions of the individual and combined effects of the SAVA 
syndemic factors on their health. Similar application and assessment of the SAVA 
framework to both nursing and interdisciplinary research questions regarding patient 
entry and adherence to HIV is warranted.  
 Since the onset of this study, a more complete conceptual framework for 
envisioning the relationship between IPV and HIV susceptibility, acquisition, and disease 
progression was published. The 2013 model includes factors that we did not measure in 
the current study such as partner characteristics and risk behaviors, childhood sexual 
assault and separate but related pathways for acute inflammatory responses (such as to an 
individual instance of sexual assault or sexually transmitted infection), and chronic 
immune dysfunction as a result of prior trauma history (Campbell, Lucea, Stockman, & 
Draughon, 2013).  An adaptation of this model is presented in Figure 5.2, including 
relationships demonstrated in the current study. This model combines HIV acquisition 
and disease progress into one outcome. While this helps to highlight the fact that trauma 
is important in assessing HIV risk both before and after diagnosis, it quickly adds to the 
complexity of the model. The use of more traditional stress and adaptation models might 
present alternate frameworks for examining risk of HIV acquisition and disease 
progression as separate outcomes. The factors presented in the Campbell model can be 
readily organized into a model similar to those presented in allostatic load literature (See 
Figure 5.3) including sources of stress (IPV, childhood sexual assault, partner behaviors, 
environment) and a series of individual responses to stress—physiological (including 
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both acute and chronic responses), psychological (PTSD, depression) and behavioral 
(substance use, adherence to care, other risk-taking behaviors), all of which in turn 
determine the ability of the individual to demonstrate adaption and allostatis over time 
(Berger, Juster, & Sarnyai, 2015; McEwen & Stellar, 1993; Sarnyai, Berger, & Jawan, 
2016). 
Participants’ interpretation of the disparate impact of SAVA variables on their 
health also provides insight for future use of the framework. Women’s reluctance to 
identify with certain roles or labels (i.e., victim or survivor of IPV, person living with 
HIV, addict, or alcoholic) may indicate that focusing attention on individual labels that 
are not immediately meaningful to a patient may present challenges to addressing these 
issues in both clinical and research settings. While use of measurement instruments that 
included specific behavioral items (i.e., hit, kicked, name calling, forced vaginal sex, 
etcetera) allowed us to utilize an inclusive definition of IPV and capture the experiences 
of those women who may not identify as being in an abusive relationship, yet still be 
subject to the negative physical and mental health consequences of that violence, it does 
not alleviate the issue of how women perceive violence in their lives. Had we not 
employed a mixed-methods technique during this study, we would not have been aware 
of the incongruities in how violence was perceived or defined by the research team and 
by the participants. Future use of the SAVA syndemic framework should take care to 
identify issues regarding how measurement tools may define individuals differently than 
they perceive themselves. While attention to measuring concepts as defined by the 
research community is needed to produce valid results, ensuring inclusion of participants’ 
perspectives is particularly relevant in translating research into practice.  
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Perhaps most important to future research is the use of long-term longitudinal 
designs of representative probability samples to measure trauma and its impact on mental 
health, physiology and health behaviors over time in order to establish causation versus 
association. Inclusion of a range of laboratory markers to assess acute and chronic 
inflammatory responses to trauma may help to identify particular time points or 
conditions in which medical interventions may be beneficial in addition to behavioral 
interventions. Inclusion of multiple data sources, including qualitative data to provide 
patient context is key to assuring results can be translated into practice.   
Summary 
 This research study aimed to better understand the relationship between IPV and 
HIV adherence and treatment outcomes among a sample of urban women. As such, this 
study adds to the limited body of literature examining the impact of IPV and trauma on 
adherence to HIV care and subsequent treatment outcomes. The impact of IPV on the 
HIV treatment outcome of CD4 count demonstrates the potential for direct physiological 
pathways between trauma and health. Longitudinal research focusing on lifetime 
experiences of trauma and including a combination of biologic, diagnostic and self-
reported data are required to more completely understand the specific pathways and 
identify areas in which interventions can be most successfully developed and utilized.  
Establishing trauma-informed clinic settings for patients living with HIV as well 
as within the related field of psychiatry and substance abuse treatment are steps that can 
be undertaken now to improve providers’ understanding of and response to the SAVA 
syndemic in urban settings. A trauma-informed approach allows for incorporation of 
understanding that not all patients will perceive individual syndemic factors in the same 
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way. It also provides multiple opportunities for engaging patients in interventions to 
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Figure 5.1. Conceptual framework of SAVA syndemic factors.  
 
 
Note: Used with permission of the author (Draughon, 2015).  
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Figure 5.2. Conceptual framework of the impact of IPV on HIV disease progression. 
 
Note: Conceptual framework, adapted from Campbell, Lucea, Stockman, & Draughon (2013). Solid lines indicate statistically 
significant relationships noted in the current study. Shaded circles and dotted lines were not measured or tested in the current study. 
Dashed lines indicate relationships tested but not found to be significant in this study.  
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APPENDIX A: POWER ANALYSIS 
An initial power analysis for Aims 1 and 2 was conducted during study design 
based on available data from the clinic and the literature using PASS Version 14 (NCSS, 
2015). 
Aim 1: Past year prevalence of IPV among the women receiving care in the 
Moore Clinic has previously been estimated at 25%, using this estimate and given a 
population of approximately 1,500 women receiving care at the clinic, sample size was 
calculated for various precision levels (Illangasekare et al., 2012). Table A.1 shows the 
sample sizes necessary to examine the true proportion with α = 0.05 and varying 
precision.   
Aim 2: Detectable odds ratios (ORs) were calculated assuming 73% of female 
patients with suppressed viral loads (<200 copies/ml) and 88% with CD4 counts greater 
than 200 supplied by the Moore Clinic as of May 2012 (personal communication, 
Richard Moore). Sample sizes were calculated assuming α =0.05 and power of 0.8 and an 
IPV rate of 25%. Table A.2 shows the necessary sample size to detect associated ORs for 
the two primary study outcomes, CD4 count <200 and detectable viral load. 
Based on the results of the two sets of sample size calculations, an initial sample 
size of 350 was chosen to allow for the detections of a moderate to large difference in 
odds for both outcomes and estimate prevalence within +/- four to five percent.  At the 
time of the original power calculation, only one study could be found for use in 
estimating effect size for the relationship between IPV and CD4 count (Schafer et al., 
2012).  They found that IPV resulted in a risk ratio of 3.97 for having a CD4 count <200 
and a risk ratio of 1.92 for having a detectable viral load.   
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After reviewing safety and prevalence data from the first 169 participants with 
completed survey and medical records data, past year prevalence was noted to be 57%, 
and a significant bivariate association between IPV and CD4 count was noted (Χ2: 4.304, 
p=0.038).  At this point, power was re-calculated using an IPV prevalence of 50% (see 
Tables A.1 and A.2), and the decision was made to stop recruitment after 260 women had 
been accrued.   
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Sample Size Needed to Estimate IPV Prevalence with Varying Precision  
 IPV Prevalence 25% IPV Prevalence 50% 
Precision 95% CI n 95% CI n 
0.06 0.19—0.31 215 0.44—0.56 260 
0.05 0.20—0.30 306 0.45—0.55 
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Table A.2  
Sample Size Needed to Detect Specified ORs for Primary Outcome Variables, power= 
0.80, α=0.05 
 
 IPV Prevalence 25%  IPV Prevalence 50% 







2.0 1158 555 293 489 
2.5 - - 163 262 
3.0 571 260 112 174 
3.5 - - 85 128 
4.0 419 185 - - 





APPENDIX B: ADDITIONAL DATA ANAYLSIS TABLES 
Table B.1  








n=214  p 
ART Prescribed in Past Year     
Yes 223 (93) 24 (96) 199 (93) 0.569 
No 16 (7) 1 (4) 15 (7)  
     
AUDIT >7*     
Yes 45 (19) 7 (28) 38 (18) 0.224 
No 192 (81) 18 (72) 174 (82)  
     
CES-D >15*     
Yes 64 (27) 8 (32) 56 (26) 0.552 
No 173 (73) 17 (68) 156 (74)  
     
Children Under 18      
Yes 49 (21) 8 (32) 41 (20) 0.132 
No 190 (80) 17 (68) 173 (81)  
     
DA Score >14 [n=124] a     
Yes 30 (24) 4 (21) 26 (25) 0.728 
No 94 (76) 15 (79) 79 (75)  
     
DAST-10 >2*     
Yes 104 (44) 12 (48) 92 (43) 0.661 
No 133 (56) 13 (52) 120 (57)  
     
Ethnicity*     
Hispanic 3 (1) 0 (0) 3 (2) 0.542 
Not Hispanic 226 (99) 25 (100) 201 (99)  
     
Employment Status     
Employed 30 (13) 5 (20) 25 (12) 0.235 
Unemployed 209 (87) 20 (80) 189 (88)  
     
Graduated from High School     
Yes 137 (58) 15 (63) 122 (58) 0.641 
No 99 (42) 9 (38) 90 (43)  
     
Insurance      
Public 231 (97) 24 (96) 207 (97) 0.848 









n=214  p 
     
Lived with partner in past 
year      
Yes 124 (52) 12 (48) 112 (52) 0.681 
No 115 (48) 13 (52) 102 (48)  
     
Partner Gender     
Male 226 (95) 25 (100) 201 (94) 0.448 
Female 12 (5) 0 (0) 12 (6)  
Transgender Female 1 (0.4) 0 (0) 1 (0.5)  
     
Past Year Drug Use     
Yes 120 (50) 17 (68) 103 (48) 0.060 
No 119 (50) 8 (32) 111 (52)  
     
Past Year IPV     
Yes 122 (51) 18 (72) 104 (49) 0.027 
No 117 (49) 7 (28) 110 (51)  
     
PCL-C >44*     
Yes  56 (24) 7 (28) 49 (23) 0.586 
No 181 (76) 18 (72) 163 (77)  
     
Race     
Black/African American 207 (87) 21 (84) 186 (87) 0.807 
White Caucasian 9 (4) 2 (8) 7 (3)  
Mixed/Other 10 (4) 1 (4) 9 (4)  
Native American 2 (1) 0 (0) 2 (1)  
Did not answer 11 (5) 1 (4) 10 (5)  
     
Relationship Status with 
most recent partner     
Married 95 (40) 6 (24) 89 (42) 0.049 
Dating 48 (20) 3 (12) 45 (21)  
Common Law 52 (22) 7 (28) 45 (21)  
Other 44 (18) 9 (36) 35 (16)  
     
Suicide risk criteria met*     
Yes  17 (7) 2 (8) 15 (7) 0.865 
No 220 (93) 23 (92) 197 (93)  
     
Notes: P-values in bold were statistically significant; ART: antiretroviral therapy; 
AUDIT: Alcohol Use Disorders Identification Tool; CES-D: Center for Epidemiologic 
Studies–Depression scale; DA: Danger Assessment; DAST-10: Drug Abuse Screening 
Tool; IPV: intimate partner violence; PCL-C: Posttraumatic Checklist- Civilian 
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Table B.2  







Viral Loan Not 
Detectable 
n=167 p 
ART Prescribed in Past Year     
Yes 223 (93) 60 (83) 163 (98) <0.001 
No 16 (7) 12 (17) 4 (2)  
     
AUDIT >7*     
Yes 45 (19) 18 (25) 27 (16) 0.102 
No 192 (81) 53 (75) 139 (84)  
     
CES-D >15*     
Yes 64 (27) 22 (31) 42 (25) 0.367 
No 173 (73) 49 (69) 124 (75)  
     
Children Under 18      
Yes 49 (21) 20 (28) 29 (17) 0.067 
No 190 (80) 52 (72) 138 (83)  
     
DA Score >14 [n=124] a     
Yes 30 (24) 11 (24) 19 (24) 0.955 
No 94 (76) 35 (76) 59 (76)  
     
DAST-10 >2*     
Yes 104 (44) 34 (48) 70 (42) 0.416 
No 133 (56) 37 (52) 96 (58)  
     
Ethnicity*     
Hispanic 3 (1) 3 (5) 0 (0) 0.007 
Not Hispanic 226 (99) 64 (96) 162 (100)  
     
Employment Status     
Employed 30 (13) 6 (8) 24 (14 ) 0.196 
Unemployed 209 (87) 66 (92) 143 (86)  
     
Graduated from High 
School*     
Yes 137 (58) 31 (44) 106 (64) 0.003 
No 99 (42) 40 (56) 59 (36)  
     
Insurance      
Public 231 (97) 69 (96) 162 (97) 0.644 
Private 8 (3) 3 (4) 5 (3)  








Viral Loan Not 
Detectable 
n=167 p 
Lived with partner in past 
year      
Yes 124 (52) 33 (46) 91 (54) 0.219 
No 115 (48) 39 (54) 76 (46)  
     
Partner Gender     
Male 226 (95) 68 (94) 158 (95) 0.291 
Female 12 (5) 3 (4) 9 (5)  
Transgender Female 1 (0.4) 1 (1) 0 (0)  
     
Past Year Drug Use     
Yes 120 (50) 45 (63) 75 (45) 0.013 
No 119 (50) 27 (38) 92 (55)  
     
Past Year IPV     
Yes 122 (51) 45 (63)  77 (46) 0.020 
No 117 (49) 27 (38) 90 (54)  
     
PCL-C >44*     
Yes  56 (24) 21 (30) 35 (21) 0.159 
No 181 (76) 50 (70) 131 (79)  
     
Race     
Black/African American 207 (87) 58 (81) 149 (89) 0.039 
White Caucasian 9 (4) 1 (1) 8 (5)  
Mixed/Other 10 (4) 5 (7) 5 (3)  
Native American 2 (1) 1 (1) 1 (1)  
Did not answer 11 (5) 7 (10) 4 (2)  
     
Relationship Status with 
most recent partner     
Married 95 (40) 38 (53) 57 (34) 0.061 
Dating 48 (20) 12 (17) 36 (22)  
Common Law 52 (22) 12 (17) 40 (24)  
Other 44 (18) 10 (14) 34 (20)  
     
Suicide risk criteria met*     
Yes  17 (7) 5 (7) 12 (7) 0.959 
No 220 (93) 66 (93) 154 (93)  
Notes: P-values in bold were statistically significant; ART: antiretroviral therapy; 
AUDIT: Alcohol Use Disorders Identification Tool; CES-D: Center for Epidemiologic 
Studies – Depression scale; DA: Danger Assessment; DAST-10: Drug Abuse Screening 
Tool; IPV: intimate partner violence; PCL-C: Posttraumatic Checklist- Civilian 
*= missing data, aDA from women reporting past year IPV only  
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Table B.3  











ART Prescribed in Past Year     
Yes 223 (93) 128 (93) 95 (94 0.690 
No 16 (7) 10 (7) 6 (6)  
     
AUDIT >7*     
Yes 45 (19) 30 (22) 15 (15) 0.162 
No 192 (81) 106 (78) 86 (85)  
     
CES-D >15*     
Yes 64 (27) 46 (34) 18 (18) 0.006 
No 173 (73) 90 (66) 83 (82)  
     
Children Under 18      
Yes 49 (21) 23 (17) 26 (26) 0.086 
No 190 (80) 115 (83) 75 (74)  
     
DA Score >14 [n=124]a     
Yes 30 (24) 18 (23) 12 (27) 0.627 
No 94 (76) 61 (77) 33 (73)  
     
DAST-10 >2*     
Yes 104 (44) 67 (49) 37 (37) 0.053 
No 133 (56) 69 (51) 64 (63)  
     
Ethnicity*     
Hispanic 3 (1) 2 (2) 1 (1) 0.785 
Not Hispanic 226 (99) 133 (99) 93 (99)  
     
Employment Status     
Employed 30 (13) 11 (8) 19 (19) 0.012 
Unemployed 209 (87) 127 (92) 82 (81)  
     
Graduated from High 
School*     
Yes 137 (58) 76 (56) 61 (62) 0.345 
No 99 (42) 61 (45) 38 (38)  
     
Insurance      
Public 231 (97) 136 (99) 95 (94) 0.057 











     
Lived with partner in past 
year      
Yes 124 (52) 77 (56) 54 (54) 0.157 
No 115 (48) 61 (44) 47 (47)  
     
Partner Gender     
Male 226 (95) 133 (96) 93 (92) 0.253 
Female 12 (5) 5 (4) 7 (7)  
Transgender Female 1 (0.4) 0 (0) 1 (1)  
     
Past Year Drug Use     
Yes 120 (50) 83 (60) 37 (37) <0.001 
No 119 (50) 55 (40) 64 (64)  
     
Past Year IPV     
Yes 122 (51) 77 (56) 45 (45) 0.086 
No 117 (49) 61 (44) 56 (55)  
     
PCL-C >44*     
Yes  56 (24) 37 (27) 19 (19) 0.132 
No 181 (76) 99 (73) 82 (81)  
     
Race     
Black/African American 207 (87) 117 (85) 90 (90) 0.161 
White Caucasian 9 (4) 4 (3) 5 (5)  
Mixed/Other 10 (4) 9 (7) 1 (1)  
Native American 2 (1) 2 (1) 0 (0)  
Did not answer 11 (5) 6 (4) 5 (5)  
     
Relationship Status with 
most recent partner     
Married 95 (40) 53 (38) 42 (42) 0.676 
Dating 48 (20) 29 (21) 19 (19)  
Common Law 52 (22) 33 (24) 19 (19)  
Other 44 (18) 23 (17) 21 (21)  
     
Suicide Risk Criteria*     
Yes  17 (7) 11 (8) 6 (6) 0.526 
No 220 (93) 125 (92) 95 (94)  
Notes: P-values in bold were statistically significant; ART: antiretroviral therapy; 
AUDIT: Alcohol Use Disorders Identification Tool; CES-D: Center for Epidemiologic 
Studies – Depression scale; DA: Danger Assessment; DAST-10: Drug Abuse Screening 
Tool; IPV: intimate partner violence; PCL-C: Posttraumatic Checklist- Civilian 





Participants Reporting Past Year Substance Abuse, Depression or PTSD Symptomology 
by type of intimate partner violence experienced, n (%) 
 
 
CES-D >15 PCL-C >44  
Past year 
drug usea  AUDIT >7  
Psychological abuse only 
(n=7) 
 
3 (43) 1 (14) 2 (29) 1 (14) 
Physical abuse only (n=2) 1 (50) 2 (100) 2 (100) 1 (50) 
 
Psychological and 
physical abuse (n=62) 
16 (26) 18 (29) 34 (55) 12 (20) 
 
Psychological and sexual 
abuse (n=5) 
3 (60) 1 (20) 3 (60) 0 (0) 
 
Physical and sexual abuse 
(n=1) 
1 (100) 0 (0) 1 (100) 0 (0) 
 
Psychological, physical 
and sexual abuse (n=45) 
22 (49) 21 (47) 27 (60) 18 (40) 
Note: AUDIT: Alcohol Use Disorders Identification Tool; CES-D: Center for 
Epidemiologic Studies–Depression scale; PCL-C: Posttraumatic Checklist–Civilian 






Qualitative Themes and Sub-themes Endorsed by Participants 
 HIV Control Group 
  Detectable VL/CD4 Count <200 
Not Detectable VL/CD4 
Count ≥200 
















































(Re)Establishing Identity and Choosing Labels          
1. Being a mom or caregiver          
2. Minimizing violence           
3. Normalizing versus stigma          
“I know what I’m suppose to do”          
1. Accepting responsibility for care          
2. Barriers to overcome          
Note: W: white; B: black; M: multiple 
*Participant not prescribed antiretroviral therapy has a detectable viral load and CD4 count >200 classified as “good control” based on 
adherence to current treatment plan 
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APPENDIX C: STUDY INSTRUMENTS 
Phase 1: Survey Measures 
 
Section: Demographic Info 
Narrative: Thank you for deciding to participate in this research study.  First we’d like to 
collect a little bit more information about you.    
 
1.a First Name  
1.b Last Name  
2. Date of birth: (mm/dd/yyyy) ____________    
3. What is the highest level of school that you have completed? 
a. 8th grade or less 
b. Some high school, but did not graduate or GED  
c. High school diploma or GED  
d. Some college  
e. Associate’s degree or vocational graduate 
f. 4 year college degree/Bachelor’s degree 
g. Post-Baccalaureate/Masters degree/Ph.D. 
4. How do you identify yourself in terms of race? (select all that apply) 
a. American Indian or Alaska Native 
b. Asian 
c. Black or African American 
d. Native Hawaiian or Pacific Islander 
e. White/Caucasian 
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f. Mixed/Other Race                 
5. How do you identify yourself in terms of ethnic origin? 
a. Hispanic, Latino or Spanish Origin 
b. Not Hispanic, Latino or Spanish Origin 
6. Do you currently have a paid job?       
a. Yes  
b. No    
7. Do you currently have health insurance? 
a. Yes 
b. No 
7.1  If Yes, What type of insurance? 
a. Private (Kaiser, BlueCross) 
b. Public (Medicare, Medicaid, SSI) 
8.  Do you have any children under 18 that you are responsible for? 
a. Yes    
b. No    
8.1 If yes, how many? 
  a. 1 
  b. 2 
c. 3 
d. 4 
e. 5 or more 
9. Are you currently in a relationship (dating, married, hooking up, living together, etc)?  
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a. Yes 
b. No  
If yes to 9: 
9.1. How would you describe your relationship with this person?  
a. Dating  
b. Married   
e. Common Law 
f. Other ________________ (specify)  
9.2. Do you currently live in the same household with this person? 
a. Yes  
b. No 
9.3. When was the first time you and your current partner started dating or 
became a couple (mm/dd/yyyy)? __/____       
9.4. Is your partner: 
 a. Male 
  b. Female 
  c. Transgender male 
  d. Transgender female                      
If no to 9: 
9.1.1. During the past year, how would you have described your most 
recent relationship? 
a. Dating  
b. Married   
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e. Common Law 
f. Other ________________ (specify)  
9.2.1. In the past year did you live in the same household with your most 
recent relationship partner? 
a. Yes  
b. No 
9.3.1. When was the first time you and your former partner started dating 
  became a couple (mm/dd/yyyy)? __/____    
9.4.2   Your most recent relationship partner was: 
 a. Male 
  b. Female 
  c. Transgender male 
 d. Transgender female         
Section: Abuse Assessment Screen 
Narrative: In the next several sections you will be asked a series of questions about the 
different types of violence and threats of violence that women sometimes report 
experiencing in relationships.  You may not have experienced these kinds of violence but 
many women have.   
1. In the past year, have you been emotionally or physically abused by your 
partner or someone important to you?  
a. Yes 
b. No 










i. Other (specify) 
2. In the past year, have you been hit, slapped, kicked or otherwise physically 
hurt someone? 
a. Yes  
b. No  









ix. Other (specify) 
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3. In the past year, have you been forced to have sexual activities by someone?  
a. Yes  
b. No 









i. Other (specify) 
4. Are you afraid of your partner or someone listed above?  
a. Yes  
b. No  










i. Other (specify) 
Section: Severity of Violence Against Women Scale (SVAWS) 
Narrative: Next is a list of behaviors your partner may have done. Describe how often in 
the past year your partner or ex-partner has done each behavior by choosing a number 
from the following scale.   
0 1 2 3 
Never Once A few times Many times 
 
How often (in the past year) has your partner: 
     _____ 1. Hit or kicked a wall, door, or furniture? 
     _____ 2. Threw, smashed or broke an object? 
     _____ 3. Drove dangerously with you in the car?      
     _____ 4.  Thrown an object at you? 
     _____ 5.  Shook a finger at you? 
     _____ 6.  Made threatening faces or gestures at you? 
     _____ 7.  Shook a fist at you? 
     _____ 8.  Acted like a bully towards you? 
     _____ 9.  Destroyed something belonging to you? 
     _____ 10.  Threatened to harm or damage things you care about? 
     _____ 11.  Threatened to destroy property? 
     _____ 12.  Threatened someone you care about? 
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     _____ 13.  Threatened to hurt you? 
     _____ 14.  Threatened to kill himself/herself? 
     _____ 15.  Threatened to kill you? 
     _____ 17.  Threatened you with a weapon? 
     _____ 16.  Threatened you with a club-like object? 
     _____ 16.  Threatened you with a knife or gun? 
     _____ 19.  Acted like he/she wanted to kill you? 
     _____ 20.  Held you down, pinning you in place? 
     _____ 21.  Pushed or shoved you? 
     _____ 22.  Shook or roughly handled you? 
     _____ 23.  Grabbed you suddenly and forcefully? 
     _____ 24.  Scratched you? 
     _____ 25.  Pulled your hair? 
     _____ 26.  Twisted your arm? 
     _____ 27.  Spanked you? 
     _____ 28.  Bit you? 
     _____ 29.  Slapped you with the palm of his/her hand? 
     _____ 30.  Slapped you with the back of his/her hand? 
     _____ 31.  Slapped you around your face or head? 
     _____ 33.  Hit you with an object? 
     _____ 36.  Punched you?  
     _____ 32.  Kicked you? 
     _____ 34.  Stomped on you? 
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     _____ 35.  Choked you? 
     _____ 37.  Burned you with something? 
     _____ 38.  Used a club-like object on you? 
     _____ 39.  Beat you up? 
     _____ 40.  Used a knife or gun on you? 
     _____ 41.  Demanded sex whether you wanted to or not? 
     _____ 42.  Made you have oral sex against your will? 
     _____ 43.  Made you have sexual intercourse against your will? 
     _____ 44.  Physically forced you to have sex? 
     _____ 45.  Made you have anal sex against your will? 
     _____ 46.  Used an object on you in a sexual way? 
Section: Reproductive Coercion 
[For women reporting male partners] 
Narrative: The next set of questions asks about your choices regarding your decision and 
your partner’s involvement in your decision to have or not have children.   
1. In the past year, has someone you were dating or going out with told you not to 
use any birth control (such as pills, shot, ring, etc.)? 
a. Yes  
b. No  
2. In the past year, has someone you were dating or going out with said he would 
leave you if you did not get pregnant? 
a. Yes  
b. No  
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3. In the past year, has someone you were dating or going out with told you he 
would have a baby with someone else if you did not get pregnant? 
a. Yes  
b. No  
4. In the past year, has someone you were dating or going out with hurt you 
physically because you did not agree to get pregnant? 
a. Yes  
b. No  
5. In the past year, has someone you were dating or going out with taken off the 
condom while you were having sex so that you would get pregnant? 
a. Yes  
b. No  
6. In the past year, has someone you were dating or going out with put holes in the 
condom so you would get pregnant? 
a. Yes  
b. No  
7. In the past year, has someone you were dating or going out with broken a condom 
on purpose while you were having sex so you would get pregnant? 
a. Yes  
b. No  
8. In the past year, has someone you were dating or going out with taken your birth 
control (such as pills) away from you or kept you from going to the clinic to get 
birth control so that you would get pregnant? 
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a. Yes  
b. No  
9. In the past year, has someone you were dating or going out with made you have 
sex without a condom so you would get pregnant? 
a. Yes  
b. No  
Section: Danger Assessment  
[For those indicating IPV on AAS or SVAWS] 
For women who report a male partner 
Narrative: Several risk factors have been associated with increased risk of re-assault of 
women in abusive relationships.  We cannot predict what will happen in your case, but 
we would like you to be aware of the danger of repeat abuse and for you to see how many 
of the risk factors apply to your situation.   
1. Has the physical violence increased in severity or frequency over the past year?      
a. Yes  
b. No  
2. Does he own a gun? 
a. Yes  
b. No  
3.  Have you ever left him after living together ? 
a. Yes  
b. No  
c.  We have never lived together  
 216 
4. Is he unemployed?  
a. Yes  
b. No  
5. Has he ever used a weapon against you or threatened you with a lethal weapon? 
a. Yes  
b. No  
6. Does he threaten to kill you? 
a. Yes  
b. No  
7. Has he avoided being arrested for domestic violence? (for example, leaving the scene 
before the police can arrive).  
a. Yes  
b. No  
8. Do you have a child that is not his? 
a. Yes  
b. No  
9. Has he ever forced you to have sex when you did not wish to do so? 
a. Yes  
b. No  
10. Does he ever try to choke you? 
a. Yes  
b. No  
11. Does he use illegal drugs? By drugs, I mean “uppers or amphetamines, speed, angel 
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dust, cocaine, crack, street drugs or mixtures?  
a. Yes  
b. No  
12. Is he an alcoholic or problem drinker?  
a. Yes  
b. No  
13. Does he control most or all of your daily activities? For instance: does he tell you 
who you can be friends with, when you can see your family, how much money you can 
use, or when you can take the car?  
a. Yes  
b. No  
14. Is he violently and constantly jealous of you? (For instance, does he say “if I can’t 
have you, no one can”)?  
a. Yes  
b. No  
15. Have you ever been beaten by him while you were pregnant? 
a. Yes  
b. No  
15a Have you ever been pregnant by him? 
a. Yes  
b. No  
16. Has he ever threatened or tried to commit suicide?  
a. Yes  
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b. No  
17. Does he threaten to harm your children? 
a. Yes  
b. No  
18. Do you believe he is capable of killing you? 
a. Yes  
b. No  
19. Does he follow or spy on you, leave threatening notes or messages on answering 
machine, destroy your property, or call you when you don’t want him to? 
a. Yes  
b. No  
20. Have you ever threatened or tried to commit suicide?  
a. Yes  
b. No  
For women who report a female partner 
Narrative: Several risk factors have been associated with increased risk of re-assault of 
women in abusive same-sex relationships.  We cannot predict what will happen in your 
case, but we would like you to be aware of the danger of repeat abuse and for you to see 
how many of the risk factors apply to your situation.   
1. Is she constantly jealous and/or possessive of you? 
a. Yes  
b. No  
2. Does she try to isolate you socially? 
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a. Yes  
b. No  
3. Has the physical violence increased in severity or frequency over the past year? 
a. Yes  
b. No  
4. Has she threatened you with a gun over the past year? 
a. Yes  
b. No  
5. Have you lived with her in the past year? 
a. Yes  
b. No  
6. Has she ever abused or threatened to abuse a previous intimate partner, or their 
family members or friends? 
a. Yes  
b. No  
7. Does she use illegal drugs, (by illegal drugs, I mean "uppers" or amphetamines, 
“meth,” speed, angel dust, cocaine, "crack," street drugs or mixtures) or abuse 
prescription medications? 
a. Yes  
b. No  
8. Is she an alcoholic or problem drinker? 
a. Yes  
b. No  
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9. Does she try to control/limit your spirituality? 
a. Yes  
b. No  
10. Does she constantly blame you and/or put you down? 
a. Yes  
b. No  
11. Has she destroyed or threatened to destroy things that belong to you? 
a. Yes  
b. No  
12. Has she threatened to harm a:  
a. Pet? 
a. Yes  
b.No  
b. Elderly family member? 
a. Yes  
b.No  
c. Person you care for with a disability? 
a. Yes  
b.No  
13. Has she ever violated a restraining order? 
a. Yes  
b. No  
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14. Does she stalk you, for example, follow or spy on you, leave threatening notes or 
messages on answering machine or cell phone, call you when you do not want her 
to? 
a. Yes  
b. No  
15. If you were being abused by her and tried to get help, do you think people would 
not take you seriously? 
a. Yes  
b. No  
16. If you were being abused by her, would fear of reinforcing negative stereotypes 
about female same-sex relationships and/or being discriminated against prevent 
you from seeking help, for example help from friends, domestic violence 
advocates, or health care providers? 
a. Yes  
b. No  
17. If you were having serious difficulties with her, would you keep it a secret out of 
fear or shame? 
a. Yes  
b. No  
18. Have you threatened or tried to kill yourself? 
a. Yes  
b. No  
Section: Post Traumatic Stress Checklist – Civilian (PCL-C) 
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Narrative: Next is a list of problems that people sometimes have in response to stressful 
life experiences. Please read each one carefully, and then check the boxes to the right to 
indicate how much you have been bothered by that problem in the past month. 
 









Repeated, disturbing memories, 
thoughts, or images of a stressful 
experience from the past?  
1 2 3 4 5 
Repeated, disturbing dreams of a 
stressful experience from the past?  1 2 3 4 5 
Suddenly acting or feeling as if a 
stressful experience were happening 
again (as if you were reliving it)?  
1 2 3 4 5 
Feeling very upset when something 
reminded you of a stressful experience 
from the past?  
1 2 3 4 5 
Having physical reactions (e.g., heart 
pounding, trouble breathing, sweating) 
when something reminded you of a 
stressful experience from the past?  
1 2 3 4 5 
Avoiding thinking about or talking 
about a stressful experience from the 
past or avoiding having feelings related 
to it?  
1 2 3 4 5 
Avoiding activities or situations 
because they reminded you of a 
stressful experience from the past?  
1 2 3 4 5 
Trouble remembering important parts 
of a stressful experience from the past?  1 2 3 4 5 
Loss of interest in activities that you 
used to enjoy?  1 2 3 4 5 
Feeling distant or cut off from other 
people?  1 2 3 4 5 
Feeling emotionally numb or being 
unable to have loving feelings for 
those close to you?  
1 2 3 4 5 
Feeling as if your future will somehow 
be cut short?  1 2 3 4 5 
Trouble falling or staying asleep?  1 2 3 4 5 
Feeling irritable or having angry 
outbursts?  1 2 3 4 5 
Having difficulty concentrating?  1 2 3 4 5 




Section: Center for Epidemiologic Studies Scale, Revised (CESD-R) 
Narrative: Next is a list of the ways you might have felt or behaved. Please check the 
boxes to tell me how often you have felt this way in the past two weeks. 













My appetite was poor.      
I could not shake off the 
blues. 
     
I had trouble keeping my 
mind on what I was doing. 
     
I felt depressed.      
My sleep was restless.      
I felt sad.      
I could not get going.      
Nothing made me happy.      
I felt like a bad person.      
I lost interest in my usual 
activities. 
     
I slept much more than usual.      
I felt like I was moving too 
slowly. 
     
I felt fidgety.      
I wished I were dead.      
I wanted to hurt myself.      
I was tired all the time.      
I did not like myself.      
I lost a lot of weight without 
trying to. 
     
I had a lot of trouble getting 
to sleep. 
     
I could not focus on the 
important things. 
     
 
Section: The Alcohol Use Disorders Identification Test (AUDIT) 
Narrative: Because alcohol use can affect your health and can interfere with certain 
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medications and treatments, it is important that we ask some questions about your use of 
alcohol. Your answers will remain confidential so please be honest. Choose the option 
that best describes your answer to each question about your use of alcoholic beverages 
during the past 6-months.  
 0 1 2 3 4 
How often do you have a 











How many drinks 
containing alcohol do you 
have on a typical day 
when you are drinking? 
 N/A 
1 or 2 3 or 4 5 or 6 7 to 9 10 or 
more 
How often do you have 
six or more drinks on one 
occasion? 
Never Less than 
monthly 
Monthly Weekly Daily or 
almost 
daily 
How often during the last 
6 months have you found 
that you were not able to 
stop drinking once you 
had started? 
Never Less than 
monthly 
Monthly Weekly Daily or 
almost 
daily 
How often during the last 
6 months have you failed 
to do what was normally 
expected of you because 
of drinking? 
Never Less than 
monthly 
Monthly Weekly Daily or 
almost 
daily 
How often during the last 
6 months have you 
needed a first drink in the 
morning to get yourself 
going after a heavy 
drinking session? 
Never Less than 
monthly 
Monthly Weekly Daily or 
almost 
daily 
How often during the last 
6 months have you had a 
feeling of guilt or 
remorse after drinking? 
Never Less than 
monthly 
Monthly Weekly Daily or 
almost 
daily 
How often during the last 
6 months have you been 
unable to remember what 
happened the night before 
because of your drinking? 
Never Less than 
monthly 




Have you or someone 
else been injured because 
of your drinking? 
No  Yes, but 






Has a relative, friend, 
doctor, or other health 
care worker been 
concerned about your 
drinking or suggested you 
cut down? 
No  Yes, but 







Section: Drug Use Questionnaire (DAST-10) 
Narrative: The following questions concern information about your possible involvement 
with drugs excluding alcohol and tobacco during the past year.  
When the words “drug abuse” are used, they mean:   
1. The use of prescribed or over-the-counter drugs in excess of the directions or 
2. Any non-medical use of drugs.   
The various types of drugs may include:  cannabis (marijuana, hash), solvents, 
tranquilizers (Valium), barbiturates, cocaine, stimulants (speed), hallucinogens (LSD) or 
narcotics (heroin).  Remember that the questions do not include alcohol or tobacco. 
Please answer every question.  If you have difficulty with a statement, then choose the 
response that is mostly right.  Remember, everything in this interview is confidential. 
 No Yes 
1. Have you used drugs other than those required for medical reasons? 0 1 
2. Do you abuse more than one drug at a time? 0 1 
3. Are you always able to stop using drugs when you want to? 0 1 
4. Have you had "blackouts" or "flashbacks" as a result of drug use? 0 1 
5. Do you ever feel bad or guilty about your drug use? 0 1 
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6. Does your partner (or parents) ever complain about your 
involvement with drugs? 
0 1 
7. Have you neglected your family because of your use of drugs? 0 1 
8. Have you engaged in illegal activities in order to obtain drugs? 0 1 
9. Have you ever experienced withdrawal symptoms (felt sick) when 
you stopped taking drugs? 
0 1 
10. Have you had medical problems as a result of your drug use (e.g., 
memory loss, hepatitis, convulsions, bleeding, etc.)?  
0 1 
 
Section: AIDS Clinical Trials Group (ACTG) Adherence Follow Up Questionnaire  
Narrative:  
Most people with HIV have many pills to take at different times during the day. 
Many people find it hard to always remember their pills: 
· Some people get busy and forget to carry their pills with them. 
· Some people find it hard to take their pills according to all the 
instructions, such as “with meals,” or “on an empty stomach,” “every 8 hours,” 
“with plenty of fluids.” 
· Some people decide to skip doses to avoid side effects or to just not be 
taking pills that day. 
We need to understand how people with HIV are really doing with their pills. 
Please tell us what you are actually doing. Don’t worry about telling us that you don’t 
take all your pills. We need to know what is really happening, not what you think we 
want to hear. 
 227 
1. In the past year has your health care provider prescribed medications for you to 
take on a regular basis? 
 a. Yes 
 b. No [If no end here] 
2. When was the last time you missed taking any of your medications? 
a. Within the past week 
b. 1-2 weeks ago 
c. 2-4 weeks ago 
d. 1-3 months ago  
e. More than 3 months ago 
f. Never skip medications  
3. Most anti-HIV medications need to be taken on a schedule, such as “2 times a 
day” or “3 times a day” or “every 8 hours.” How closely did you follow your 
specific schedule over the last four days? 
a. Never  
b. Some of the time 
c. About half of the time  
d. Most of the time 
e. All of the time 
4. Do any of your anti-HIV medications have special instructions, such as “take with 




4a. If Yes, how often did you follow those special 
instructions over the last four days? 
a. Never  
b. Some of the time 
c. About half of the time  
d. Most of the time 
e. All of the time 
5.  Some people find that they forget to take their pills on the weekend days. Did 




Narrative: People may miss taking their medications for various reasons. Here is a list of 
possible reasons why you may have missed taking any medications within the past 
month. 
In the past month, how often have you missed taking your medications because you: 
 Never Rarely Sometime
s 
Often 
1. Were away from home?      
2. Were busy with other things?      
3. Simply forgot?      
4. Had too many pills to take?      
5. Wanted to avoid side effects?      
6. Did not want others to notice you 
taking medication? 
    
7. Had a change in daily routine?      
8. Felt like the drug was toxic/harmful?      
9. Fell asleep/slept through dose time?      
10. Felt sick or ill?      
11. Felt depressed/overwhelmed?      
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12. Had problem taking pills at specified 
times (with meals, on empty stomach, 
etc.)? 
    
13. Ran out of pills?      




Phase 1: Medical Records Abstraction Tool 
Section: Demographics 
1. Participant ID: 
 
2. DOB (mm/dd/yyyy):  
 
3. Date of survey (mm/dd/yyyy):  
 




5. If yes, what type of health insurance? 
a. Private insurance (such as Kaiser, Blue Cross Blue Shield) 
b. Public insurance (such as Medicaid, Medicare, SSI)  
 
Section: Laboratory Values 
1. Most recent CD4 count:  
1.1. Date of most recent CD4 count (mm/dd/yyyy):   
 
2. Most recent viral load:  
2.1. Date of most recent viral load (mm/dd/yyyy):   
 
3. CD4 nadir:  
3.1. Date of CD4 nadir (mm/dd/yyyy):   
 
Section: Clinic Visits, Hospitalizations, Infections and Treatments 
1. Number of scheduled clinic visits in 1 year prior to survey:  
a. Type of clinic (free text) for each visit.   
2. Number of missed clinic visits in 1 year prior to survey:  
a. Type of clinic missed (free text) for each missed visit above. 
3. Number of hospitalization in the year prior to survey: 
 231 
a. Reasons for hospitalization(s) (free text, separate box for each hospitalization 
above) 
b. Total number of inpatient hospital days in the year prior to survey:  








I. Documented treatment 




I. Documented treatment 




I. Documented treatment 
II. No documented treatment 
d. Herpes Simplex Virus 
a. Negative 
b. Positive 
I. Documented treatment 




I. Documented treatment 




I. Documented treatment 
II. No documented treatment 
 





6. Number of non-STI infections documented in the year prior to survey: 
 
6.1 For each infection: 
Infection type (free text box):  












  7.1.1 If yes to 7.1, what behavior is noted? (select all that apply) 
i. IVDU current in past year 
ii. IVDU history  
iii. Non-IV illicit drug use current in past year 
iv. Non-IV illicit drug use history 
v. Methadone maintenance program 
vi. Suboxone maintenance program 
 
8. Was the patient prescribed ART in the past year?  
 
9. Was the patient’s ART regimen changed in the past year? 
9.1 Date most recent ART regimen started (mm/dd/yyyy): 
 
10. What ARTs are included in the patient’s current regimen? (select all that apply) 
  
Multi-class Combination Products 
a. Atripla (efavirenz, emtricitabine and tenofovir) 
b. Complera (emtricitabine, rilpivirine, and tenofovir)  
c. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) 
 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
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d. Combivir (lamivudine and zidovudine) 
e. Emtriva (emtricitabine, FTC) 
f. Epivir (lamivudine, 3TC) 
g. Epzicom (abacavir and lamivudine) 
h. Hivid (zalcitabine, dideoxycytidine, ddC (no longer marketed)) 
i. Retrovir (zidovudine, azidothymidine, AZT, ZDV) 
j. Trizivir (abacavir, zidovudine, and lamivudine) 
k. Truvada (tenofovir and emtricitabine) 
l. Videx EC (enteric coated didanosine, ddI EC) 
m. Videx (didanosine, dideoxyinosine, ddI) 
n. Viread (tenofovir, TDF) 
o. Zerit (stavudine, d4T) 
p. Ziagen (abacavir, ABC) 
 
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
q. Edurant (rilpivirine) 
r. Intelence (etravirine) 
s. Rescriptor (delavirdine, DLV) 
t. Sustiva (efavirenz, EFV) 
u. Viramune (nevirapine, NVP) 
v. Viramune XR (nevirapine, NVP) 
  
Protease Inhibitors  (PIs) 
w. Agenerase (amprenavir, APV)  
x. Aptivus (tipranavir, TPV) 
y. Crixivan (indinavir, IDV) 
z. Fortovase (saquinavir) 
aa. Invirase (saquinavir mesylate, SQV) 
bb. Kaletra (lopinavir and ritonavir, LPV/RTV) 
cc. Lexiva (Fosamprenavir Calcium, FOS-APV) 
dd. Norvir (ritonavir, RTV) 
ee. Prezista (darunavir) 
ff. Reyataz (atazanavir, ATV) 
gg. Viracept (nelfinavir mesylate, NFV) 
 
Fusion Inhibitors 
hh. Fuzeon (enfuvirtide, T-20) 
 
Entry Inhibitors  




jj. Isentress (raltegravir) 
 
Other 
kk. (include free text box to specify) 
 
Section: AIDS Defining Illnesses 
1. Candidiasis of bronchi, trachea, or lungs  
a. Yes 
b. No 
2. Candidiasis of esophagus†  
a. Yes 
b. No 
3. Cervical cancer, invasive§  
a. Yes 
b. No 
4. Coccidioidomycosis, disseminated or extrapulmonary  
a. Yes 
b. No 
5. Cryptococcosis, extrapulmonary  
a. Yes 
b. No 
6. Cryptosporidiosis, chronic intestinal (>1 month's duration)  
a. Yes 
b. No 




8. Cytomegalovirus retinitis (with loss of vision)† (CMV) 
a. Yes 
b. No 
9. Encephalopathy, HIV related  
a. Yes 
b. No 
10. Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or 
esophagitis (onset at age >1 month)  
a. Yes 
b. No 




12. Isosporiasis, chronic intestinal (>1 month's duration) 
a. Yes 
b. No 
13. Kaposi sarcoma†  
a. Yes 
b. No 
14. Lymphoma, Burkitt (or equivalent term)  
a. Yes 
b. No 
15. Lymphoma, immunoblastic (or equivalent term)  
a. Yes 
b. No 
16. Lymphoma, primary, of brain  
a. Yes 
b. No 












20. Pneumocystis jirovecii pneumonia† (pneumocystic carinii; PCP; PJP) 
a. Yes 
b. No 
21. Pneumonia, recurrent†§  
a. Yes 
b. No 
22. Progressive multifocal leukoencephalopathy (PML) 
a. Yes 
b. No 
23. Salmonella septicemia, recurrent  
a. Yes 
b. No 
24. Toxoplasmosis of brain, onset at age >1 month†  
a. Yes 
b. No 




26. Other documented diagnosis of AIDS 
a. Yes 
b. No 
a. If yes, provide rationale for AIDS diagnosis (free text box)  
 
Section: MRA Complete 
 










Phase 2: Interview Guide (Version 1) 
OVERALL HEALTH SYSTEM and HIV TREATMENT EXPEREINCE 
 
Tell me about your experiences with health care systems.  
Probes: Interactions with doctors and nurses. Types of care you receive – 
HIV, gyn, preventative, follow up. 
 
What have your experiences with health care been like in since you have been coming to 
the Moore Clinic? 
 
I know HIV treatment can be complex and challenging to manage tell me about how you 
manage your treatment.    
Probes: What things make it easier for you to manage your HIV 
treatment? What things make it harder for you to manage your HIV 
treatment?  
 
MENTAL HEALTH [PCL Score ____ CESD Score _____] 
 
We talked about your experiences with the health system in general and with your HIV 
providers, can you tell me a little about how your mental health needs are addressed? 
Probes: How does feeling sad or depressed change how you manage your 
health care? How does feeling anxious or nervous change how you 
manage your health care? 
 
SUBSTANCE ABUSE [SA in self report ______ SA in chart review _____] 
 
On the survey you indicated that you have used illegal drugs in the past year, can you talk 
to me more about this? 
Probes: How often do you use? How does it impact your day to day life 
(treatment programs, finances)? 
 
How do you think your drug use has affected your ability to manage your health care and 
HIV treatment? 
Probes: Does it interfere with making and keeping appointments? Taking 
medications? Paying for medications? 
 
How has your drug use been addressed by your health care team?  
Probes: Have your doctors or nurses asked you about drug use?  Have 
they provided you with any resources / referrals? What things that they 
did were helpful? Not helpful?  
 
INTIMATE PARTNER VIOLENCE 
 
If abuser is current partner:  
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When you filled out the survey it asked questions about your relationship with your 
partner / boyfriend / husband. Are you still in a relationship with the same person?   
 
If yes: Can you share with me what your current relationship with looks like?  
If no: Go to previous partner section.   
 
How does your partner change how you participate in your HIV treatment?  
Probes: What things does your partner do that make it easier to manage 
your HIV treatment? Harder to manage your HIV treatment?  
 
What things do you do to keep up with your treatment when your partner is interfering?   
 
It sounds like there are many ways that your relationship affects your HIV care, how has 
your health care provider addressed your relationship in your HIV care? 
 
If abuser is a previous partner: 
 
When you filled out the survey it asked questions about your relationship with your ex-
partner / boyfriend / husband.  
 
Can you tell me about what that relationship looked like? 
 
How did your partner change how you participate in your HIV treatment?  
Probes: What things does your partner do that make it easier to manage 
your HIV treatment? Harder to manage your HIV treatment?  
 
What things did you do to keep up with your treatment when your partner is interfering?   
 
It sounds like there are many ways that your relationship affects your HIV care, how has 
your health care provider addressed your relationship in your HIV care? 
 
REPRODUCTIVE COERCION [PC _____ BCS _____] 
 
I’d also like to know more about your reproductive health and reproductive choices. 
Some women who have experienced violence in their relationship also talk about feeling 
pressured regarding their reproductive choices.   
 
Can you tell me how you make decisions regarding having or not having children?  
Probes: Who is involved in decision-making? Who do you talk to? Where 
do you get information from? 
   
What roles has your partner (ex-partner) played in your decision making regarding 
having or not having children? 
 
How has your health care provider addressed your sexual health and reproductive choices 





We have talked about a lot of things that effect how you manage your HIV treatment 
(your personal relationships, sexual health, mental health, substance use) what advice 
would you give to women in your situation regarding how to best manage the many piece 
involved in their health care?  
 
What things do you wish your health care providers would do to make it easier for you to 
participate in care? 
Probes: What additional resources would be helpful? 
 
Is there anything else important that you would like to share that I didn’t ask about? 
 
General Prompts:  Tell me more about that… Give me an example of that… Describe a 
time when… What does that look like? 
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Phase 2: Interview Guide (Version 2) 
OVERALL HEALTH SYSTEM and HIV TREATMENT EXPEREINCE 
 
Tell me about a bit about your HIV experience. 
What have your experiences with health care been like in since you have been coming to 
the Moore Clinic? 
 
Probes: Interactions with doctors and nurses. Types of care you receive – 
HIV, gyn, preventative, follow up. 
 
I know HIV treatment can be complex and challenging to manage tell me about how you 
manage your treatment.    
Probes: What things make it easier for you to manage your HIV 
treatment? What things make it harder for you to manage your HIV 
treatment?  
 
MENTAL HEALTH [PCL Score ____ CESD Score _____] 
 
Most people with HIV experience stress or anxiety related to managing their care 
(medications, appointment, finances…).  What kinds of stress have you experienced 
related to your HIV? 
 
How have your doctors addressed this stress? 
Probes: How does feeling sad or depressed change how you manage your 
health care? How does feeling anxious or nervous change how you 
manage your health care? 
 
INTIMATE PARTNER VIOLENCE 
 
Another source of stress for many people is their relationships. Can you tell me about 
your recent relationships?  
 
Probes: What kind of things do you argue about? What do these 
arguments look like?  Are they ever physical? Did that look like other 
relationships you’ve had?  
 
How have your relationships changed how you participate in your HIV treatment?  
 
Probes: What things does your partner do that make it easier to manage 







REPRODUCTIVE COERCION [PC _____ BCS _____] 
 
I’d also like to know more about your reproductive health and reproductive choices. 
Some women who have experienced violence in their relationship also talk about feeling 
pressured regarding their reproductive choices.   
 
Can you tell me how you make decisions regarding having or not having children?  
Probes: Who is involved in decision-making? Who do you talk to? Where 
do you get information from? 
   
What roles has your partner (ex-partner) played in your decision making regarding 
having or not having children? 
 
How has your health care provider addressed your sexual health and reproductive choices 
in your HIV care?  
 
SUBSTANCE ABUSE [SA in self report ______ SA in chart review _____] 
 
One way that folks deal with stress in through drugs or alcohol. Have drugs or alcohol 
played a role in your HIV care?  
 
Probes: How often do you use? How does it impact your day to day life 
(treatment programs, finances)? 
 
Does it interfere with making and keeping appointments? Taking medications? 
Paying for medications? 
 
How has your drug/alcohol use been addressed by your health care team?  
Probes: Have your doctors or nurses asked you about drug use?  Have 
they provided you with any resources / referrals? What things that they 




We have talked about a lot of types of stress, what advice would you give to women in 
your situation regarding how to best manage the many piece involved in their health 
care?  
 
What things do your wish your health care providers do that help? 
What things do you wish your health care providers would do to help?  
Probes: What additional resources would be helpful? 
 
Is there anything else important that you would like to share that I didn’t ask about? 
 
General Prompts:  Tell me more about that… Give me an example of that… Describe a 
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removal products. PI: Jocelyn Anderson, MSN & Erin Pollitt, 
MHA. Johns Hopkins University School of Nursing/Mercy 
Medical Center.  Role: Co-Principal Investigator  
 
 
2014- Evaluation and dissemination of a smartphone application to 
improve access to medical forensic care following sexual assault 
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2013- Effects of Partner Violence and Mental Health on HIV Disease 
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2012-2015 Effectiveness of a Safety Intervention for Dating Violence 
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(Eds). Marital Rape: Consent, Marriage and Social Change in Global Context. 
Oxford University Press.   
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Peer Reviewed – International 
 
September 16, 2015 Anderson, J.C. (Presenter), Campbell, J.C, & Glass, N. Effects of 
partner violence on adherence to HIV care and treatment markers 
among women in Baltimore City. Sexual Violence Research 
Initiative Forum, Stellenbosch, South Africa 
 
November 2014 Campbell, J. C. (Presenter), Anderson, J. C. (Presenter), 
Stockman, J., Callwood, G. & Campbell, D.   Direct and Indirect 
Effects of Head Injuries and Depression on Physical Health 
Symptoms in Abused Women, International Council on Women’s 
Health Issues, Cape Town, South Africa. 
 
November 2014 Campbell, J. C. (Presenter), Draughon, J. E., Lucea, M. B., 
Stockman, J. K. Campbell, D., Anderson, J. C. (Presenter). HIV 
Risk Among Abused Women of African Descent: Results from the 
ACAAWS Study. International Council on Women’s Health Issues, 
Cape Town, South Africa. 
 
October 22, 2013 Anderson, J.C. (Presenter), Stockman, J., Sabri, B., Campbell, 
D.W, Campbell, J.C. Injuries in African American and African 
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Caribbean Women: The Role of Intimate Partner Violence, 
International Association of Forensic Nurses, Anaheim, CA. 
 
June 18, 2013 Anderson, J. C. (Presenter), Campbell, J.C., Draughon, J., Lucea, 
M.B., Campbell, D. Impact of intimate partner violence on 
sexually transmitted infections and reproductive health in women 
of African descent: Results from the ACAAWS Study, Nursing 
Network Against Violence Against Women International, 
Vancouver, British Columbia, Canada.  
 
October 13, 2012 Draughon, J.E (Presenter), Anderson, J.C., Hanson, B., & 
Sheridan, D.J. HIV post-exposure prophylaxis practices: A survey 
of sexual assault and forensic nurse examiner program 
coordinators. International Association of Forensic Nurse 
Scientific Assembly. Fajardo, Puerto Rico.  
 
March 6, 2012 Anderson, J. C. (Presenter) & Sheridan, D. J. Genital Injury 
Following Consensual and Nonconsensual Intercourse: State of 
the Science, Nursing Network on Violence Against Women 
International, Charlottesville, VA.  
 
Peer Reviewed – National 
 
October 30, 2015 Anderson, J.C. & Campbell, J.C (Presenter). Effects of Partner 
Violence on Mental Health and HIV Disease Progression in 
Women: Preliminary Results. Association of Nurses in AIDS Care, 
Annual Conference. Chicago, IL 
 
March 21, 2015 Campbell, J.C. (Presenter), McFadgion, A. (Presenter), Anderson, 
J.C. (Presenter), & Bergin, A.. The Impact of Traumatic Brain 
Injury: Screening protocol and Response for Medical and 
Advocacy Services, National Conference on Health and Domestic 
Violence, Washington, DC.   
 
March 20, 2015 Stockman, J. (Presenter), Alexander, K. (Presenter) & Anderson, 
J.C. (Presenter) A Double-edged Sword: Gender-based Violence 
and HIV Among Vulnerable Women in the United States, 
(Symposium) National Conference on Health and Domestic 
Violence, Washington, DC.  
 
September 19, 2014 Campbell, J.C. (Presenter), Anderson, J.C., Stockman, J., Gill, J., 
Callwood, G., Campbell, D.W. Head Injuries and Healthcare 
Visits Among African American and African Caribbean Women 
Who Have Experienced Intimate Partner Abuse, Council for the 
Advancement of Nursing Science, Washington, DC.  
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June 1, 2013 Shillam, C. (Presenter), Anderson, J. (Presenter), & Taylor, L. 
(Presenter)  Multi-faceted Curriculum Designed to Meet the Needs 
of Students with Multiple Learning Styles, Lilly Conference on 
College and University Teaching, Bethesda, MD  
 
April 18, 2013 Anderson, J.C. (Presenter), Merl, K., Glass, N. The IRIS Project: 
Using the Internet for IPV Research and Intervention, Academy 
on Violence and Abuse, Minneapolis, MN.  
 
April 18, 2013  Anderson, J.C. (Presenter), Stockman, J., Sabri, B., McFadgion, 
A. Campbell, D.W, Campbell, J.C. Injuries in African American 
and African Caribbean Women: The Role of Intimate Partner 
Violence, Academy on Violence and Abuse, Minneapolis, MN.  
 
Peer Reviewed – Local 
 
October 21, 2015 Pollitt, E. (Presenter) & Anderson, J.C. (Presenter) Testing 
Common Topical Products to Determine Fluorescence or 
Absorption of Alternate Light (Phase II): Research Findings and 
Clinical Implications for ALS Use in Forensic Examiner 
Programs. Mercy Medical Center Evidence Based Practice 
Symposium, Baltimore, MD. (Winner Best Poster/Presentation) 
 
Invited - International 
 
March 22, 2016 Faugno, D., Allen, A., Holbrook, D., (Moderators). SAFE Case 
Review, Invited Case Presentation. End Violence Against Women 
International: International Conference on Sexual Assault, 
Domestic Violence and Engaging Men and Boys. Washington, 
DC. 
 
October 29&30, 2015 Parrish, J. (Presenter), Marcozzi, H. (Presenter), Pollitt, E. 
(Presenter), Anderson, J. (Presenter), Stahlmann, N. (Presenter), 
& Costello, A. (Presenter) Alternate Light Source: Application and 
Integration (Workshop). IAFN: International Conference on 
Forensic Nursing Science and Practice.  Orlando, FL   
 
Invited – Local 
 
April 20, 2016 Pollitt, E. & Anderson, J. Alternate Light Source Use in Forensic 
Examinations, Recent Research at the Dynamics of Strangulation 
and Alternate Light Source Use in Forensic Exams Training, 
Mercy Medical Center, Baltimore, MD 
 
March 5, 2016 Anderson, J. (Presenter)  & Patch, M. (Presenter) Intimate 
Partner Violence…What Do I Do?: Practical Pearls for Nursing 
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Care. Black Nurses Association of Greater Washington DC Area, 
2016 Annual Salute to the Black Nurse of the Year and 
Scholarship Awards Luncheon, Washington, DC 
 
October 13, 2015 Effects of Partner Violence and Mental Health on HIV Disease 
Progression in Women - My F31 Process. Johns Hopkins 
University School of Nursing, NR110.826 Special Topics in 
Violence Research, Baltimore, MD 
 
April 22, 2014 Effects of Partner Violence and Mental Health on HIV Disease 
Progression in Women - My F31 Process. Johns Hopkins 
University School of Nursing, NR110.826 Special Topics in 
Violence Research, Baltimore, MD 
 
April 14, 2014 Sexual Assault Nursing.  Johns Hopkins University School of 
Nursing, Midwifery Interest Group, Baltimore, MD 
 
February 28, 2012 Glass, N. E. (Presenter) & Anderson, J. C. (Presenter) The IRIS 
Project: Recruitment and Retention Strategies for Internet-Based 
IPV Research, Johns Hopkins University School of Nursing, 
NR110.826 Special Topics in Violence Research, Baltimore, MD 
 
January 17, 2012 Refining Your Neurological Assessment Skills, Advanced Clinical 
Topics in Neuroscience Nursing, Johns Hopkins Hospital, 
Baltimore, MD 
 
November 30, 2010 Prevalence of Delirium in Trauma Patients, Johns Hopkins 
University School of Nursing, NR110.522: Clinical Nurse 
Specialist Outcomes Specialty, Baltimore, MD 
 
November 16, 2010 Elevated ICP and Cryptotococcyl Meningitis, Neuroscience 
Nursing Grand Rounds, Johns Hopkins Hospital, Baltimore, MD 
 
November 2010 Delirium and Agitation, ICU and IMC Education Day 2010, 
University of Maryland, R Adams Cowley Shock Trauma Center, 
Baltimore, MD 
 
June 2010 Sepsis a Forensic Perspective, Johns Hopkins University School of 
Nursing, NR110.521: Clinical Nurse Specialist Role Specialty, 
Baltimore, MD 
 
July 14, 2010 Worst Headache of Her Life, Neuroscience Nursing Grand 
Rounds, Johns Hopkins Hospital, Baltimore, MD 
 
December 2009 Best Practice: Timely Initiation of Palliative Care in the Older 
Adult with Life-threatening Illness, Johns Hopkins University 
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School of Nursing, NR110.536: Health Assessment and 
Measurement: Adult/Geriatric Variations, Baltimore, MD 
 
April 2009 Clinical Rounds: Glioblastoma Multiforme, Johns Hopkins 
University School of Nursing, NR110.502: 
Physiological/Pathophysiological Basis for Advanced Nursing 
Practice, Baltimore, MD 
 
Peer Reviewed Poster Presentations 
 
July 18-22, 2016 Anderson, J.C., (Presenter). Glass, N., Farley, J. and Campbell, 
J.C. Prevalence of intimate partner violence and physical and 
mental health outcomes of women living with HIV in an urban 
clinic setting. AIDS 2016, The 21st International AIDS Society 
Conference. Durban, South Africa. 
 
May 2016 Grace, K.T. (Presenter) & Anderson, J.C. Reproductive coercion: 
A systematic review. American College of Nurse Midwives 61st 
Annual Meeting, Albuquerque, NM. 
 
March 22-24, 2016 Breads, J. (Presenter), Anderson, J., & Neverdon, T. Addressing 
the Unique Needs of Immigrant and Refugee Survivors of Sexual 
Assault and Domestic Violence in Baltimore City.  End Violence 
Against Women International: International Conference on Sexual 
Assault, Domestic Violence and Engaging Men and Boys. 
Washington, DC. (Awarded: first place in poster presentation) 
 
October 28-31, 2015 Pollitt, E. (Presenter) & Anderson, J.C. (Presenter) Testing 
Common Topical Products to Determine Fluorescence or 
Absorption of Alternate Light: Research Findings and Clinical 
Implications for ALS Use in Forensic Examiner Programs. IAFN: 
International Conference on Forensic Nursing Science and 
Practice.  Orlando, FL (Awarded: third place in poster 
presentation) 
 
October 21, 2015 Pollitt, E. (Presenter) & Anderson, J.C. (Presenter) Testing 
Common Topical Products to Determine Fluorescence or 
Absorption of Alternate Light (Phase II): Research Findings and 
Clinical Implications for ALS Use in Forensic Examiner 
Programs. Mercy Medical Center Evidence Based Practice 
Symposium, Baltimore, MD. (Awarded: Best Poster/Presentation) 
 
September 2015 Anderson, J. C. (Presenter) & Pollitt, E. Alternate Light Source 
in Forensic Examiner Programs: Research Findings and Clinical 




April 9-11, 2015 Williams, J. (Presenter), Jensen, J. (Presenter), & Anderson, J.C. 
The Impact of IPV, PTSD, and Depression on Antiretroviral 
Adherence Among HIV Positive Women. Nursing Network on 
Violence Against Women International, Atlanta GA 
 
November 2014 Anderson, J.C. (Presenter), Glass, N. E., Farley, J. & Campbell, 
J.C. A Mixed Methods Study to Examine the Effects of Intimate 
Partner Violence and Mental Health on HIV Disease Progression 
in Women. International Council on Women’s Health Issues, Cape 






2014   BMJ Open 
2014   Journal of Women’s Health Care 
2014     Journal of the International AIDS Society 






2013 – 2014  Academy on Violence and Abuse 
 
2012 –  Nursing Network on Violence Against Women International  
2015 –  Student Advisory Committee Member 
 
2010 – 2012 American Association of Neuroscience Nurses 
2015 – 2016 
 
2008 –  Sigma Theta Tau, Nursing Honor Society 
 
2008 –  International Association of Forensic Nurses 
2016 –  MD/DC Chapter Treasurer 
 
Expert Witness Testimony 
 
June 20, 2016 Expert witness for the prosecution, State of Maryland vs. James 
Caldwell, Baltimore City Circuit Court 
January 13, 2016 Expert witness for the prosecution, State of Maryland vs. Robert 
Jackson, Baltimore City Circuit Court 
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May 14, 2015 Expert witness for the petitioner, Bush vs. Bush-Hill, Protective 




June 20, 2015 Danger Assessment Certification Training, Greater Baltimore 
Medical Center, Towson, MD, 4 Hours  
 
April 1, 2015 District of Columbia Forensic Nurse Examiners Mock Trial and 
Trial Preparation, Washington, DC, 4 hours 
 
January 30, 2015 Human Trafficking Medical Screening Protocol Training, Mercy 
Medical Center, Baltimore, MD 5.75 hours 
 
May 27, 2014 Research Ethics Workshops About Responsibilities and Duties of 
Scientists (REWards) training, Johns Hopkins Medicine Office of 
Continuing Medical Education, Baltimore, MD, 6 hours 
 
October 2013 Forensic Nurse Examiner – Adult/Adolescent Training Course, 
Towson, MD; 40 hours 
 
June 2013 Qualitative Analysis, University of North Carolina, Chapel Hill, 
Chapel Hill, NC; 32 hours 
 
September 2012 Workshop on Principles and Strategies of Teaching and online 
training modules on teaching strategies and evaluation. 
Johns Hopkins University School of Nursing, Baltimore, MD; 6 
hours 
 
September 2012 Online training module: Simulation in Nursing Education, Johns 
Hopkins University School of Nursing, Baltimore, MD; 3 hours 
 
June 2011 Danger Assessment Certification  
 
September 2010 Certified Neuroscience Registered Nurse Review Course, Johns 
Hopkins Hospital, Baltimore, MD; 21 contact hours 
 
August 2009 Forensic Nurse Examiner – Adult/Adolescent Training Course, 




July 2015-June 2016 Futures Without Violence Campus Leadership Fellow 
 
May 18, 2015 Johns Hopkins Women’s Health Research Group, Annual 
Symposium Planning Committee Member 
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May 14-16, 2014 National Institute of Justice / National Science Foundation 
Workshop on Preventing Intimate Partner Violence, Graduate 
Student Participant 
 
2010-2011 Member, National Association of Clinical Nurse Specialists, 
Chesapeake Bay Chapter working group to draft legislation for 
Clinical Nurse Specialist Advanced Practice Registered Nursing 
role for Maryland Board of Nursing  
 
 





April 12, 2016 Trainer, Trauma-Informed Care Training, Johns Hopkins Medical 
Institutions Urban Health Residency Program, Baltimore, MD 
 
March 21, 2016 Guest Instructor, Inter-professional Military Sexual Assault Care 
Training, Uniform Health Services University, Bethesda, MD 
 
February 16, 2016 Guest Lecturer, Sexual Assault Nursing, NR110.593 Family 
Violence, Johns Hopkins University School of Nursing, Baltimore, 
MD 
 
Fall 2015 Guest Lecturer, Medical Forensic Examinations in Low Resource 
Settings, Confronting Gender Based Violence in India, Massive 
Open Online Course hosted by Johns Hopkins School of Public 
Health, Baltimore, MD 
 
June 3, 2015 Guest Lecturer, Evidence Collection in Trauma Patients, Sinai 
Hospital Trauma Education Days, Baltimore, MD 
 
May 6, 2015 Guest Lecturer, Sexual Violence and Medical History Taking, 
Johns Hopkins University School of Medicine “Taking an 
Excellent Sexual History” Event, Baltimore, MD 
 
March 12, 2015 Guest Lecturer, Medical Forensic History Taking, Mercy Medical 
Center Forensic Nurse Examiner Training, Baltimore, MD 
 
February 24, 2015 Guest Lecturer, Sexual Assault Nursing, NR110.593 Family 




November 11, 2014 Guest Lecturer, Intimate Partner Violence and the Role of the 
Forensic Nurse Examiner, Orthopedic Resident Training, Johns 
Hopkins University School of Medicine, Baltimore, MD 
 
March 11, 2014 Guest Lecturer, Sexual Assault Nursing, NR110.593 Family 
Violence, Johns Hopkins University School of Nursing, Baltimore, 
MD 
 
Fall 2013 Clinical Instructor, NR110.315 Adult Health I, Johns Hopkins 
University School of Nursing, Baltimore, MD  
 
Fall 2013 Teaching Assistant, NR110.633 Injury Pathology and Advanced 
Trauma Assessments, Johns Hopkins University School of 
Nursing, Baltimore, MD 
 
Fall 2013 Teaching Assistant, NR110.628 Fundamentals of Forensic 
Nursing, Johns Hopkins University School of Nursing, Baltimore, 
MD 
 
Spring 2013 Standardized Patient. NR110.312 Psychiatric and Mental Health 
Nursing. Johns Hopkins University School of Nursing, Baltimore, 
MD  
 
Spring 2013 Teaching Assistant, NR110.315 Adult Health I, Johns Hopkins 
University School of Nursing, Baltimore, MD 
 
Fall 2012 Standardized Patient. NR110.312 Psychiatric and Mental Health 
Nursing. Johns Hopkins University School of Nursing, Baltimore, 
MD 
 
Fall 2012 Teaching Assistant, NR110.315 Adult Health I, Johns Hopkins 
University School of Nursing, Baltimore, MD 
 
February 21, 2012 Guest Lecturer, Sexual Assault Nursing, NR110.593 Family 
Violence, Johns Hopkins University School of Nursing, Baltimore, 
MD 
 
Fall 2006 Teaching Assistant, DANC196 Modern Dance Technique, St. 
Cloud University, Department of Theatre, Film Studies and Dance, 
St. Cloud, MN 
 
Spring 2005 Teaching Assistant, BIO204 Human Anatomy and Physiology II, 






2013-2014 Johns Hopkins University School of Nursing, PhD Student Ethics 
Committee representative  
 





2016 Joseph Crowley, MSN Student, Johns Hopkins University School 
of Nursing, Helene Fuld Patient Safety and Quality Fellowship 
 
2015 Margaret Schultz, BSN Student, Johns Hopkins University School 
of Nursing Research Honors Program 
 
2015 Melinda Chau, BSN Student, Johns Hopkins University School of 
Nursing Research Honors Program 
Project: Rates of Non-Adherence of Medical Appointments by 
Type for Women Living With HIV 
 
2014 Jessica Williams, BSN Student, Johns Hopkins University School 
of Nursing Research Honors Program 
Project: The Impact of IPV, PTSD and Depression on 
Antiretroviral Adherence Among HIV Positive Women  
 
2014 Jennifer Jensen, BSN Student, Johns Hopkins University School of 
Nursing Research Honors Program 
  Project: The Impact of IPV, PTSD and Depression on 
Antiretroviral Adherence Among HIV Positive Women 
 
